<!DOCTYPE HTML PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html class="js_en" xml:lang="en" xmlns="http://www.w3.org/1999/xhtml" lang="en"><head>
<meta http-equiv="content-type" content="text/html; charset=UTF-8"><script src="2004%20Int%20J%20Cancer%20Zellweger_files/rental-link.html"></script>
<title>Expression patterns of potential therapeutic targets in prostate 
cancer - Zellweger - 2004 - International Journal of Cancer - Wiley 
Online Library</title><meta name="robots" content="noarchive"><meta http-equiv="X-UA-Compatible" content="IE=EmulateIE7"><link rel="stylesheet" type="text/css" media="screen,print" href="2004%20Int%20J%20Cancer%20Zellweger_files/importAll.css"><link rel="stylesheet" type="text/css" media="print" href="2004%20Int%20J%20Cancer%20Zellweger_files/print.css"><!--[if IE 6]>
	   <link rel="stylesheet" href="http://onlinelibrarystatic.wiley.com/css/ie6.css" type="text/css" media="screen,print" />
	   <link rel="stylesheet" href="http://onlinelibrarystatic.wiley.com/css/simpleForm_ie6.css" type="text/css" media="screen,print" />
    <![endif]--><!--[if IE 7]>
	   <link rel="stylesheet" href="http://onlinelibrarystatic.wiley.com/css/ie7.css" type="text/css" media="screen" />
	   <link rel="stylesheet" href="http://onlinelibrarystatic.wiley.com/css/simpleForm_ie7.css" type="text/css" media="screen,print" />
    <![endif]--><script type="text/javascript" xml:space="preserve">
        document.documentElement.className = "js_en";
    </script><link rel="stylesheet" type="text/css" media="screen,print" href="2004%20Int%20J%20Cancer%20Zellweger_files/fullText.css"><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_doi" content="10.1002/ijc.20615"><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_abstract_html_url" content="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/abstract"><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_pdf_url" content="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/pdf"><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_fulltext_html_url" content="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full"><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_volume" content="113"><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_issue" content="4"><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_firstpage" content="619"><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_lastpage" content="628"><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_journal_title" content="International Journal of Cancer"><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_publisher" content="Wiley Subscription Services, Inc., A Wiley Company"><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_issn" content="1097-0215"><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_keywords" content="tissue microarray"><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_keywords" content="immunohistochemistry"><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_keywords" content="progression"><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_keywords" content="hormone‐refractory"><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_keywords" content="therapy"><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_authors" content="Zellweger, Tobias; Ninck, Christoph; Bloch, Michael; Mirlacher, Martina; Koivisto, Pasi A.; Helin, Heikki J.; Mihatsch, Michael J.; Gasser, Thomas C.; Bubendorf, Lukas"><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_title" content="Expression patterns of potential therapeutic targets in prostate cancer"><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_online_date" content="2004/10/07"><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_language" content="en"><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_date" content="2005/02/10"><script type="text/javascript" xml:space="preserve">
            function RightslinkPopUp(url)
            {      
                 window.open(encodeURI(url),"Rightslink","location=no,toolbar=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,width=650,height=550");
            } 
        </script></head><body><div id="skip"><a href="#content" shape="rect">Skip to Main Content</a></div><div id="leftBorder">         <div id="rightBorder">   <div id="leaderBoard">     <script language="JavaScript" src="2004%20Int%20J%20Cancer%20Zellweger_files/ijc_002.js" type="text/javascript" xml:space="preserve">
    </script>      <noscript><a href="http://ad.uk.doubleclick.net/jump/wly.onco.radthr_000091/ij-cancer_IJC;tile=1;sz=728x90;doi=10.1002/ijc.20615;ord=1053086706?" target="_blank" shape="rect">
            <img src="http://ad.uk.doubleclick.net/ad/wly.onco.radthr_000091/ij-cancer_IJC;tile=1;sz=728x90;doi=10.1002/ijc.20615;ord=1053086706?" border="0" alt="" />

        </a></noscript> </div><div id="header"> <div id="globalMenu">     <a href="http://onlinelibrary.wiley.com/" title="return to home page" shape="rect"><img src="2004%20Int%20J%20Cancer%20Zellweger_files/siteLogo.gif" alt="Wiley Online Library" id="siteLogo"></a>     <p>         <a href="http://onlinelibrary.wiley.com/" id="home" shape="rect">Home</a>         <a href="http://onlinelibrary.custhelp.com/" id="help" shape="rect">Help</a>     </p>     <div>         <ul><li><a href="http://onlinelibrary.wiley.com/browse/publications" shape="rect">PUBLICATIONS</a></li><li><a href="http://onlinelibrary.wiley.com/browse/subjects" shape="rect">BROWSE BY SUBJECT</a></li><li><a href="http://olabout.wiley.com/WileyCDA/Section/id-390229.html" shape="rect">RESOURCES</a><div id="resourcesMenu"><ul><li><a href="http://olabout.wiley.com/WileyCDA/Section/id-390244.html">Training and Tutorials</a></li><li><a href="http://olabout.wiley.com/WileyCDA/Section/id-404512.html">For Researchers</a></li><li><a href="http://olabout.wiley.com/WileyCDA/Section/id-404513.html">For Librarians</a></li><li><a href="http://olabout.wiley.com/WileyCDA/Section/id-404518.html">For Societies</a></li><li><a href="http://olabout.wiley.com/WileyCDA/Section/id-404516.html">For Authors</a></li><li><a href="http://olabout.wiley.com/WileyCDA/Section/id-390236.html">For Advertisers</a></li><li><a href="http://olabout.wiley.com/WileyCDA/Section/id-390242.html">For Media</a></li><li><a href="http://olabout.wiley.com/WileyCDA/Section/id-390243.html">For Agents</a></li></ul></div></li><li><a href="http://olabout.wiley.com/WileyCDA/Section/id-390001.html" shape="rect">ABOUT US</a></li></ul>     </div> </div><div id="coBranding"> </div>              <div id="login">             <form method="post" action="/j_spring_security_check" id="loginForm" enctype="application/x-www-form-urlencoded"><fieldset>                     <legend>LOGIN</legend>                     <div id="loginInFormInner">                      <label id="emailLabel" for="loginEmail" class="hide">Enter e-mail address</label>                      <input name="j_username" id="loginEmail" type="text">                      <div>                          <label id="passwordLabel" for="loginPassword" class="hide">Enter password</label>                          <input id="loginPassword" value="" name="j_password" type="password">                          <input name="submit" id="loginSubmit" src="2004%20Int%20J%20Cancer%20Zellweger_files/loginSubmit.png" value="Go" alt="Login" type="image">                      </div>                          <input name="_spring_security_remember_me" id="loginRememberMe" checked="checked" type="checkbox">                      <label for="loginRememberMe">REMEMBER ME</label>                     </div>                 </fieldset></form>             <ul id="loginOptions"><li><a href="http://onlinelibrary.wiley.com/user-registration" title="NOT REGISTERED" shape="rect">NOT REGISTERED ?</a></li><li><a href="http://onlinelibrary.wiley.com/user/forgottenpassword" id="forgottenPassword" title="FORGOTTEN PASSWORD ?" shape="rect">FORGOTTEN PASSWORD ?</a></li><li><a href="http://onlinelibrary.wiley.com/login-options" title="INSTITUTIONAL LOGIN" shape="rect">INSTITUTIONAL LOGIN &gt;</a></li></ul>         </div>      </div> <div id="breadcrumb"> </div>  <div id="pageNavAndTools">            <div class="menuGroup">     <h2>JOURNAL TOOLS</h2>     <ul class="titleTools"><li>                             <a href="http://onlinelibrary.wiley.com/getEmailAlert?id=10.1002%2F%28ISSN%291097-0215&amp;originUrl=%2Fdoi%2F10.1002%2Fijc.20615%2Ffull" class="getEmailAlerts" shape="rect">Get New Content Alerts</a>         </li><li>             <a class="rss" href="http://onlinelibrary.wiley.com/rss/journal/10.1002/%28ISSN%291097-0215" shape="rect">Get RSS feed</a>         </li><li>                 <a href="http://onlinelibrary.wiley.com/saveTitle?id=10.1002%2F%28ISSN%291097-0215&amp;type=JOURNAL&amp;originUrl=%2Fdoi%2F10.1002%2Fijc.20615%2Ffull" class="saveToProfile" shape="rect">Save to My Profile</a>         </li><li>                 <a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.v126:1/issuetoc" class="getSampleCopy" shape="rect">Get Sample Copy</a>             </li></ul> </div>             <div class="menuGroup">  <h2>JOURNAL MENU</h2>  <ul><li><a href="http://onlinelibrary.wiley.com/journal/10.1002/%28ISSN%291097-0215" title="Journal Home" shape="rect">Journal Home</a></li></ul> </div> <div class="menuGroup">     <h3>FIND ISSUES</h3>     <ul><li><a href="http://onlinelibrary.wiley.com/journal/10.1002/%28ISSN%291097-0215/currentissue" title="Current Issue" id="currentIssueLink" shape="rect">Current Issue</a></li><li><a href="http://onlinelibrary.wiley.com/journal/10.1002/%28ISSN%291097-0215/issues" title="All Issues" shape="rect">All Issues</a></li></ul> </div>                    <div class="menuGroup">         <h3>FIND ARTICLES</h3>         <ul><li><a href="http://onlinelibrary.wiley.com/journal/10.1002/%28ISSN%291097-0215/earlyview" title="Early View" id="earlyViewLink" shape="rect">Early View</a></li><li><a href="http://onlinelibrary.wiley.com/journal/10.1002/%28ISSN%291097-0215/accepted" title="Accepted Articles" id="acceptedArticlesLink" shape="rect">Accepted Articles</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="http://onlinelibrary.wiley.com/journal/10.1002/%28ISSN%291097-0215/homepage/MostAccessed.html" title="Most Accessed" shape="rect">Most Accessed</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="http://onlinelibrary.wiley.com/journal/10.1002/%28ISSN%291097-0215/homepage/editor_s_choice.htm" title="Editors' Choice" shape="rect">Editors' Choice</a></li></ul>     </div>                  <div class="menuGroup">         <h3>GET ACCESS</h3>          <ul><li>                 <a href="http://ordering.onlinelibrary.wiley.com/subs.asp?ref=1097-0215&amp;doi=10.1002/%28ISSN%291097-0215" title="Subscribe / Renew" shape="rect">Subscribe / Renew</a>             </li></ul>     </div>                  <div class="menuGroup">         <h3>FOR CONTRIBUTORS</h3>         <ul><li xmlns="http://www.w3.org/1999/xhtml"><a href="http://onlinelibrary.wiley.com/journal/10.1002/%28ISSN%291097-0215/homepage/ForAuthors.html" title="Author Guidelines" shape="rect">Author Guidelines</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="http://mc.manuscriptcentral.com/ijc-wiley" title="Submit an Article" shape="rect">Submit an Article</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="http://wileyonlinelibrary.com/onlineopen" title="OnlineOpen" shape="rect">OnlineOpen</a></li></ul>     </div>                  <div class="menuGroup">         <h3>ABOUT THIS JOURNAL</h3>         <ul><li xmlns="http://www.w3.org/1999/xhtml"><a href="http://onlinelibrary.wiley.com/journal/10.1002/%28ISSN%291097-0215/homepage/ProductInformation.html" title="Overview" shape="rect">Overview</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="http://onlinelibrary.wiley.com/journal/10.1002/%28ISSN%291097-0215/homepage/EditorialBoard.html" title="Editorial Board" shape="rect">Editorial Board</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="http://onlinelibrary.wiley.com/journal/10.1002/%28ISSN%291097-0215/homepage/Contact.html" title="Contact" shape="rect">Contact</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="http://onlinelibrary.wiley.com/journal/10.1002/%28ISSN%291097-0215/homepage/Advertise.html" title="Advertise" shape="rect">Advertise</a></li></ul>     </div>                  <div class="menuGroup">         <h2>SPECIAL FEATURES</h2>         <ul><li xmlns="http://www.w3.org/1999/xhtml"><a href="http://onlinelibrary.wiley.com/journal/10.1002/%28ISSN%291097-0215/homepage/article_spotlight.htm" title="Spotlights" shape="rect">Spotlights</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="http://onlinelibrary.wiley.com/journal/10.1002/%28ISSN%291097-0215/homepage/special_sections.htm" title="Special Sections" shape="rect">Special Sections</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="http://onlinelibrary.wiley.com/journal/10.1002/%28ISSN%291097-0215/homepage/professional_opportunities.htm" title="Professional Opportunities" shape="rect">Professional Opportunities</a></li></ul>     </div>             <script language="JavaScript" src="2004%20Int%20J%20Cancer%20Zellweger_files/ijc.js" type="text/javascript" xml:space="preserve"></script> <noscript><a href="http://ad.uk.doubleclick.net/jump/wly.onco.radthr_000091/ij-cancer_IJC;tile=2;sz=160x600,160x320,160x160,120x600;doi=10.1002/ijc.20615;ord=1053086706?" target="_blank" shape="rect">
        <img src="http://ad.uk.doubleclick.net/ad/wly.onco.radthr_000091/ij-cancer_IJC;tile=2;sz=160x600,160x320,160x160,120x600;doi=10.1002/ijc.20615;ord=1053086706?" border="0" alt="" />
    </a></noscript>  </div>  <div id="content">     <div xmlns="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" id="banner" style="background-image: url(&quot;http://onlinelibrary.wiley.com/store/10.1002/(ISSN)1097-0215/asset/olbannerwallpaper.jpg?v=1&amp;s=2adbcfb7786fd2fae65b8e05a3c150a8f78d4c5e&quot;);"><img class="left" src="2004%20Int%20J%20Cancer%20Zellweger_files/olbannerleft.jpg" alt=""><img class="right" src="2004%20Int%20J%20Cancer%20Zellweger_files/olbannerright.jpg" alt=""></div>      <div id="mainContent">                                                                                                 <div xmlns="http://www.w3.org/1999/xhtml" class="citation articleInformationHeader" id="titleMeta"><div id="articleDesc"><p class="articleCategory">Early Detection and Diagnosis</p><div id="articleTitle" embargounit=""><span class="freeAccess" title="You have full text access to this OnlineOpen article">You have full text access to this OnlineOpen article</span><h1 class="articleTitle">Expression patterns of potential therapeutic targets in prostate cancer</h1></div><div id="articleMeta"><ol id="authors"><li id="au1">Tobias Zellweger<sup>1</sup>, </li><li id="au2">Christoph Ninck<sup>2</sup>, </li><li id="au3">Michael Bloch<sup>2</sup>, </li><li id="au4">Martina Mirlacher<sup>2</sup>, </li><li id="au5">Pasi A. Koivisto<sup>3</sup>, </li><li id="au6">Heikki J. Helin<sup>4</sup>, </li><li id="au7">Michael J. Mihatsch<sup>2</sup>, </li><li id="au8">Thomas C. Gasser<sup>1</sup>, </li><li id="au9">Lukas Bubendorf<sup>2,*,<a href="#fn1" shape="rect">†</a></sup></li></ol><p id="publishedOnlineDate">Article first published online: 7 OCT 2004</p><p id="doi">DOI:&nbsp;10.1002/ijc.20615</p><p id="copyright" class="copyright">Copyright © 2004 Wiley-Liss, Inc.</p></div><div id="articleParent"><p class="articleCategory">                 Issue               </p><div id="cover" class="journal"><div class="imgShadow"><img src="2004%20Int%20J%20Cancer%20Zellweger_files/cover.gif" alt="International Journal of Cancer" title="International Journal of Cancer"></div></div><div id="metaData"><h2 id="productTitle">International Journal of Cancer</h2><div id="issueDetails"><p class="articleDetails"><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.v113:4/issuetoc" shape="rect"><span id="volumeNumber">Volume 113</span>,  <span id="issueNumber">Issue 4</span>, </a> <span id="issuePages">pages 619–628</span>, <span id="issueDate">10 February 2005</span></p></div></div></div></div><div id="additionalInformation"><p class="articleCategory">Additional Information<a href="#">(Show All)</a></p><p id="toggleAddInfo"><a href="#">How to Cite</a><a href="#">Author Information</a><a href="#">Publication History</a><a href="#">Funding Information</a></p><div style="clear: left;"><div id="howToCite"><h4>How to Cite</h4><p id="citation">Zellweger,
 T., Ninck, C., Bloch, M., Mirlacher, M., Koivisto, P. A., Helin, H. J.,
 Mihatsch, M. J., Gasser, T. C. and Bubendorf, L. (2005), Expression 
patterns of potential therapeutic targets in prostate cancer. 
International Journal of Cancer, 113:&nbsp;619–628. 
doi:&nbsp;10.1002/ijc.20615</p></div><div id="authorsDetail"><h4>Author Information</h4><ol id="authorsAffiliations"><li class="affiliation"><sup>1</sup><p>Department of Urology, University of Basel, Liestal, Switzerland</p></li><li class="affiliation"><sup>2</sup><p>Institute for Pathology, University of Basel, Basel, Switzerland</p></li><li class="affiliation"><sup>3</sup><p>Laboratory of Cancer Genetics, Tampere University Hospital, Tampere, Finland</p></li><li class="affiliation"><sup>4</sup><p>Department of Pathology, Tampere University Hospital, Tampere, Finland</p></li></ol><p id="contactDetails"><span class="email-label">Email: </span><span class="email">Lukas Bubendorf (lbubendorf@uhbs.ch) </span></p><p id="correspondence">*Correspondence: Lukas Bubendorf, Institute for Pathology, University of Basel, Schönbeinstrasse 40, 4031 Basel, Switzerland</p><ol id="footnotes" class="noteGroup custom"><li id="fn1"><span class="bullet"><sup>†</sup></span><div class="para"><p>Fax: +0041-61-265 3194</p></div></li></ol></div><div id="publicationHistoryDetails"><h4>Publication History</h4><ol><li>Issue published online: 30 NOV 2004</li><li>Article first published online: 7 OCT 2004</li><li>Manuscript Accepted: 3 AUG 2004</li><li>Manuscript Received: 11 APR 2004</li></ol></div><div id="fundingInfo" class="fundingInfo"><h4>Funded by</h4><ul><li>CaP CURE Foundation</li></ul></div></div></div></div>                            </div> <div id="promosAndTools">                      <form method="post" action="/advanced/search/results" id="searchSite" class="searchForm" name="advancedSearchForm" enctype="application/x-www-form-urlencoded"><fieldset>                 <h2>SEARCH</h2>                 <div class="searchCriteria">                     <label for="scope">Search Scope</label>                     <select id="scope" name="scope"><option value="allContent">All content</option><option value="publicationTitles">Publication titles</option><option value="journal">In this journal</option><option value="issue" selected="selected">In this issue</option><option value="byCitation">By Citation</option></select>                     <div>                         <label for="searchText">Search String</label>                         <input id="searchText" name="query" type="text">                         <input name="searchSubmit2" id="searchSiteSubmit" src="2004%20Int%20J%20Cancer%20Zellweger_files/searchSubmit.png" value="Go" alt="Search" type="image">                     </div>                         <input value="10.1002/(ISSN)1097-0215" name="publicationDoi" type="hidden">                         <input value="10.1002/ijc.v113:4" name="issueDoi" type="hidden">                     <input value="1" name="start" type="hidden">                     <input value="20" name="resultsPerPage" type="hidden">                 </div>             </fieldset><ul class="extraSearchOptions"><li><a href="http://onlinelibrary.wiley.com/advanced/search" shape="rect">Advanced &gt;</a></li><li><a href="http://onlinelibrary.wiley.com/myprofile/displaySavedSearches" shape="rect">Saved Searches &gt;</a></li></ul></form>          <form method="post" action="/search/citation/results" id="searchByCitation" class="searchForm" name="citationSearchForm" enctype="application/x-www-form-urlencoded"><fieldset>                 <h2>SEARCH BY CITATION</h2>                  <div class="searchCriteria">                   <div class="volume">                     <label for="volume">Volume:</label>     <input id="volume" name="volume" class="searchVolume" type="text">                     </div>                    <div class="issue">                      <label for="issue">Issue:</label>     <input id="issue" name="issue" class="searchIssue" type="text">                     </div>                    <div class="page">                      <label for="page">Page:</label>     <input id="page" name="page" class="searchPage" type="text">                     </div>                    <input name="citationSearchSubmit" id="citationSearchSubmit" src="2004%20Int%20J%20Cancer%20Zellweger_files/searchSubmit.gif" value="Go" alt="Search" type="image">                  </div>     <input id="publicationDoi" name="publicationDoi" value="10.1002/(ISSN)1097-0215" type="hidden">           </fieldset></form>                 <div xmlns:w="http://www.wiley.com/namespaces/wiley" class="menuGroup"><h2>ARTICLE TOOLS</h2><ul class="titleTools"><li class="pdf"><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/pdf" title="Article in pdf format" id="journalToolsPdfLink" shape="rect">Get PDF (681K)</a></li><li class="save"><a href="http://onlinelibrary.wiley.com/saveContent?doi=10.1002%252Fijc.20615&amp;originUrl=%2Fdoi%2F10.1002%2Fijc.20615%2Ffull" title="Save to My Profile" shape="rect">Save to My Profile</a></li><li class="email"><a href="http://onlinelibrary.wiley.com/emailArticleLink?doi=10.1002/ijc.20615" shape="rect">E-mail Link to this Article</a></li><li class="citation"><a href="http://onlinelibrary.wiley.com/documentcitationdownload?publicationDoi=10.1002/%28ISSN%291097-0215&amp;doi=10.1002/ijc.20615&amp;type=journal" shape="rect">Export Citation for this Article</a></li><li><a shape="rect" class="getEmailAlerts" href="http://onlinelibrary.wiley.com/getCitationAlert?id=10.1002%2Fijc.20615&amp;originUrl=%2Fdoi%2F10.1002%2Fijc.20615%2Ffull">Get Citation Alerts</a></li><li class="requestPermissions"><a href="javascript:RightslinkPopUp('https://s100.copyright.com/AppDispatchServlet?publisherName=Wiley&amp;publication=IJC&amp;title=Expression%20patterns%20of%20potential%20therapeutic%20targets%20in%20prostate%20cancer&amp;publicationDate=10%20FEB%202005&amp;author=Tobias%20Zellweger,Christoph%20Ninck,Michael%20Bloch,Martina%20Mirlacher,Pasi%20A.%20Koivisto,Heikki%20J.%20Helin,Michael%20J.%20Mihatsch,Thomas%20C.%20Gasser,Lukas%20Bubendorf&amp;startPage=619&amp;endPage=628&amp;copyright=Copyright%20%C2%A9%202004%20Wiley%E2%80%90Liss,%20Inc.&amp;contentID=10.1002/ijc.20615&amp;orderBeanReset=True')" shape="rect">Request Permissions</a></li></ul></div>  </div>      <div id="productContent">                               <div xmlns="http://www.w3.org/1999/xhtml" class="tabbedContent"><ul><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/abstract" title="Link to article abstract" shape="rect">Abstract</a></li><li class="active"><span>Article</span></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/references" title="Link to article references" shape="rect">References</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/citedby" title="Other articles that have cited this article" shape="rect">Cited By</a></li></ul></div>          <div xmlns:doc="urn://wiley-online-library/content/document" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml" class="viewFullArticleAndPdf"><div class="viewFullArticleAndPdfOptions"><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/pdf" title="Article in pdf format" class="pdfLink" shape="rect">Get PDF (681K)</a></div></div>                 <div xmlns="http://www.w3.org/1999/xhtml" id="fulltext"><div class="keywords"><h3 class="keywordsHeading">Keywords:</h3><div class="keywordLists"><ul class="keywordList" id="abstractKeywords1"><li>tissue microarray;</li><li>immunohistochemistry;</li><li>progression;</li><li>hormone-refractory;</li><li>therapy</li></ul></div></div><div id="abstract"><div class="headingCont"><select style="visibility: visible; width: 238px;" class="jumpSelect"><option selected="selected" value="jumpTo">Jump to…</option><option value="#leftBorder">Top of page</option><option value="#abstract">Abstract</option><option value="#sec1-1">Material and methods</option><option value="#sec1-2">Results</option><option value="#sec1-3">Discussion</option><option value="#sec1-ack-1">Acknowledgements</option><option value="#wol-references">References</option></select><h3>Abstract</h3></div><ol style="display: none;" class="jumpList"><li><a href="#leftBorder" shape="rect">Top of page</a></li><li><a href="#abstract" shape="rect">Abstract</a></li><li><a href="#sec1-1" shape="rect">Material and methods</a></li><li><a href="#sec1-2" shape="rect">Results</a></li><li><a href="#sec1-3" shape="rect">Discussion</a></li><li><a href="#sec1-ack-1" shape="rect">Acknowledgements</a></li><li><a href="#wol-references" shape="rect">References</a></li></ol><div class="para"><p>Androgen
 withdrawal is the only effective therapy for patients with advanced 
prostate cancer, but progression to androgen independence ultimately 
occurs in almost all patients. Novel therapeutic strategies targeting 
molecular mechanisms that mediate resistance to hormonal and 
chemotherapeutic treatment are highly warranted. Here, we aimed to 
evaluate the expression of potential therapeutic targets in advanced 
prostate cancer. A tissue microarray (TMA) containing samples from 535 
tissue blocks was constructed, including benign prostatic hyperplasia as
 controls (<em>n</em> = 65), prostatic intraepithelial neoplasia (PIN; <em>n</em> = 78), clinically localized prostate cancers (<em>n</em> = 181), as well as hormone-refractory local recurrences (<em>n</em> = 120) and distant metastases (<em>n</em>
 = 91). The expression of 13 different proteins was analyzed using 
immunohistochemistry (Bcl-2, p53, ILK, Syndecan-1, MUC-1, EGFR, 
HER2/neu, HSP-90, Ep-CAM, MMP-2, CD-10, CD-117 and Ki67). Significant 
overexpression in hormone-refractory prostate cancer and metastatic 
tissue compared to localized prostate cancer was found for Ki67 (64% <em>vs</em>. 9%), Bcl-2 (11% <em>vs</em>. 1%), p53 (35% <em>vs</em>. 4%), Syndecan-1 (38% <em>vs</em>. 3%), EGFR (16% <em>vs</em>. 1%) and HER2/neu (16% <em>vs</em>.
 0%). Overexpression of CD-117 was restricted to 1 single metastasis. 
All other markers did not show relevant differences in expression 
between subgroups. Taken together, p53, Bcl-2, Syndecan-1, EGFR and 
HER2/neu are preferentially expressed in hormone-refractory and 
metastatic prostate cancer. Selected inhibition of these targets might 
offer a strategy to treat advanced tumors and prevent further 
progression. Treatment decisions should not be based on findings in 
primary tumors but rather on tissues from recurrent or metastatic 
lesions.</p></div></div><div class="section" id="sec1-bdy-1"><div class="para"><p>Prostate
 cancer is the most commonly diagnosed malignancy and the second leading
 cause of cancer mortality in men in Western industrialized countries.<a href="#bib1" rel="references:#bib1" class="referenceLink" title="Link to bibliographic citation" shape="rect">1</a>
 Androgen withdrawal is the only effective therapy for patients with 
advanced disease. Approximately 80% of patients achieve symptomatic 
and/or objective response after androgen ablation. However, progression 
to androgen independence ultimately occurs in almost all patients.<a href="#bib2" rel="references:#bib2" class="referenceLink" title="Link to bibliographic citation" shape="rect">2</a>
 Although numerous nonhormonal agents have been evaluated in patients 
with hormone-refractory prostate cancer, these agents have limited 
antitumor activity with an objective response rate &lt;20% and no 
demonstrated survival benefit.<a href="#bib3" rel="references:#bib3" class="referenceLink" title="Link to bibliographic citation" shape="rect">3</a>, <a href="#bib4" rel="references:#bib4" class="referenceLink" title="Link to bibliographic citation" shape="rect">4</a>
 Therefore, the identification and selected inhibition of molecular 
targets that mediate the progression of prostate cancer will have great 
impact on future treatment concepts. Possible targeted therapies include
 antibodies to inactivate specific proteins, vaccination against 
tumor-specific antigens, antisense oligonucleotides aimed against 
messenger RNA, molecules that block specific proteins and pathways or 
gene therapy for insertion of wild-type genes to restore the function of
 defective tumor-suppressor genes.<a href="#bib5" rel="references:#bib5" class="referenceLink" title="Link to bibliographic citation" shape="rect">5</a></p></div><div class="para"><p>A
 variety of new therapies for selected inhibition of therapeutic targets
 are currently under clinical evaluation in advanced prostate cancer, 
including antisense Bcl-2 therapy (Genasense®, Genta, Inc., Berkeley 
Heights, NJ). Clinical phase I studies are planned with ZD1839 (Iressa®,
 AstraZeneca, Macclesfield, UK), which is a potent and specific 
inhibitor of EGFR tyrosine kinase activity.<a href="#bib6" rel="references:#bib6" class="referenceLink" title="Link to bibliographic citation" shape="rect">6</a></p></div><div class="para"><p>The
 selection of patients for targeted therapies should be based on the 
presence of specific gene alterations or protein expression profiles in a
 given tumor. For example, the humanized antibody trastuzumab 
(Herceptin®, Roche, Basel, Switzerland), which is directed against the 
HER2/neu receptor, is only effective against breast cancers with 
HER2/neu amplification and overexpression but not in those with a normal
 HER2/neu status.<a href="#bib7" rel="references:#bib7" class="referenceLink" title="Link to bibliographic citation" shape="rect">7</a></p></div><div class="para"><p>Accordingly,
 it is not surprising that a series of advanced prostate cancers, which 
were HER2/neu negative, did not respond to trastuzumab in a phase II 
clinical trial.<a href="#bib8" rel="references:#bib8" class="referenceLink" title="Link to bibliographic citation" shape="rect">8</a>
 Testing the prevalence of targeted molecular alterations in large 
numbers of tumors is crucial in order to estimate the chance of success 
of specific therapies in particular tumor types prior to clinical 
application.</p></div><div class="para"><p>High-throughput analysis of 
tissue microarrays (TMA) allows rapid molecular profiling of large 
numbers of tumors in a single experiment.<a href="#bib9" rel="references:#bib9" class="referenceLink" title="Link to bibliographic citation" shape="rect">9</a>, <a href="#bib10" rel="references:#bib10" class="referenceLink" title="Link to bibliographic citation" shape="rect">10</a>
 Here, we constructed a progression TMA with specimens from 535 patients
 to analyze the protein expression profiles of potential therapeutic 
targets across the whole spectrum of prostate cancer progression.</p></div><div class="para"><p>Candidate
 proteins were chosen depending on the availability of known or 
suggested targeted therapeutic regimens, including HER2/neu, epidermal 
growth factor receptor (EGFR), epithelial cellular adhesion molecule 
(Ep-CAM), Syndecan-1 (CD-138), matrix metalloproteinase 2 (MMP-2), 
integrin-linked kinase (ILK), urinary mucine 1 (MUC-1), heat-shock 
protein 90 (HSP90), Bcl-2, p53, CD-10 (neutral endopeptidase) and CD-117
 (tyrosine phosphatase) (Table <a href="#tbl1" rel="references:#tbl1" class="tableLink" title="Link to table" shape="rect">I</a><a href="#bib6" rel="references:#bib6" class="referenceLink" title="Link to bibliographic citation" shape="rect">6</a>, <a href="#bib11" rel="references:#bib11" class="referenceLink" title="Link to bibliographic citation" shape="rect">11</a>, <a href="#bib12" rel="references:#bib12" class="referenceLink" title="Link to bibliographic citation" shape="rect">12</a>, <a href="#bib13" rel="references:#bib13" class="referenceLink" title="Link to bibliographic citation" shape="rect">13</a>, <a href="#bib14" rel="references:#bib14" class="referenceLink" title="Link to bibliographic citation" shape="rect">14</a>, <a href="#bib15" rel="references:#bib15" class="referenceLink" title="Link to bibliographic citation" shape="rect">15</a>, <a href="#bib16" rel="references:#bib16" class="referenceLink" title="Link to bibliographic citation" shape="rect">16</a>, <a href="#bib17" rel="references:#bib17" class="referenceLink" title="Link to bibliographic citation" shape="rect">17</a>, <a href="#bib18" rel="references:#bib18" class="referenceLink" title="Link to bibliographic citation" shape="rect">18</a>, <a href="#bib19" rel="references:#bib19" class="referenceLink" title="Link to bibliographic citation" shape="rect">19</a>, <a href="#bib20" rel="references:#bib20" class="referenceLink" title="Link to bibliographic citation" shape="rect">20</a>, <a href="#bib21" rel="references:#bib21" class="referenceLink" title="Link to bibliographic citation" shape="rect">21</a>, <a href="#bib22" rel="references:#bib22" class="referenceLink" title="Link to bibliographic citation" shape="rect">22</a>, <a href="#bib23" rel="references:#bib23" class="referenceLink" title="Link to bibliographic citation" shape="rect">23</a>, <a href="#bib24" rel="references:#bib24" class="referenceLink" title="Link to bibliographic citation" shape="rect">24</a>, <a href="#bib25" rel="references:#bib25" class="referenceLink" title="Link to bibliographic citation" shape="rect">25</a>, <a href="#bib26" rel="references:#bib26" class="referenceLink" title="Link to bibliographic citation" shape="rect">26</a>, <a href="#bib27" rel="references:#bib27" class="referenceLink" title="Link to bibliographic citation" shape="rect">27</a>, <a href="#bib28" rel="references:#bib28" class="referenceLink" title="Link to bibliographic citation" shape="rect">28</a>, <a href="#bib29" rel="references:#bib29" class="referenceLink" title="Link to bibliographic citation" shape="rect">29</a>, <a href="#bib30" rel="references:#bib30" class="referenceLink" title="Link to bibliographic citation" shape="rect">30</a>, <a href="#bib31" rel="references:#bib31" class="referenceLink" title="Link to bibliographic citation" shape="rect">31</a>, <a href="#bib32" rel="references:#bib32" class="referenceLink" title="Link to bibliographic citation" shape="rect">32</a>).
 Our data show that several of these proteins are often expressed in 
advanced prostate cancers, qualifying them as promising therapeutic 
targets.</p></div><div class="table" id="tbl1"><table class="topbotR"><caption><span class="tTitle"><span class="label">Table&nbsp;I.&nbsp;</span>Analyzed Candidate Markers and Potential Treatment Strategies</span></caption><thead class="vBottom"><tr class="rsep hCenter"><th rowspan="1" colspan="1">Candidate protein</th><th rowspan="1" colspan="1">Synonym(s)</th><th rowspan="1" colspan="1">Possible treatment strategy (alone or in combination with chemotherapeutics)</th><th rowspan="1" colspan="1">Selected references</th></tr></thead><tbody class="vTop"><tr class="norsep hLeft"><td rowspan="1" colspan="1">Bcl-2</td><td rowspan="1" colspan="1">B-Cell CLL/Lymphoma 2</td><td rowspan="1" colspan="1">Antisense Bcl-2 oligonucleotides (Genasense®)</td><td rowspan="1" colspan="1"><a href="#bib11" rel="references:#bib11" class="referenceLink" title="Link to bibliographic citation" shape="rect">11</a>, <a href="#bib12" rel="references:#bib12" class="referenceLink" title="Link to bibliographic citation" shape="rect">12</a></td></tr><tr class="norsep hLeft"><td rowspan="1" colspan="1">CD-10</td><td rowspan="1" colspan="1">Neutral Endopeptidase (NEP), Neprilysin</td><td rowspan="1" colspan="1">Monoclonal antibodies</td><td rowspan="1" colspan="1"><a href="#bib13" rel="references:#bib13" class="referenceLink" title="Link to bibliographic citation" shape="rect">13</a>, <a href="#bib14" rel="references:#bib14" class="referenceLink" title="Link to bibliographic citation" shape="rect">14</a></td></tr><tr class="norsep hLeft"><td rowspan="1" colspan="1">CD-117</td><td rowspan="1" colspan="1">Tyrosine Phosphatase</td><td rowspan="1" colspan="1">Imatinib (Glivec®)</td><td rowspan="1" colspan="1"><a href="#bib15" rel="references:#bib15" class="referenceLink" title="Link to bibliographic citation" shape="rect">15</a>, <a href="#bib16" rel="references:#bib16" class="referenceLink" title="Link to bibliographic citation" shape="rect">16</a></td></tr><tr class="norsep hLeft"><td rowspan="1" colspan="1">Epidermal Growth Factor Receptor (EGFR)</td><td rowspan="1" colspan="1">ErbB1, ErbB Oncogene</td><td rowspan="1" colspan="1">ZD1839, gefitinib (Iressa®)</td><td rowspan="1" colspan="1"><a href="#bib6" rel="references:#bib6" class="referenceLink" title="Link to bibliographic citation" shape="rect">6</a>, <a href="#bib17" rel="references:#bib17" class="referenceLink" title="Link to bibliographic citation" shape="rect">17</a></td></tr><tr class="norsep hLeft"><td rowspan="1" colspan="1">Epithelial Cellular Adhesion Molecule (EpCAM)</td><td rowspan="1" colspan="1">Tumor-associated calcium signal transducer 1</td><td rowspan="1" colspan="1">Bispecific antibodies</td><td rowspan="1" colspan="1"><a href="#bib18" rel="references:#bib18" class="referenceLink" title="Link to bibliographic citation" shape="rect">18</a>, <a href="#bib19" rel="references:#bib19" class="referenceLink" title="Link to bibliographic citation" shape="rect">19</a></td></tr><tr class="norsep hLeft"><td rowspan="1" colspan="1">HER2/neu</td><td rowspan="1" colspan="1">cErbB2</td><td rowspan="1" colspan="1">Trastuzumab (Herceptin®)</td><td rowspan="1" colspan="1"><a href="#bib20" rel="references:#bib20" class="referenceLink" title="Link to bibliographic citation" shape="rect">20</a>, <a href="#bib21" rel="references:#bib21" class="referenceLink" title="Link to bibliographic citation" shape="rect">21</a></td></tr><tr class="norsep hLeft"><td rowspan="1" colspan="1">Heat-shock Protein 90 (HSP90)</td><td rowspan="1" colspan="1">Lipopolysaccharide-associated protein 2</td><td rowspan="1" colspan="1">17-allylaminogeldanamycin (17AAG)</td><td rowspan="1" colspan="1"><a href="#bib22" rel="references:#bib22" class="referenceLink" title="Link to bibliographic citation" shape="rect">22</a>, <a href="#bib23" rel="references:#bib23" class="referenceLink" title="Link to bibliographic citation" shape="rect">23</a></td></tr><tr class="norsep hLeft"><td rowspan="1" colspan="1">Integrin-linked Kinase (ILK)</td><td rowspan="1" colspan="1">p59</td><td rowspan="1" colspan="1">Non-steroidal anti-inflammatory drugs (NSAIDs)</td><td rowspan="1" colspan="1"><a href="#bib24" rel="references:#bib24" class="referenceLink" title="Link to bibliographic citation" shape="rect">24</a>, <a href="#bib25" rel="references:#bib25" class="referenceLink" title="Link to bibliographic citation" shape="rect">25</a></td></tr><tr class="norsep hLeft"><td rowspan="1" colspan="1">Matrix Metalloproteinase 2 (MMP-2)</td><td rowspan="1" colspan="1">Collagenase Type IV A Gelatinase A</td><td rowspan="1" colspan="1">MMP-Inhibitor (Roche 28-2653)</td><td rowspan="1" colspan="1"><a href="#bib26" rel="references:#bib26" class="referenceLink" title="Link to bibliographic citation" shape="rect">26</a>, <a href="#bib27" rel="references:#bib27" class="referenceLink" title="Link to bibliographic citation" shape="rect">27</a></td></tr><tr class="norsep hLeft"><td rowspan="1" colspan="1">Transmembrane Mucin 1 (MUC-1)</td><td rowspan="1" colspan="1">Urinary Mucin 1</td><td rowspan="1" colspan="1">Monoclonal antibodies (DF3, B27.29)</td><td rowspan="1" colspan="1"><a href="#bib28" rel="references:#bib28" class="referenceLink" title="Link to bibliographic citation" shape="rect">28</a>, <a href="#bib29" rel="references:#bib29" class="referenceLink" title="Link to bibliographic citation" shape="rect">29</a></td></tr><tr class="norsep hLeft"><td rowspan="1" colspan="1">p53</td><td rowspan="1" colspan="1">Tumor protein p53 (TP53)</td><td rowspan="1" colspan="1">Transfection using wild-type p53, Adenoviral-mediated gene transfer</td><td rowspan="1" colspan="1"><a href="#bib30" rel="references:#bib30" class="referenceLink" title="Link to bibliographic citation" shape="rect">30</a>, <a href="#bib31" rel="references:#bib31" class="referenceLink" title="Link to bibliographic citation" shape="rect">31</a></td></tr><tr class="norsep hLeft"><td rowspan="1" colspan="1">Syndecan-1</td><td rowspan="1" colspan="1">CD 138</td><td rowspan="1" colspan="1">Monoclonal Antibodies</td><td rowspan="1" colspan="1"><a href="#bib32" rel="references:#bib32" class="referenceLink" title="Link to bibliographic citation" shape="rect">32</a></td></tr></tbody></table></div></div><div class="section" id="sec1-1"><div class="headingCont"><select style="visibility: visible; width: 238px;" class="jumpSelect"><option selected="selected" value="jumpTo">Jump to…</option><option value="#leftBorder">Top of page</option><option value="#abstract">Abstract</option><option value="#sec1-1">Material and methods</option><option value="#sec1-2">Results</option><option value="#sec1-3">Discussion</option><option value="#sec1-ack-1">Acknowledgements</option><option value="#wol-references">References</option></select><h3>Material and methods</h3></div><ol style="display: none;" class="jumpList"><li><a href="#leftBorder" shape="rect">Top of page</a></li><li><a href="#abstract" shape="rect">Abstract</a></li><li><a href="#sec1-1" shape="rect">Material and methods</a></li><li><a href="#sec1-2" shape="rect">Results</a></li><li><a href="#sec1-3" shape="rect">Discussion</a></li><li><a href="#sec1-ack-1" shape="rect">Acknowledgements</a></li><li><a href="#wol-references" shape="rect">References</a></li></ol><div class="section" id="sec2-1"><h4>Patients and specimens</h4><div class="para"><p>Formalin-fixed
 and paraffin-embedded tumor and control specimens were from the 
archives of the Institute for Pathology, University of Basel and the 
Tampere University Hospital. All tumors and controls were reviewed by 
one pathologist (L.B.). The least differentiated tumor area was selected
 for the tissue microarray. The specimens that were interpretable for 
immunohistochemistry included a) transurethral resections from 65 
patients with BPH as controls; b) samples from 78 high-grade prostatic 
intraepithelial neoplasias (PIN) and c) 181 clinically localized 
prostate cancers from transurethral resections (T1a/b; <em>n</em> = 95) and radical prostatectomy specimens (pT2a–pT3b; <em>n</em>
 = 86); d) transurethral resections from 120 hormone-refractory local 
recurrences and e) 91 metastases collected at the autopsies from 
patients who had undergone androgen deprivation by orchiectomy and had 
subsequently died of end-stage metastatic prostate cancer. Metastatic 
tissues were from pelvic, paraaortal or mediastinal lymph nodes (<em>n</em> = 24), lung (<em>n</em> = 28), liver (<em>n</em> = 19), adrenal gland (<em>n</em> = 11), pleura (<em>n</em> = 4), kidney (<em>n</em> = 2), dura mater (<em>n</em> = 2) and ureter (<em>n</em> = 1).</p></div></div><div class="section" id="sec2-2"><h4>Construction of tissue microarrays</h4><div class="para"><p>The prostate tissue microarray was constructed as described.<a href="#bib9" rel="references:#bib9" class="referenceLink" title="Link to bibliographic citation" shape="rect">9</a>
 Briefly, 1 core tissue-biopsy (diameter 0.6 mm) was taken from the 
least differentiated region of individual paraffin-embedded prostate 
tumors (donor blocks) and precisely arrayed into a new recipient 
paraffin block (35 mm × 20 mm) with a semiautomated instrument. After 
the block construction was completed, 5 μm sections were cut with a 
microtome using an adhesive-coated tape sectioning system (Instrumedics,
 Hackensack, NJ) to support the adhesion of the array elements. The 
presence of tumor tissue on the arrayed samples was verified on a 
hematoxylin-eosin-stained section (Fig. <a href="#fig1" rel="references:#fig1" class="figureLink" title="Link to figure" shape="rect">1</a>).
 The number of samples varies slightly between the individual marker 
analyses because of variability in the number of interpretable specimens
 on TMA sections.</p></div><div class="figure hh" id="fig1"><div class="caption" id="fig1_caption"><p><span class="label">Figure&nbsp;1. </span>Prostate progression tissue microarray containing specimens from 470 tumors and 65 benign controls (hematoxylin-eosin staining).</p></div><a class="figZoom" title="Link to full-size figure" href="http://onlinelibrary.wiley.com/store/10.1002/ijc.20615/asset/image_n/nfig001.jpg?v=1&amp;t=gj17uspu&amp;s=9e4a470bd146f890824c3d697cf076215fee9584" shape="rect"><img id="fig1_img" alt="thumbnail image" src="2004%20Int%20J%20Cancer%20Zellweger_files/tfig001.gif"></a></div></div><div class="section" id="sec2-3"><h4>Immunohistochemistry</h4><div class="para"><p>TMA
 sections were used for immunohistochemical staining with 13 different 
antibodies. Standard indirect immunoperoxidase procedures (ABC-Elite, 
Vector Laboratories, Burlingame, CA) were used for detection of the 
secondary antibodies. The primary antibodies, their dilutions and 
pretreatment conditions are listed in Table <a href="#tbl2" rel="references:#tbl2" class="tableLink" title="Link to table" shape="rect">II</a>.
 Diaminobenzidine was used as a chromogen. The primary antibody was 
omitted for negative controls. All slides were read by 1 pathologist 
(L.B.). Nuclear Ki67 immunostaining was visually scored and stratified 
into 6 groups (negative, &gt;5%, 5–9%, 10–20%, 21–50%, and &gt;50%). A 
high Ki67 Labelling Index (LI) was defined as positivity in &gt;20% of 
the tumor cell nuclei. The intensity of immunostaining for all other 
proteins was visually scored and stratified into 4 groups (negative, 
weak, moderate and strong). As in previous studies, at least a moderate 
staining intensity was requested in &gt;10% of tumor cells within a 
tissue spot to define positivity.<a href="#bib33" rel="references:#bib33" class="referenceLink" title="Link to bibliographic citation" shape="rect">33</a>, <a href="#bib34" rel="references:#bib34" class="referenceLink" title="Link to bibliographic citation" shape="rect">34</a>, <a href="#bib35" rel="references:#bib35" class="referenceLink" title="Link to bibliographic citation" shape="rect">35</a>
 Heterogeneity of marker expression was usually low or absent on the 
individual TMA spots. Tumor samples without any reactivity for Ki67 LI 
were excluded from analysis because reduced immunoreactivity was 
assumed. In Bcl-2 analysis, lymphocytes and basal cells from admixed 
benign glands served as internal positive staining controls. For Ki67 
and p53 analysis, only nuclear staining was considered.</p></div><div class="table" id="tbl2"><table class="topbotR"><caption><span class="tTitle"><span class="label">Table&nbsp;II.&nbsp;</span>Antibodies and Antigen-Retrieval Techniques Applied<a href="#fn2" rel="references:#fn2" class="noteLink" title="Link to note" shape="rect">1</a></span></caption><thead class="vBottom"><tr class="rsep hCenter"><th rowspan="1" colspan="1">Protein (antibody)</th><th rowspan="1" colspan="1">Retrieval</th><th rowspan="1" colspan="1">Source</th><th rowspan="1" colspan="1">Dilution</th></tr></thead><tfoot><tr><td colspan="4" rowspan="1"><div class="noteGroup"><ul id="footnotes" class="noteGroup custom"><li id="fn2"><span class="bullet">1</span><div class="text"><p>For
 all proteins (except Ki67) positivity was defined as at least moderate 
staining intensity in &gt;10% of tumor cells. MW = microwave, PK = 
pressure cooker.</p></div></li></ul></div></td></tr></tfoot><tbody class="vTop"><tr class="norsep hLeft"><td rowspan="1" colspan="1">Bcl-2</td><td rowspan="1" colspan="1">MW, 98°C, 60 min</td><td rowspan="1" colspan="1">DAKO</td><td rowspan="1" colspan="1">1:400</td></tr><tr class="norsep hLeft"><td rowspan="1" colspan="1">CD-10</td><td rowspan="1" colspan="1">MW, 98°C, 60 min</td><td rowspan="1" colspan="1">Novocastra</td><td rowspan="1" colspan="1">1:50</td></tr><tr class="norsep hLeft"><td rowspan="1" colspan="1">CD-117</td><td rowspan="1" colspan="1">PK, 121°C, 5 min</td><td rowspan="1" colspan="1">DAKO</td><td rowspan="1" colspan="1">1:300</td></tr><tr class="norsep hLeft"><td rowspan="1" colspan="1">Epidermal Growth Factor Receptor (EGFR)</td><td rowspan="1" colspan="1">Pronase, 37°C, 30 min</td><td rowspan="1" colspan="1">Zymed</td><td rowspan="1" colspan="1">1.200</td></tr><tr class="norsep hLeft"><td rowspan="1" colspan="1">Epithelial Cellular Adhesion Molecule (EpCAM)</td><td rowspan="1" colspan="1">MW, 80°C, 30 min</td><td rowspan="1" colspan="1">Novocastra</td><td rowspan="1" colspan="1">1:800</td></tr><tr class="norsep hLeft"><td rowspan="1" colspan="1">HER2/neu</td><td rowspan="1" colspan="1">MW, 98°C, 60 min</td><td rowspan="1" colspan="1">DAKO</td><td rowspan="1" colspan="1">1:2000</td></tr><tr class="norsep hLeft"><td rowspan="1" colspan="1">Heat-shock Protein 90 (HSP90)</td><td rowspan="1" colspan="1">MW, 98°C, 60 min</td><td rowspan="1" colspan="1">Novocastra</td><td rowspan="1" colspan="1">1:400</td></tr><tr class="norsep hLeft"><td rowspan="1" colspan="1">Integrin-linked Kinase (ILK)</td><td rowspan="1" colspan="1">MW, 98°C, 60 min</td><td rowspan="1" colspan="1">Upstate Biotech.</td><td rowspan="1" colspan="1">1:3200</td></tr><tr class="norsep hLeft"><td rowspan="1" colspan="1">Ki67 (Mib1)</td><td rowspan="1" colspan="1">PK, 121°C, 5 min</td><td rowspan="1" colspan="1">DAKO</td><td rowspan="1" colspan="1">1:800</td></tr><tr class="norsep hLeft"><td rowspan="1" colspan="1">Matrix Metalloproteinase 2 (MMP-2)</td><td rowspan="1" colspan="1">MW, 98°C, 30 min</td><td rowspan="1" colspan="1">Neomarkers</td><td rowspan="1" colspan="1">1:200</td></tr><tr class="norsep hLeft"><td rowspan="1" colspan="1">Transmembrane Mucin 1 (MUC-1)</td><td rowspan="1" colspan="1">PK, 121°C, 5 min</td><td rowspan="1" colspan="1">Transgene</td><td rowspan="1" colspan="1">1:1800</td></tr><tr class="norsep hLeft"><td rowspan="1" colspan="1">p53</td><td rowspan="1" colspan="1">MW, 98°C, 60 min</td><td rowspan="1" colspan="1">DAKO</td><td rowspan="1" colspan="1">1:200</td></tr><tr class="norsep hLeft"><td rowspan="1" colspan="1">Syndecan-1</td><td rowspan="1" colspan="1">MW, 98°C, 60 min</td><td rowspan="1" colspan="1">DAKO</td><td rowspan="1" colspan="1">1:200</td></tr></tbody></table></div></div><div class="section" id="sec2-4"><h4>Statistical analysis</h4><div class="para"><p>Contingency
 table analysis and chi-square tests were used to study the relationship
 between the expression of different markers and histological subgroups.
 The levels of statistical significance were set at least at <em>p</em> &lt; 0.05 (2-sided), and all statistical calculations were performed using JMP 3.0 software (SAS Institute, Inc., Cary, NC).</p></div></div></div><div class="section" id="sec1-2"><div class="headingCont"><select style="visibility: visible; width: 238px;" class="jumpSelect"><option selected="selected" value="jumpTo">Jump to…</option><option value="#leftBorder">Top of page</option><option value="#abstract">Abstract</option><option value="#sec1-1">Material and methods</option><option value="#sec1-2">Results</option><option value="#sec1-3">Discussion</option><option value="#sec1-ack-1">Acknowledgements</option><option value="#wol-references">References</option></select><h3>Results</h3></div><ol style="display: none;" class="jumpList"><li><a href="#leftBorder" shape="rect">Top of page</a></li><li><a href="#abstract" shape="rect">Abstract</a></li><li><a href="#sec1-1" shape="rect">Material and methods</a></li><li><a href="#sec1-2" shape="rect">Results</a></li><li><a href="#sec1-3" shape="rect">Discussion</a></li><li><a href="#sec1-ack-1" shape="rect">Acknowledgements</a></li><li><a href="#wol-references" shape="rect">References</a></li></ol><div class="section" id="sec2-5"><h4>Histology</h4><div class="para"><p>Gleason grade, assessed in all prostate cancer tissue core specimens,<a href="#bib36" rel="references:#bib36" class="referenceLink" title="Link to bibliographic citation" shape="rect">36</a> was strongly associated with the stage of progression (Fig. <a href="#fig2" rel="references:#fig2" class="figureLink" title="Link to figure" shape="rect">2</a>, <em>p</em> &lt; 0.001).</p></div><div class="figure hh" id="fig2"><div class="caption" id="fig2_caption"><p><span class="label">Figure&nbsp;2. </span>Gleason grades in localized, hormone-resistant and metastatic prostate cancer (<em>p</em>
 &lt; 0.001). Loc.Pca, localized prostate cancer; HR Pca, 
hormone-refractory prostate cancer; Pca Metas, prostate cancer 
metastases.</p></div><a class="figZoom" title="Link to full-size figure" href="http://onlinelibrary.wiley.com/store/10.1002/ijc.20615/asset/image_n/nfig002.gif?v=1&amp;t=gj17usqa&amp;s=5d3467774ed5f1e7d92fc9bd0e80ee34b565d231" shape="rect"><img id="fig2_img" alt="thumbnail image" src="2004%20Int%20J%20Cancer%20Zellweger_files/tfig002.gif"></a></div></div><div class="section" id="sec2-6"><h4>Immunohistochemistry</h4><div class="para"><p>Representative examples of immunohistochemical staining of BPH, PIN and prostate cancer specimens are shown in Figure <a href="#fig3" rel="references:#fig3" class="figureLink" title="Link to figure" shape="rect">3</a>.
 A high Ki67 Labelling Index (LI) (&gt;20%) was found in most 
hormone-refractory and metastatic prostate cancers as compared to BPH, 
PIN and localized prostate cancer (<em>p</em> &lt; 0.001). A high Ki67 LI was significantly associated with recurrent and metastatic disease and high Gleason Grade (<em>p</em> &lt; 0.0001; Fig. <a href="#fig4" rel="references:#fig4" class="figureLink" title="Link to figure" shape="rect">4</a><em>a</em>).</p></div><div class="figure hh" id="fig3"><div class="caption" id="fig3_caption"><p><span class="label">Figure&nbsp;3. </span>Representative immunostainings (×400): (<em>a</em>) p53, (<em>b</em>) Bcl-2, PIN, (<em>c</em>) Bcl-2 negative prostate cancer (Pca) with lymphocytes as positive internal control, (<em>d</em>) Bcl-2 positive Pca. (<em>e</em>) Pca's positive for CD-138 (Syndecan), (<em>f</em>) HER2/neu, (<em>g</em>) EGFR, (<em>h</em>) Ep-CAM. (<em>i</em>) MMP-2 negative Pca with endothelial cells as internal positive control, (<em>j</em>) MMP-2 positive Pca. Pca's positive for (<em>k</em>) MUC-1, (<em>l</em>) HSP-90, (<em>m</em>) ILK, (<em>n</em>) CD-10 and (<em>o</em>) CD-117.</p></div><a class="figZoom" title="Link to full-size figure" href="http://onlinelibrary.wiley.com/store/10.1002/ijc.20615/asset/image_n/nfig003.jpg?v=1&amp;t=gj17usqf&amp;s=44d4d96840919d0e93651b01854c6730c95435c3" shape="rect"><img id="fig3_img" alt="thumbnail image" src="2004%20Int%20J%20Cancer%20Zellweger_files/tfig003.gif"></a></div><div class="figure hh" id="fig4"><div class="caption" id="fig4_caption"><p><span class="label">Figure&nbsp;4. </span>(<em>a</em>,<em>b</em>)
 Growth fraction (Ki67 Labelling Index) and expression profiles of 
candidate markers in BPH, PIN and across prostate cancer progression. A 
Ki67 LI &gt; 20% was defined as high. For the other markers, positivity 
was defined as at least moderate staining intensity in &gt;10% of the 
tumor cells. BPH = benign prostatic hyperplasia, PIN, high-grade 
prostatic intraepithelial neoplasia; Loc. Pca, localized prostate 
cancer; HR Pca, hormone-refractory prostate cancer; Pca Metas, prostate 
cancer metastases. Note that that for better visualization, scales in (<em>b</em>) have been changed to a maximum of 50% on the y-axis.</p></div><a class="figZoom" title="Link to full-size figure" href="http://onlinelibrary.wiley.com/store/10.1002/ijc.20615/asset/image_n/nfig004.gif?v=1&amp;t=gj17usqi&amp;s=dc2c2cb4a6a273aab96e5e01da552225409cc1bf" shape="rect"><img id="fig4_img" alt="thumbnail image" src="2004%20Int%20J%20Cancer%20Zellweger_files/tfig004.gif"></a></div><div class="para"><p>The
 expression profiles of all analyzed candidate markers in BPH, PIN and 
across prostate cancer progression are shown in Figure <a href="#fig4" rel="references:#fig4" class="figureLink" title="Link to figure" shape="rect">4</a><em>a</em>,<em>b</em>
 (except for CD-117). Significant overexpression in hormone-refractory 
prostate cancer and metastatic tissue compared to localized prostate 
cancer was found for Ki67 (64% <em>vs</em>. 9%), p53 (35% <em>vs</em>. 4%), Bcl-2 (11% <em>vs</em>. 1%), Syndecan-1 (38% <em>vs</em>. 3%), EGFR (16% <em>vs</em>. 1%) and HER2/neu (16% <em>vs</em>. 0%). Expression of these proteins was significantly associated with both high Gleason grade and high KI67 LI (<em>p</em> &lt; 0.01; Tables <a href="#tbl3" rel="references:#tbl3" class="tableLink" title="Link to table" shape="rect">III</a> and <a href="#tbl4" rel="references:#tbl4" class="tableLink" title="Link to table" shape="rect">IV</a>). The expression levels of p53, Bcl-2 and Syndecan-1 were significantly associated with each other (<em>p</em>
 &lt; 0.05, data not shown). There was a higher prevalence of Bcl-2 
expression in PIN lesions as compared to localized prostate cancers 
(13.3 <em>vs</em>. 1.3%, <em>p</em> &lt; 0.05) as previously shown by other authors.<a href="#bib37" rel="references:#bib37" class="referenceLink" title="Link to bibliographic citation" shape="rect">37</a>, <a href="#bib38" rel="references:#bib38" class="referenceLink" title="Link to bibliographic citation" shape="rect">38</a></p></div><div class="table" id="tbl3"><table class="topbotR"><caption><span class="tTitle"><span class="label">Table&nbsp;III.&nbsp;</span>Association Between Protein Expression and Gleason Grades</span></caption><thead class="vBottom"><tr class="rsep hCenter"><th rowspan="1" colspan="1">Protein</th><th rowspan="1" colspan="1">Gleason 2</th><th rowspan="1" colspan="1">Gleason 3</th><th rowspan="1" colspan="1">Gleason 4</th><th rowspan="1" colspan="1">Gleason 5</th><th rowspan="1" colspan="1"><em>p</em>-value</th></tr></thead><tbody class="vTop"><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">Bcl-2 pos (<em>n</em> = 16)</td><td class="hChar" rowspan="1" colspan="1">0</td><td class="hChar" rowspan="1" colspan="1">0</td><td class="hChar" rowspan="1" colspan="1">4</td><td class="hChar" rowspan="1" colspan="1">12</td><td class="hChar" rowspan="1" colspan="1">0.0017</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">Bcl-2 neg (<em>n</em> = 201)</td><td class="hChar" rowspan="1" colspan="1">14</td><td class="hChar" rowspan="1" colspan="1">3</td><td class="hChar" rowspan="1" colspan="1">79</td><td class="hChar" rowspan="1" colspan="1">105</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">CD-10 pos (<em>n</em> = 116)</td><td class="hChar" rowspan="1" colspan="1">7</td><td class="hChar" rowspan="1" colspan="1">29</td><td class="hChar" rowspan="1" colspan="1">33</td><td class="hChar" rowspan="1" colspan="1">47</td><td class="hChar" rowspan="1" colspan="1">0.2</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">CD-10 neg (<em>n</em> = 160)</td><td class="hChar" rowspan="1" colspan="1">5</td><td class="hChar" rowspan="1" colspan="1">50</td><td class="hChar" rowspan="1" colspan="1">44</td><td class="hChar" rowspan="1" colspan="1">61</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">CD-117 pos (<em>n</em> = 1)</td><td class="hChar" rowspan="1" colspan="1">0</td><td class="hChar" rowspan="1" colspan="1">0</td><td class="hChar" rowspan="1" colspan="1">1</td><td class="hChar" rowspan="1" colspan="1">0</td><td class="hChar" rowspan="1" colspan="1">0.45</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">CD-117 neg (<em>n</em> = 292)</td><td class="hChar" rowspan="1" colspan="1">14</td><td class="hChar" rowspan="1" colspan="1">85</td><td class="hChar" rowspan="1" colspan="1">78</td><td class="hChar" rowspan="1" colspan="1">115</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">EGFR pos (<em>n</em> = 25)</td><td class="hChar" rowspan="1" colspan="1">0</td><td class="hChar" rowspan="1" colspan="1">1</td><td class="hChar" rowspan="1" colspan="1">7</td><td class="hChar" rowspan="1" colspan="1">17</td><td class="hChar" rowspan="1" colspan="1">0.000001</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">EGFR neg (<em>n</em> = 253)</td><td class="hChar" rowspan="1" colspan="1">14</td><td class="hChar" rowspan="1" colspan="1">82</td><td class="hChar" rowspan="1" colspan="1">69</td><td class="hChar" rowspan="1" colspan="1">88</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">EpCAM pos (<em>n</em> = 265)</td><td class="hChar" rowspan="1" colspan="1">13</td><td class="hChar" rowspan="1" colspan="1">79</td><td class="hChar" rowspan="1" colspan="1">79</td><td class="hChar" rowspan="1" colspan="1">94</td><td class="hChar" rowspan="1" colspan="1">0.000001</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">EpCAM neg (<em>n</em> = 29)</td><td class="hChar" rowspan="1" colspan="1">0</td><td class="hChar" rowspan="1" colspan="1">3</td><td class="hChar" rowspan="1" colspan="1">4</td><td class="hChar" rowspan="1" colspan="1">22</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">HER2/neu pos (<em>n</em> = 15)</td><td class="hChar" rowspan="1" colspan="1">0</td><td class="hChar" rowspan="1" colspan="1">0</td><td class="hChar" rowspan="1" colspan="1">9</td><td class="hChar" rowspan="1" colspan="1">6</td><td class="hChar" rowspan="1" colspan="1">0.0007</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">HER2/neu neg (<em>n</em> = 294)</td><td class="hChar" rowspan="1" colspan="1">11</td><td class="hChar" rowspan="1" colspan="1">77</td><td class="hChar" rowspan="1" colspan="1">67</td><td class="hChar" rowspan="1" colspan="1">94</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">HSP 90 pos (<em>n</em> = 211)</td><td class="hChar" rowspan="1" colspan="1">4</td><td class="hChar" rowspan="1" colspan="1">62</td><td class="hChar" rowspan="1" colspan="1">53</td><td class="hChar" rowspan="1" colspan="1">92</td><td class="hChar" rowspan="1" colspan="1">0.000001</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">HSP 90 neg (<em>n</em> = 32)</td><td class="hChar" rowspan="1" colspan="1">5</td><td class="hChar" rowspan="1" colspan="1">11</td><td class="hChar" rowspan="1" colspan="1">10</td><td class="hChar" rowspan="1" colspan="1">6</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">ILK pos (<em>n</em> = 113)</td><td class="hChar" rowspan="1" colspan="1">0</td><td class="hChar" rowspan="1" colspan="1">37</td><td class="hChar" rowspan="1" colspan="1">36</td><td class="hChar" rowspan="1" colspan="1">40</td><td class="hChar" rowspan="1" colspan="1">0.0036</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">ILK neg (<em>n</em> = 126)</td><td class="hChar" rowspan="1" colspan="1">8</td><td class="hChar" rowspan="1" colspan="1">33</td><td class="hChar" rowspan="1" colspan="1">30</td><td class="hChar" rowspan="1" colspan="1">55</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">Ki67 high (<em>n</em> = 42)</td><td class="hChar" rowspan="1" colspan="1">0</td><td class="hChar" rowspan="1" colspan="1">0</td><td class="hChar" rowspan="1" colspan="1">2</td><td class="hChar" rowspan="1" colspan="1">40</td><td class="hChar" rowspan="1" colspan="1">0.000001</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">Ki67 low (<em>n</em> = 171)</td><td class="hChar" rowspan="1" colspan="1">12</td><td class="hChar" rowspan="1" colspan="1">75</td><td class="hChar" rowspan="1" colspan="1">44</td><td class="hChar" rowspan="1" colspan="1">40</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">MMP-2 pos (<em>n</em> = 157)</td><td class="hChar" rowspan="1" colspan="1">5</td><td class="hChar" rowspan="1" colspan="1">51</td><td class="hChar" rowspan="1" colspan="1">48</td><td class="hChar" rowspan="1" colspan="1">53</td><td class="hChar" rowspan="1" colspan="1">0.000001</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">MMP-2 neg (<em>n</em> = 122)</td><td class="hChar" rowspan="1" colspan="1">8</td><td class="hChar" rowspan="1" colspan="1">29</td><td class="hChar" rowspan="1" colspan="1">28</td><td class="hChar" rowspan="1" colspan="1">57</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">MUC-1 pos (<em>n</em> = 108)</td><td class="hChar" rowspan="1" colspan="1">2</td><td class="hChar" rowspan="1" colspan="1">28</td><td class="hChar" rowspan="1" colspan="1">35</td><td class="hChar" rowspan="1" colspan="1">43</td><td class="hChar" rowspan="1" colspan="1">0.0008</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">MUC-1 neg (<em>n</em> = 148)</td><td class="hChar" rowspan="1" colspan="1">8</td><td class="hChar" rowspan="1" colspan="1">44</td><td class="hChar" rowspan="1" colspan="1">37</td><td class="hChar" rowspan="1" colspan="1">59</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">P53 pos (<em>n</em> = 46)</td><td class="hChar" rowspan="1" colspan="1">0</td><td class="hChar" rowspan="1" colspan="1">1</td><td class="hChar" rowspan="1" colspan="1">8</td><td class="hChar" rowspan="1" colspan="1">37</td><td class="hChar" rowspan="1" colspan="1">0.00001</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">P53 neg (<em>n</em> = 241)</td><td class="hChar" rowspan="1" colspan="1">13</td><td class="hChar" rowspan="1" colspan="1">79</td><td class="hChar" rowspan="1" colspan="1">70</td><td class="hChar" rowspan="1" colspan="1">79</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">Syndecan-1 pos (<em>n</em> = 41)</td><td class="hChar" rowspan="1" colspan="1">0</td><td class="hChar" rowspan="1" colspan="1">2</td><td class="hChar" rowspan="1" colspan="1">12</td><td class="hChar" rowspan="1" colspan="1">27</td><td class="hChar" rowspan="1" colspan="1">0.000001</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">Syndecan-1 neg (<em>n</em> = 245)</td><td class="hChar" rowspan="1" colspan="1">14</td><td class="hChar" rowspan="1" colspan="1">81</td><td class="hChar" rowspan="1" colspan="1">67</td><td class="hChar" rowspan="1" colspan="1">83</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td></tr></tbody></table></div><div class="table" id="tbl4"><table class="topbotR"><caption><span class="tTitle"><span class="label">Table&nbsp;IV.&nbsp;</span>Association Between Protein Expression Levels (POS/NEG) and Ki67 LI (LOW/HIGH)</span></caption><thead class="vBottom"><tr class="rsep hCenter"><th rowspan="1" colspan="1">Protein</th><th rowspan="1" colspan="1">Low Ki67 LI (0–20% pos. cells)</th><th rowspan="1" colspan="1">High Ki67 LI (21–100% pos. cells)</th><th rowspan="1" colspan="1"><em>p</em>-value</th></tr></thead><tbody class="vTop"><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">Bcl-2 pos (<em>n</em> = 27)</td><td class="hChar" rowspan="1" colspan="1">19</td><td class="hChar" rowspan="1" colspan="1">8</td><td class="hChar" rowspan="1" colspan="1">0.001</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">Bcl-2 neg (<em>n</em> = 390)</td><td class="hChar" rowspan="1" colspan="1">353</td><td class="hChar" rowspan="1" colspan="1">37</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">CD10 pos (<em>n</em> = 204)</td><td class="hChar" rowspan="1" colspan="1">184</td><td class="hChar" rowspan="1" colspan="1">20</td><td class="hChar" rowspan="1" colspan="1">0.09</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">CD10 neg (<em>n</em> = 178)</td><td class="hChar" rowspan="1" colspan="1">155</td><td class="hChar" rowspan="1" colspan="1">23</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">CD117 pos (<em>n</em> = 1)</td><td class="hChar" rowspan="1" colspan="1">1</td><td class="hChar" rowspan="1" colspan="1">0</td><td class="hChar" rowspan="1" colspan="1">0.4</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">CD117 neg (<em>n</em> = 395)</td><td class="hChar" rowspan="1" colspan="1">350</td><td class="hChar" rowspan="1" colspan="1">45</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">EGFR pos (<em>n</em> = 26)</td><td class="hChar" rowspan="1" colspan="1">17</td><td class="hChar" rowspan="1" colspan="1">9</td><td class="hChar" rowspan="1" colspan="1">0.0013</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">EGFR neg (<em>n</em> = 361)</td><td class="hChar" rowspan="1" colspan="1">328</td><td class="hChar" rowspan="1" colspan="1">33</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">EpCAM pos (<em>n</em> = 338)</td><td class="hChar" rowspan="1" colspan="1">299</td><td class="hChar" rowspan="1" colspan="1">39</td><td class="hChar" rowspan="1" colspan="1">0.27</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">EpCAM neg (<em>n</em> = 57)</td><td class="hChar" rowspan="1" colspan="1">51</td><td class="hChar" rowspan="1" colspan="1">6</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">HER2/neu pos (<em>n</em> = 14)</td><td class="hChar" rowspan="1" colspan="1">13</td><td class="hChar" rowspan="1" colspan="1">1</td><td class="hChar" rowspan="1" colspan="1">0.225</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">HER2/neu neg (<em>n</em> = 353)</td><td class="hChar" rowspan="1" colspan="1">312</td><td class="hChar" rowspan="1" colspan="1">41</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">HSP90 pos (<em>n</em> = 280)</td><td class="hChar" rowspan="1" colspan="1">238</td><td class="hChar" rowspan="1" colspan="1">42</td><td class="hChar" rowspan="1" colspan="1">0.000001</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">HSP90 neg (<em>n</em> = 60)</td><td class="hChar" rowspan="1" colspan="1">60</td><td class="hChar" rowspan="1" colspan="1">0</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">ILK pos (<em>n</em> = 131)</td><td class="hChar" rowspan="1" colspan="1">110</td><td class="hChar" rowspan="1" colspan="1">21</td><td class="hChar" rowspan="1" colspan="1">0.22</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">ILK neg (<em>n</em> = 205)</td><td class="hChar" rowspan="1" colspan="1">183</td><td class="hChar" rowspan="1" colspan="1">22</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">MMP-2 pos (<em>n</em> = 196)</td><td class="hChar" rowspan="1" colspan="1">178</td><td class="hChar" rowspan="1" colspan="1">18</td><td class="hChar" rowspan="1" colspan="1">0.36</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">MMP-2 neg (<em>n</em> = 190)</td><td class="hChar" rowspan="1" colspan="1">164</td><td class="hChar" rowspan="1" colspan="1">26</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">MUC1 pos (<em>n</em> = 128)</td><td class="hChar" rowspan="1" colspan="1">110</td><td class="hChar" rowspan="1" colspan="1">18</td><td class="hChar" rowspan="1" colspan="1">0.1</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">MUC1 neg (<em>n</em> = 229)</td><td class="hChar" rowspan="1" colspan="1">204</td><td class="hChar" rowspan="1" colspan="1">25</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">P53 pos (<em>n</em> = 55)</td><td class="hChar" rowspan="1" colspan="1">36</td><td class="hChar" rowspan="1" colspan="1">19</td><td class="hChar" rowspan="1" colspan="1">0.000001</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">P53 neg (<em>n</em> = 348)</td><td class="hChar" rowspan="1" colspan="1">322</td><td class="hChar" rowspan="1" colspan="1">26</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">Syndecan-1 pos (<em>n</em> = 49)</td><td class="hChar" rowspan="1" colspan="1">36</td><td class="hChar" rowspan="1" colspan="1">13</td><td class="hChar" rowspan="1" colspan="1">0.000001</td></tr><tr class="norsep"><td class="hLeft" rowspan="1" colspan="1">Syndecan-1 neg (<em>n</em> = 344)</td><td class="hChar" rowspan="1" colspan="1">313</td><td class="hChar" rowspan="1" colspan="1">31</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td></tr></tbody></table></div><div class="para"><p>Ep-CAM
 and HSP-90 were also significantly overexpressed in high-grade PIN and 
prostate cancer as compared to BPH, consistent with previous reports.<a href="#bib39" rel="references:#bib39" class="referenceLink" title="Link to bibliographic citation" shape="rect">39</a>, <a href="#bib40" rel="references:#bib40" class="referenceLink" title="Link to bibliographic citation" shape="rect">40</a>
 No evident variability of expression was seen for both proteins across 
various stages of prostate cancer progression. Similar expression 
profiles were found for ILK and MMP-2. Overexpression of these proteins 
was rare (MMP-2) or absent (ILK) in benign prostatic glands, with a 
marked increase of expression in high-grade PIN and prostate cancer. 
However, there was no significant increase of ILK or MMP-2 expression 
with the stage of prostate cancer progression. MUC-1 tended to become 
gradually more expressed from benign to premalignant and malignant 
tissue samples (<em>p</em> &gt; 0.05.).</p></div><div class="para"><p>The
 expression profile of CD-10 (neutral endopeptidase) differed from the 
other marker profiles in this study. CD-10 was overexpressed in all BPH 
samples and approximately half of the PIN and prostate cancer samples 
with no significant difference between hormone-refractory and metastatic
 prostate cancers as compared to androgen-dependent localized tumors. 
CD-117 (c-kit tyrosine phosphatase) expression was found in 1 single 
distant metastasis but not in any other specimen. The reactivity of this
 antibody was verified in mast cells serving as internal controls.</p></div></div></div><div class="section" id="sec1-3"><div class="headingCont"><select style="visibility: visible; width: 238px;" class="jumpSelect"><option selected="selected" value="jumpTo">Jump to…</option><option value="#leftBorder">Top of page</option><option value="#abstract">Abstract</option><option value="#sec1-1">Material and methods</option><option value="#sec1-2">Results</option><option value="#sec1-3">Discussion</option><option value="#sec1-ack-1">Acknowledgements</option><option value="#wol-references">References</option></select><h3>Discussion</h3></div><ol style="display: none;" class="jumpList"><li><a href="#leftBorder" shape="rect">Top of page</a></li><li><a href="#abstract" shape="rect">Abstract</a></li><li><a href="#sec1-1" shape="rect">Material and methods</a></li><li><a href="#sec1-2" shape="rect">Results</a></li><li><a href="#sec1-3" shape="rect">Discussion</a></li><li><a href="#sec1-ack-1" shape="rect">Acknowledgements</a></li><li><a href="#wol-references" shape="rect">References</a></li></ol><div class="para"><p>TMA technology is a powerful tool for rapid testing of molecular markers in hundreds of tumors in a single experiment.<a href="#bib9" rel="references:#bib9" class="referenceLink" title="Link to bibliographic citation" shape="rect">9</a>, <a href="#bib10" rel="references:#bib10" class="referenceLink" title="Link to bibliographic citation" shape="rect">10</a>
 Previous studies from our laboratory have shown that the analysis of 1 
minute tissue sample (diameter 0.6 mm) per tumor provides highly 
representative epidemiologic information.<a href="#bib41" rel="references:#bib41" class="referenceLink" title="Link to bibliographic citation" shape="rect">41</a>
 The strong confirmation of the previously known association of high 
expression levels of Ki67, Bcl-2 and p53 with advanced prostate cancer 
stage<a href="#bib42" rel="references:#bib42" class="referenceLink" title="Link to bibliographic citation" shape="rect">42</a>, <a href="#bib43" rel="references:#bib43" class="referenceLink" title="Link to bibliographic citation" shape="rect">43</a>, <a href="#bib44" rel="references:#bib44" class="referenceLink" title="Link to bibliographic citation" shape="rect">44</a>, <a href="#bib45" rel="references:#bib45" class="referenceLink" title="Link to bibliographic citation" shape="rect">45</a>
 provide again strong support for our experimental approach for the 
identification of progression associated markers in our study.</p></div><div class="para"><p>This
 project was focused on potential and established therapeutic targets, 
several of which have previously not been examined in a large number of 
prostate cancers. A significant overexpression in hormone-refractory and
 metastatic tissue as compared to localized prostate cancer was found 
for p53, Bcl-2, Syndecan-1, EGFR and HER2/neu. Except for Syndecan-1, 
which has previously not been analyzed in advanced prostate cancers, 
these results confirm earlier findings from smaller cohorts.<a href="#bib46" rel="references:#bib46" class="referenceLink" title="Link to bibliographic citation" shape="rect">46</a>, <a href="#bib47" rel="references:#bib47" class="referenceLink" title="Link to bibliographic citation" shape="rect">47</a>, <a href="#bib48" rel="references:#bib48" class="referenceLink" title="Link to bibliographic citation" shape="rect">48</a>, <a href="#bib49" rel="references:#bib49" class="referenceLink" title="Link to bibliographic citation" shape="rect">49</a>, <a href="#bib50" rel="references:#bib50" class="referenceLink" title="Link to bibliographic citation" shape="rect">50</a>
 Our data add a further argument to the growing evidence that these 
proteins may contribute to the progression to late-stage, prostate 
cancer and encourage further experimental and clinical trials aiming at 
their inhibition. The low prevalence of Bcl-2 overexpression in 105 
hormone-refractory cancers (10.5%) conflicts with the results from 2 
other studies where Bcl-2 overexpression was reported in almost 100% of 
small series of hormone-refractory prostate cancers.<a href="#bib48" rel="references:#bib48" class="referenceLink" title="Link to bibliographic citation" shape="rect">48</a>, <a href="#bib51" rel="references:#bib51" class="referenceLink" title="Link to bibliographic citation" shape="rect">51</a>
 The reasons for this striking difference remains unclear. Most likely 
it is due to differences in the experimental conditions or cut-offs 
used. The paramount influence of experimental conditions on the reported
 prevalences of immunohistochemical Bcl-2 expression is illustrated by 
variations described from 46–81% in breast cancer,<a href="#bib52" rel="references:#bib52" class="referenceLink" title="Link to bibliographic citation" shape="rect">52</a>, <a href="#bib53" rel="references:#bib53" class="referenceLink" title="Link to bibliographic citation" shape="rect">53</a> 15–59% in squamous cell carcinoma of the lung<a href="#bib54" rel="references:#bib54" class="referenceLink" title="Link to bibliographic citation" shape="rect">54</a>, <a href="#bib55" rel="references:#bib55" class="referenceLink" title="Link to bibliographic citation" shape="rect">55</a> and 2–38% in clinically localized prostate cancers.<a href="#bib56" rel="references:#bib56" class="referenceLink" title="Link to bibliographic citation" shape="rect">56</a>, <a href="#bib57" rel="references:#bib57" class="referenceLink" title="Link to bibliographic citation" shape="rect">57</a>
 It is unlikely that a sampling error due to the TMA approach is 
responsible for the low incidence of positive cases in our study. Also 
in our routine diagnostic prostate core needle biopsy specimens less 
than 5% of the prostate cancers are Bcl-2 positive (own unpublished 
data). A proper immunohistochemical reaction in our study was confirmed 
by the presence of Bcl-2 positive lymphocytes or basal cells from 
adjacent benign glands, which were present in most of TMA specimens. Our
 data suggest that response to therapies directed against Bcl-2 can only
 be expected in a minor fraction of hormone-refractory prostate cancers.</p></div><div class="para"><p>The
 preferential overexpression of HER2/neu in hormone-refractory and 
metastatic prostate cancers is in accordance with previous 
immunohistochemical studies and supports experimental evidence, 
suggesting that HER2/neu might be involved in hormone-refractory growth 
of prostate cancer.<a href="#bib49" rel="references:#bib49" class="referenceLink" title="Link to bibliographic citation" shape="rect">49</a>, <a href="#bib50" rel="references:#bib50" class="referenceLink" title="Link to bibliographic citation" shape="rect">50</a>, <a href="#bib58" rel="references:#bib58" class="referenceLink" title="Link to bibliographic citation" shape="rect">58</a>
 Accordingly, HER2/neu overexpression has been implicated in the ligand 
independent activation of the androgen receptor and in the development 
of hormone-refractory tumor growth <em>in vitro</em>.<a href="#bib50" rel="references:#bib50" class="referenceLink" title="Link to bibliographic citation" shape="rect">50</a>, <a href="#bib59" rel="references:#bib59" class="referenceLink" title="Link to bibliographic citation" shape="rect">59</a>, <a href="#bib60" rel="references:#bib60" class="referenceLink" title="Link to bibliographic citation" shape="rect">60</a>
 However, treatment with the anti-HER2/neu antibody trastuzumab 
(Herceptin®), which is efficient in breast cancers with 
amplification-driven HER2/neu overexpression,<a href="#bib61" rel="references:#bib61" class="referenceLink" title="Link to bibliographic citation" shape="rect">61</a>
 has failed in advanced prostate cancers despite experimental evidence 
of favorable response of prostate cancer xenograft models.<a href="#bib8" rel="references:#bib8" class="referenceLink" title="Link to bibliographic citation" shape="rect">8</a>, <a href="#bib62" rel="references:#bib62" class="referenceLink" title="Link to bibliographic citation" shape="rect">62</a>
 The reasons for treatment failure of Herceptin® in advanced prostate 
cancer is not entirely clear. It might be explained be the lack of 
HER2/neu gene amplification in prostate cancer<a href="#bib63" rel="references:#bib63" class="referenceLink" title="Link to bibliographic citation" shape="rect">63</a>, <a href="#bib64" rel="references:#bib64" class="referenceLink" title="Link to bibliographic citation" shape="rect">64</a> and the low prevalence of HER2/neu overexpression, when the standardized Hercep-Test® kit to predict therapy response is used.<a href="#bib65" rel="references:#bib65" class="referenceLink" title="Link to bibliographic citation" shape="rect">65</a>
 In the absence of gene HER2/neu amplification, protein expression may 
not reach the high levels that are required for response to Herceptin® 
therapy. The broad range of HER2/neu overexpression in prostate cancer 
reported in the literature may be due to technical factors such as 
different antibodies, protocols, fixations and different scoring 
procedures.<a href="#bib58" rel="references:#bib58" class="referenceLink" title="Link to bibliographic citation" shape="rect">58</a>, <a href="#bib66" rel="references:#bib66" class="referenceLink" title="Link to bibliographic citation" shape="rect">66</a></p></div><div class="para"><p>EGFR,
 another member of the transmembrane tyrosine kinase receptor family, 
revealed a similar expression pattern as HER2/neu. In preclinical 
studies, ZD1839 (Iressa®, AstraZeneca Pharmaceuticals, Macclesfield, 
UK), a selective inhibitor of epidermal growth factor receptor-tyrosine 
kinase, produced growth inhibition in a wide variety of common solid 
tumor types including human prostate tumor xenografts.<a href="#bib17" rel="references:#bib17" class="referenceLink" title="Link to bibliographic citation" shape="rect">17</a>, <a href="#bib67" rel="references:#bib67" class="referenceLink" title="Link to bibliographic citation" shape="rect">67</a>, <a href="#bib68" rel="references:#bib68" class="referenceLink" title="Link to bibliographic citation" shape="rect">68</a>
 Early results from clinical phase I trials in patients with advanced 
prostate cancers suggest that ZD 1839 offers an acceptable tolerability 
profile and promising clinical efficacy.<a href="#bib69" rel="references:#bib69" class="referenceLink" title="Link to bibliographic citation" shape="rect">69</a>, <a href="#bib70" rel="references:#bib70" class="referenceLink" title="Link to bibliographic citation" shape="rect">70</a>
 Most recent studies in nonsmall cell lung cancers suggest that 
activating EGFR mutations can predict the sensitivity to ZD 1839.<a href="#bib71" rel="references:#bib71" class="referenceLink" title="Link to bibliographic citation" shape="rect">71</a>, <a href="#bib72" rel="references:#bib72" class="referenceLink" title="Link to bibliographic citation" shape="rect">72</a>
 Further studies are needed to investigate whether such mutations of the
 EGFR gene are also present in a subgroup of advanced prostate cancers.</p></div><div class="para"><p>Overexpression
 of syndecan-1 in recurrent hormone refractory prostate cancer confirms 
previous results from DNA microarray studies in the CWR22 xenograft 
model system where syndecan-1 was strongly upregulated in the 
hormone-refractory xenograft CWR22R as compared to the hormone-sensitive
 parent tumor CWR22.<a href="#bib73" rel="references:#bib73" class="referenceLink" title="Link to bibliographic citation" shape="rect">73</a>
 We recently found a prognostic importance for Syndecan-1 in prostate 
cancers from 551 patients with clinical long-time follow-up information.<a href="#bib35" rel="references:#bib35" class="referenceLink" title="Link to bibliographic citation" shape="rect">35</a> Syndecan-1 (CD-138) binds to various matrix proteins and to a large number of heparin-binding polypeptide growth factors.<a href="#bib74" rel="references:#bib74" class="referenceLink" title="Link to bibliographic citation" shape="rect">74</a>, <a href="#bib75" rel="references:#bib75" class="referenceLink" title="Link to bibliographic citation" shape="rect">75</a>, <a href="#bib76" rel="references:#bib76" class="referenceLink" title="Link to bibliographic citation" shape="rect">76</a>
 Syndecan-1 might contribute to prostate cancer progression by providing
 heparan sulfate chains to both fibroblast growth factor receptor-1 
(FGFR1)- and FGFR2-signaling complexes.<a href="#bib77" rel="references:#bib77" class="referenceLink" title="Link to bibliographic citation" shape="rect">77</a>
 Recent experiments show that coating myeloma cells with anti-Syndecan-1
 antibodies promotes cross-presentation of cellular antigens by 
dendritic cells to autologous T cells from healthy donors, thereby 
offering one possible strategy for immunotherapy.<a href="#bib32" rel="references:#bib32" class="referenceLink" title="Link to bibliographic citation" shape="rect">32</a></p></div><div class="para"><p>Proteins
 with enhanced expression in advanced stages are preferable therapeutic 
targets, since the abortion of their progression promoting properties 
may lead to regression or inhibit tumor growth. However, also proteins 
that were not directly associated with progression in this study such as
 MUC-1, ILK, HSP-90, MMP-2, CD-10 and Ep-CAM could be of therapeutic 
interest, as they might still be part of critical pathways sustaining a 
basic level of tumor growth. Expression of human MUC-1 (urinary mucin 
1), a membrane bound glycoprotein, slowly but gradually increased from 
BPH to PIN and throughout the various stages of prostate cancer. MUC-1 
overexpression in cancer cells interferes with cell adhesion and shields
 the tumor cell from immune recognition, thus favoring tumor progression
 and development of metastases.<a href="#bib78" rel="references:#bib78" class="referenceLink" title="Link to bibliographic citation" shape="rect">78</a>
 It has previously been suggested that overexpression of MUC-1 
correlated with higher Gleason grades and advanced pathologic stage.<a href="#bib79" rel="references:#bib79" class="referenceLink" title="Link to bibliographic citation" shape="rect">79</a>
 Several clinical phase I/II trials were recently announced using 
interleukin-2 based vaccines targeting the MUC-1 peptide for the 
treatment of recurrent or progressive prostate cancer.<a href="#bib80" rel="references:#bib80" class="referenceLink" title="Link to bibliographic citation" shape="rect">80</a>, <a href="#bib81" rel="references:#bib81" class="referenceLink" title="Link to bibliographic citation" shape="rect">81</a></p></div><div class="para"><p>As
 previously suggested, overexpression of integrin-linked kinase (ILK) 
was restricted to high-grade PIN and invasive cancer but did not occur 
in benign prostatic hyperplasia.<a href="#bib82" rel="references:#bib82" class="referenceLink" title="Link to bibliographic citation" shape="rect">82</a>
 This is in accordance with earlier experimental evidence indicating 
that ILK might act as a proto-oncogene by inducing tumorigenicity of 
epithelial cells in nude mice.<a href="#bib83" rel="references:#bib83" class="referenceLink" title="Link to bibliographic citation" shape="rect">83</a>
 In prostate cancer, ILK is negatively regulated by the tumor suppressor
 PTEN and has been shown to be upregulated in tumors with PTEN mutation,
 which frequently occurs in late-stage prostate cancers.<a href="#bib84" rel="references:#bib84" class="referenceLink" title="Link to bibliographic citation" shape="rect">84</a>, <a href="#bib85" rel="references:#bib85" class="referenceLink" title="Link to bibliographic citation" shape="rect">85</a>
 ILK is therefore being considered as a promising therapeutic target in 
tumors with PTEN mutations, and selective small molecule inhibitors of 
ILK have been developed.<a href="#bib25" rel="references:#bib25" class="referenceLink" title="Link to bibliographic citation" shape="rect">25</a>
 ILK is also involved in the Wnt-1 signaling pathway, leading to 
stabilization of beta-catenin and enhanced gene transcription, which is a
 critical early mechanism of colorectal carcinogenesis.<a href="#bib24" rel="references:#bib24" class="referenceLink" title="Link to bibliographic citation" shape="rect">24</a>, <a href="#bib86" rel="references:#bib86" class="referenceLink" title="Link to bibliographic citation" shape="rect">86</a>
 Interestingly, the nonsteroidal anti-inflammatory drugs acetylsalicylic
 acid and sulindac have been shown to inhibit ILK signaling in the colon
 carcinoma cell line Caco-2.<a href="#bib24" rel="references:#bib24" class="referenceLink" title="Link to bibliographic citation" shape="rect">24</a></p></div><div class="para"><p>We previously found that CD-10 expression is suppressed after neoadjuvant androgen withdrawal of prostate cancer,<a href="#bib35" rel="references:#bib35" class="referenceLink" title="Link to bibliographic citation" shape="rect">35</a> suggesting that CD-10 is androgen-regulated, possibly through a androgen response element of the CD-10 gene.<a href="#bib87" rel="references:#bib87" class="referenceLink" title="Link to bibliographic citation" shape="rect">87</a>
 Retained expression in about half of hormone-refractory prostate 
cancers in our study could reflect a nonligand induced restoration of 
the androgen-receptor pathway, which has been suggested as a possible 
mechanism of hormonal therapy escape.<a href="#bib73" rel="references:#bib73" class="referenceLink" title="Link to bibliographic citation" shape="rect">73</a>, <a href="#bib88" rel="references:#bib88" class="referenceLink" title="Link to bibliographic citation" shape="rect">88</a></p></div><div class="para"><p>The
 tyrosine phosphatase inhibitor imatinib (STI 571, Glivec®, Novartis) 
leads to dramatic treatment responses in chronic myelogeneous leukemias 
and gastrointestinal stromal tumors, which show strong expression of 
CD-117, a product of the proto-oncogene c-kit.<a href="#bib89" rel="references:#bib89" class="referenceLink" title="Link to bibliographic citation" shape="rect">89</a>, <a href="#bib90" rel="references:#bib90" class="referenceLink" title="Link to bibliographic citation" shape="rect">90</a>
 In contrast, CD-117 was not expressed in any prostatic tissue except 
for 1 metastasis. To evaluate the therapeutic potential of imatinib for 
the treatment of advanced prostate cancer, further studies are required 
investigating the expression profiles of other tyrosine kinases 
inhibited by Imatinib such as platelet derived growth factor receptor 
(PDGFR).</p></div><div class="para"><p>Despite the apparent advantages of TMA analyses, several technical aspects still need to be considered.<a href="#bib10" rel="references:#bib10" class="referenceLink" title="Link to bibliographic citation" shape="rect">10</a>
 The prevalence of marker positivity from TMA experiments can be an 
underestimate of the true prevalence due to heterogeneity. However, this
 sampling bias affects different prognostic groups or tumor stages to an
 equal degree. Therefore, differences in prognosis or stage distribution
 can still reliably be detected using 1 single tissue core per tumor, as
 long as the TMA contains a sufficiently high number of different 
samples.<a href="#bib10" rel="references:#bib10" class="referenceLink" title="Link to bibliographic citation" shape="rect">10</a>, <a href="#bib34" rel="references:#bib34" class="referenceLink" title="Link to bibliographic citation" shape="rect">34</a>
 The results of molecular analyses can be affected by the degree of 
tissue preservation in different types of tissue specimens. In our 
study, the expression profiles of most analyzed proteins were 
unexpectedly lower in the metastases from autopsies than in the 
hormone-refractory local recurrences from resection specimens. This 
phenomenon is most likely due to an increased decay of some proteins in 
postmortem autopsy tissues as compared to biopsies or surgical 
resections.<a href="#bib91" rel="references:#bib91" class="referenceLink" title="Link to bibliographic citation" shape="rect">91</a>, <a href="#bib92" rel="references:#bib92" class="referenceLink" title="Link to bibliographic citation" shape="rect">92</a> Therefore, data from autopsy tissues should generally be interpreted with caution.</p></div><div class="para"><p>In
 conclusion, our study shows that p53, Bcl-2, Syndecan-1, EGFR and 
HER2/neu are predominantly expressed in hormone-refractory and 
metastatic prostate cancer, thus being valuable targets for further 
therapeutic evaluations. However, since these markers are only expressed
 in a fraction of advanced tumors, it will be necessary to assess the 
efficacy of targeted therapies in relation to the marker expression in 
the individual patients rather than looking at a raw overall efficacy. 
Once such therapies reach clinical routine, the patients will need to be
 selected based on the marker profile of their tumors, which can easily 
be assessed using immunohistochemistry on biopsies from local 
recurrences or distant metastases. It remains to be shown if some 
targeted therapies against progression-related markers may also be 
effective in tumors in an adjuvant setting, <em>before</em> development of hormone-refractory growth or metastases, <em>e.g</em>., in asymptomatic patients with rising PSA-values after radiotherapy or radical prostatectomy.</p></div></div><div class="section" id="sec1-ack-1"><div class="headingCont"><select style="visibility: visible; width: 238px;" class="jumpSelect"><option selected="selected" value="jumpTo">Jump to…</option><option value="#leftBorder">Top of page</option><option value="#abstract">Abstract</option><option value="#sec1-1">Material and methods</option><option value="#sec1-2">Results</option><option value="#sec1-3">Discussion</option><option value="#sec1-ack-1">Acknowledgements</option><option value="#wol-references">References</option></select><h3>Acknowledgements</h3></div><ol style="display: none;" class="jumpList"><li><a href="#leftBorder" shape="rect">Top of page</a></li><li><a href="#abstract" shape="rect">Abstract</a></li><li><a href="#sec1-1" shape="rect">Material and methods</a></li><li><a href="#sec1-2" shape="rect">Results</a></li><li><a href="#sec1-3" shape="rect">Discussion</a></li><li><a href="#sec1-ack-1" shape="rect">Acknowledgements</a></li><li><a href="#wol-references" shape="rect">References</a></li></ol><div class="para"><p>The
 authors thank Mrs. R. Epper and Y. Knecht who performed the 
immunohistochemical stainings, and the staff of the Pathology 
Department, University of Basel for their excellent technical support.</p></div></div><div id="wol-references" class="bibliography"><div class="headingCont"><select style="visibility: visible; width: 238px;" class="jumpSelect"><option selected="selected" value="jumpTo">Jump to…</option><option value="#leftBorder">Top of page</option><option value="#abstract">Abstract</option><option value="#sec1-1">Material and methods</option><option value="#sec1-2">Results</option><option value="#sec1-3">Discussion</option><option value="#sec1-ack-1">Acknowledgements</option><option value="#wol-references">References</option></select><h3>References</h3></div><ol style="display: none;" class="jumpList"><li><a href="#leftBorder" shape="rect">Top of page</a></li><li><a href="#abstract" shape="rect">Abstract</a></li><li><a href="#sec1-1" shape="rect">Material and methods</a></li><li><a href="#sec1-2" shape="rect">Results</a></li><li><a href="#sec1-3" shape="rect">Discussion</a></li><li><a href="#sec1-ack-1" shape="rect">Acknowledgements</a></li><li><a href="#wol-references" shape="rect">References</a></li></ol><ul class="custom"><li id="bib1"><span class="bullet">1</span><div class="text"><cite id="cit2">  <span class="author">Hsing AW</span>, <span class="author">Tsao L</span>, <span class="author">Devesa SS</span>. <span class="articleTitle">International trends and patterns of prostate cancer incidence and mortality</span>. <span class="journalTitle">Int J Cancer</span>  <span class="pubYear">2000</span>; <span class="vol">85</span>: <span class="pageFirst">60</span>–<span class="pageLast">7</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/%28SICI%291097-0215%2820000101%2985:1%3C60::AID-IJC11%3E3.0.CO;2-B/abstract" shape="rect">Abstract</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/%28SICI%291097-0215%2820000101%2985:1%3C60::AID-IJC11%3E3.0.CO;2-B/full" shape="rect">Full Article (HTML)</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/%28SICI%291097-0215%2820000101%2985:1%3C60::AID-IJC11%3E3.0.CO;2-B/pdf" shape="rect">PDF(117K)</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/%28SICI%291097-0215%2820000101%2985:1%3C60::AID-IJC11%3E3.0.CO;2-B/references" shape="rect">References</a></li></ul></div><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Int%20J%20Cancer&amp;rft.atitle=International%20trends%20and%20patterns%20of%20prostate%20cancer%20incidence%20and%20mortality&amp;rft.volume=85&amp;rft.spage=60&amp;rft.epage=7&amp;rft.date=2000&amp;rft.aulast=Hsing&amp;rft.aufirst=AW&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib2"><span class="bullet">2</span><div class="text"><cite id="cit3">  <span class="author">Denis L</span>, <span class="author">Murphy GP</span>. <span class="articleTitle">Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer</span>. <span class="journalTitle">Cancer</span>  <span class="pubYear">1993</span>; <span class="vol">72</span>: <span class="pageFirst">3888</span>–<span class="pageLast">95</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/1097-0142%2819931215%2972:12%2B%3C3888::AID-CNCR2820721726%3E3.0.CO;2-B/abstract" shape="rect">Abstract</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/1097-0142%2819931215%2972:12%2B%3C3888::AID-CNCR2820721726%3E3.0.CO;2-B/pdf" shape="rect">PDF(773K)</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/1097-0142%2819931215%2972:12%2B%3C3888::AID-CNCR2820721726%3E3.0.CO;2-B/references" shape="rect">References</a></li></ul></div><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer&amp;rft.atitle=Overview%20of%20phase%20III%20trials%20on%20combined%20androgen%20treatment%20in%20patients%20with%20metastatic%20prostate%20cancer&amp;rft.volume=72&amp;rft.spage=3888&amp;rft.epage=95&amp;rft.date=1993&amp;rft.aulast=Denis&amp;rft.aufirst=L&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib3"><span class="bullet">3</span><div class="text"><cite id="cit4">  <span class="author">Carroll PR</span>, <span class="author">Kantoff PW</span>, <span class="author">Balk SP</span>, <span class="author">Brown MA</span>, <span class="author">D'Amico A V</span>, <span class="author">George DJ</span>, <span class="author">Grossfeld GD</span>, <span class="author">Johnson CS</span>, <span class="author">Kelly WK</span>, <span class="author">Klotz L</span>, <span class="author">Lee WR</span>, <span class="author">Lubeck DP</span>, et al. <span class="articleTitle">Overview consensus statement: newer approaches to androgen deprivation therapy in prostate cancer</span>. <span class="journalTitle">Urology</span>  <span class="pubYear">2002</span>; <span class="vol">60</span>: <span class="pageFirst">1</span>–<span class="pageLast">6</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1016/S0090-4295%2802%2901559-5" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=12231036" shape="rect">PubMed</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Urology&amp;rft.atitle=Overview%20consensus%20statement%3A%20newer%20approaches%20to%20androgen%20deprivation%20therapy%20in%20prostate%20cancer&amp;rft.volume=60&amp;rft.spage=1&amp;rft.epage=6&amp;rft.date=2002&amp;rft.aulast=Carroll&amp;rft.aufirst=PR&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib4"><span class="bullet">4</span><div class="text"><cite id="cit5">  <span class="author">Gilligan T</span>, <span class="author">Kantoff PW</span>. <span class="articleTitle">Chemotherapy for prostate cancer</span>. <span class="journalTitle">Urology</span>  <span class="pubYear">2002</span>; <span class="vol">60</span>: <span class="pageFirst">94</span>–<span class="pageLast">100</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1016/S0090-4295%2802%2901583-2" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=12231060" shape="rect">PubMed</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Urology&amp;rft.atitle=Chemotherapy%20for%20prostate%20cancer&amp;rft.volume=60&amp;rft.spage=94&amp;rft.epage=100&amp;rft.date=2002&amp;rft.aulast=Gilligan&amp;rft.aufirst=T&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib5"><span class="bullet">5</span><div class="text"><cite id="cit6">  <span class="author">Morris MJ</span>, <span class="author">Scher HI</span>. <span class="articleTitle">Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies</span>. <span class="journalTitle">Surg Oncol</span>  <span class="pubYear">2002</span>; <span class="vol">11</span>: <span class="pageFirst">13</span>–<span class="pageLast">23</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1016/S0960-7404%2802%2900006-3" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=12031864" shape="rect">PubMed</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Surg%20Oncol&amp;rft.atitle=Novel%20therapies%20for%20the%20treatment%20of%20prostate%20cancer%3A%20current%20clinical%20trials%20and%20development%20strategies&amp;rft.volume=11&amp;rft.spage=13&amp;rft.epage=23&amp;rft.date=2002&amp;rft.aulast=Morris&amp;rft.aufirst=MJ&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib6"><span class="bullet">6</span><div class="text"><cite id="cit7">  <span class="author">Wakeling AE</span>, <span class="author">Guy SP</span>, <span class="author">Woodburn JR</span>, <span class="author">Ashton SE</span>, <span class="author">Curry BJ</span>, <span class="author">Barker AJ</span>, <span class="author">Gibson KH</span>. <span class="articleTitle">ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy</span>. <span class="journalTitle">Cancer Res</span>  <span class="pubYear">2002</span>; <span class="vol">62</span>: <span class="pageFirst">5749</span>–<span class="pageLast">54</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=12384534" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD38XotFyktr8%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer%20Res&amp;rft.atitle=ZD1839%20%28Iressa%29%3A%20an%20orally%20active%20inhibitor%20of%20epidermal%20growth%20factor%20signaling%20with%20potential%20for%20cancer%20therapy&amp;rft.volume=62&amp;rft.spage=5749&amp;rft.epage=54&amp;rft.date=2002&amp;rft.aulast=Wakeling&amp;rft.aufirst=AE&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib7"><span class="bullet">7</span><div class="text"><cite id="cit8">  <span class="author">Vogel CL</span>, <span class="author">Cobleigh MA</span>, <span class="author">Tripathy D</span>, <span class="author">Gutheil JC</span>, <span class="author">Harris LN</span>, <span class="author">Fehrenbacher L</span>, <span class="author">Slamon DJ</span>, <span class="author">Murphy M</span>, <span class="author">Novotny WF</span>, <span class="author">Burchmore M</span>, <span class="author">Shak S</span>, <span class="author">Stewart SJ</span>, et al. <span class="articleTitle">Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer</span>. <span class="journalTitle">J Clin Oncol</span>  <span class="pubYear">2002</span>; <span class="vol">20</span>: <span class="pageFirst">719</span>–<span class="pageLast">26</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1200/JCO.20.3.719" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11821453" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD38XhsVGmt7o%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Clin%20Oncol&amp;rft.atitle=Efficacy%20and%20safety%20of%20trastuzumab%20as%20a%20single%20agent%20in%20first%E2%80%90line%20treatment%20of%20HER2%E2%80%90overexpressing%20metastatic%20breast%20cancer&amp;rft.volume=20&amp;rft.spage=719&amp;rft.epage=26&amp;rft.date=2002&amp;rft.aulast=Vogel&amp;rft.aufirst=CL&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib8"><span class="bullet">8</span><div class="text"><cite id="cit9">  <span class="author">Morris MJ</span>, <span class="author">Reuter VE</span>, <span class="author">Kelly WK</span>, <span class="author">Slovin SF</span>, <span class="author">Kenneson K</span>, <span class="author">Verbel D</span>, <span class="author">Osman I</span>, <span class="author">Scher HI</span>. <span class="articleTitle">HER-2 profiling and targeting in prostate carcinoma</span>. <span class="journalTitle">Cancer</span>  <span class="pubYear">2002</span>; <span class="vol">94</span>: <span class="pageFirst">980</span>–<span class="pageLast">6</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/cncr.10339/abstract" shape="rect">Abstract</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/cncr.10339/full" shape="rect">Full Article (HTML)</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/cncr.10339/pdf" shape="rect">PDF(84K)</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/cncr.10339/references" shape="rect">References</a></li></ul></div><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer&amp;rft.atitle=HER%E2%80%902%20profiling%20and%20targeting%20in%20prostate%20carcinoma&amp;rft.volume=94&amp;rft.spage=980&amp;rft.epage=6&amp;rft.date=2002&amp;rft.aulast=Morris&amp;rft.aufirst=MJ&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib9"><span class="bullet">9</span><div class="text"><cite id="cit10">  <span class="author">Kononen J</span>, <span class="author">Bubendorf L</span>, <span class="author">Kallioniemi A</span>, <span class="author">Barlund M</span>, <span class="author">Schraml P</span>, <span class="author">Leighton S</span>, <span class="author">Torhorst J</span>, <span class="author">Mihatsch MJ</span>, <span class="author">Sauter G</span>, <span class="author">Kallioniemi OP</span>. <span class="articleTitle">Tissue microarrays for high-throughput molecular profiling of tumor specimens</span>. <span class="journalTitle">Nat Med</span>  <span class="pubYear">1998</span>; <span class="vol">4</span>: <span class="pageFirst">844</span>–<span class="pageLast">7</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1038/nm0798-844" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=9662379" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DyaK1cXktlKntr8%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nat%20Med&amp;rft.atitle=Tissue%20microarrays%20for%20high%E2%80%90throughput%20molecular%20profiling%20of%20tumor%20specimens&amp;rft.volume=4&amp;rft.spage=844&amp;rft.epage=7&amp;rft.date=1998&amp;rft.aulast=Kononen&amp;rft.aufirst=J&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib10"><span class="bullet">10</span><div class="text"><cite id="cit11">  <span class="author">Bubendorf L</span>, <span class="author">Nocito A</span>, <span class="author">Moch H</span>, <span class="author">Sauter G</span>. <span class="articleTitle">Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies</span>. <span class="journalTitle">J Pathol</span>  <span class="pubYear">2001</span>; <span class="vol">195</span>: <span class="pageFirst">72</span>–<span class="pageLast">9</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/path.893/abstract" shape="rect">Abstract</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/path.893/full" shape="rect">Full Article (HTML)</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/path.893/pdf" shape="rect">PDF(295K)</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/path.893/references" shape="rect">References</a></li></ul></div><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Pathol&amp;rft.atitle=Tissue%20microarray%20%28TMA%29%20technology%3A%20miniaturized%20pathology%20archives%20for%20high%E2%80%90throughput%20in%20situ%20studies&amp;rft.volume=195&amp;rft.spage=72&amp;rft.epage=9&amp;rft.date=2001&amp;rft.aulast=Bubendorf&amp;rft.aufirst=L&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib11"><span class="bullet">11</span><div class="text"><cite id="cit12">  <span class="author">Banerjee D</span>. <span class="articleTitle">Genasense (Genta, Inc.)</span>. <span class="journalTitle">Curr Opin Investig Drugs</span>  <span class="pubYear">2001</span>; <span class="vol">2</span>: <span class="pageFirst">574</span>–<span class="pageLast">80</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11566020" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3MXjs12htb8%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Curr%20Opin%20Investig%20Drugs&amp;rft.atitle=Genasense%20%28Genta%2C%20Inc.%29&amp;rft.volume=2&amp;rft.spage=574&amp;rft.epage=80&amp;rft.date=2001&amp;rft.aulast=Banerjee&amp;rft.aufirst=D&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib12"><span class="bullet">12</span><div class="text"><cite id="cit13">  <span class="author">Tolcher AW</span>, <span class="author">Reyno L</span>, <span class="author">Venner PM</span>, <span class="author">Ernst SD</span>, <span class="author">Moore M</span>, <span class="author">Geary RS</span>, <span class="author">Chi K</span>, <span class="author">Hall S</span>, <span class="author">Walsh W</span>, <span class="author">Dorr A</span>, <span class="author">Eisenhauer E</span>. <span class="articleTitle">A
 randomized phase II and pharmacokinetic study of the antisense 
oligonucleotides ISIS 3521 and ISIS 5132 in patients with 
hormone-refractory prostate cancer</span>. <span class="journalTitle">Clin Cancer Res</span>  <span class="pubYear">2002</span>; <span class="vol">8</span>: <span class="pageFirst">2530</span>–<span class="pageLast">5</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=12171880" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD38XmvVahsrs%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clin%20Cancer%20Res&amp;rft.atitle=A%20randomized%20phase%20II%20and%20pharmacokinetic%20study%20of%20the%20antisense%20oligonucleotides%20ISIS%203521%20and%20ISIS%205132%20in%20patients%20with%20hormone%E2%80%90refractory%20prostate%20cancer&amp;rft.volume=8&amp;rft.spage=2530&amp;rft.epage=5&amp;rft.date=2002&amp;rft.aulast=Tolcher&amp;rft.aufirst=AW&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib13"><span class="bullet">13</span><div class="text"><cite id="cit14">  <span class="author">Krull F</span>, <span class="author">Holzer U</span>, <span class="author">Ihle J</span>, <span class="author">Bethge W</span>, <span class="author">Fierlbeck G</span>, <span class="author">Kalland T</span>, <span class="author">Dohlsten M</span>, <span class="author">Niethammer D</span>, <span class="author">Dannecker GE</span>. <span class="articleTitle">Superantigen-induced lysis of melanoma cells</span>. <span class="journalTitle">Melanoma Res</span>  <span class="pubYear">1997</span>; <span class="vol">7</span>: <span class="pageFirst">214</span>–<span class="pageLast">22</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1097/00008390-199706000-00005" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=9195560" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DyaK2sXkt1Oqsb4%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Melanoma%20Res&amp;rft.atitle=Superantigen%E2%80%90induced%20lysis%20of%20melanoma%20cells&amp;rft.volume=7&amp;rft.spage=214&amp;rft.epage=22&amp;rft.date=1997&amp;rft.aulast=Krull&amp;rft.aufirst=F&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib14"><span class="bullet">14</span><div class="text"><cite id="cit15">  <span class="author">Pan C</span>, <span class="author">Cardarelli PM</span>, <span class="author">Nieder MH</span>, <span class="author">Pickford LB</span>, <span class="author">Gangwar S</span>, <span class="author">King DJ</span>, <span class="author">Yarranton GT</span>, <span class="author">Buckman D</span>, <span class="author">Roscoe W</span>, <span class="author">Zhou F</span>, <span class="author">Salles A</span>, <span class="author">Chen TH</span>, et al. <span class="articleTitle">CD10
 is a key enzyme involved in the activation of tumor-activated peptide 
prodrug CPI-0004Na and novel analogues: implications for the design of 
novel peptide prodrugs for the therapy of CD10+ tumors</span>. <span class="journalTitle">Cancer Res</span>  <span class="pubYear">2003</span>; <span class="vol">63</span>: <span class="pageFirst">5526</span>–<span class="pageLast">31</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=14500390" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3sXntlersr0%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer%20Res&amp;rft.atitle=CD10%20is%20a%20key%20enzyme%20involved%20in%20the%20activation%20of%20tumor%E2%80%90activated%20peptide%20prodrug%20CPI%E2%80%900004Na%20and%20novel%20analogues%3A%20implications%20for%20the%20design%20of%20novel%20peptide%20prodrugs%20for%20the%20therapy%20of%20CD10%2B%20tumors&amp;rft.volume=63&amp;rft.spage=5526&amp;rft.epage=31&amp;rft.date=2003&amp;rft.aulast=Pan&amp;rft.aufirst=C&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib15"><span class="bullet">15</span><div class="text"><cite id="cit16">  <span class="author">Tiffany NM</span>, <span class="author">Wersinger EM</span>, <span class="author">Garzotto M</span>, <span class="author">Beer TM</span>. <span class="articleTitle">Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer</span>. <span class="journalTitle">Urology</span>  <span class="pubYear">2004</span>; <span class="vol">63</span>: <span class="pageFirst">934</span>–<span class="pageLast">9</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1016/j.urology.2003.12.022" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=15134984" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:STN:280:DC%2BD2c3jvVCrtw%3D%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Urology&amp;rft.atitle=Imatinib%20mesylate%20and%20zoledronic%20acid%20in%20androgen%E2%80%90independent%20prostate%20cancer&amp;rft.volume=63&amp;rft.spage=934&amp;rft.epage=9&amp;rft.date=2004&amp;rft.aulast=Tiffany&amp;rft.aufirst=NM&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib16"><span class="bullet">16</span><div class="text"><cite id="cit17">  <span class="author">Uehara H</span>, <span class="author">Kim SJ</span>, <span class="author">Karashima T</span>, <span class="author">Shepherd DL</span>, <span class="author">Fan D</span>, <span class="author">Tsan R</span>, <span class="author">Killion JJ</span>, <span class="author">Logothetis C</span>, <span class="author">Mathew P</span>, <span class="author">Fidler IJ</span>. <span class="articleTitle">Effects
 of blocking platelet-derived growth factor-receptor signaling in a 
mouse model of experimental prostate cancer bone metastases</span>. <span class="journalTitle">J Natl Cancer Inst</span>  <span class="pubYear">2003</span>; <span class="vol">95</span>: <span class="pageFirst">458</span>–<span class="pageLast">70</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=12644539" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3sXisFCqs7w%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Natl%20Cancer%20Inst&amp;rft.atitle=Effects%20of%20blocking%20platelet%E2%80%90derived%20growth%20factor%E2%80%90receptor%20signaling%20in%20a%20mouse%20model%20of%20experimental%20prostate%20cancer%20bone%20metastases&amp;rft.volume=95&amp;rft.spage=458&amp;rft.epage=70&amp;rft.date=2003&amp;rft.aulast=Uehara&amp;rft.aufirst=H&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib17"><span class="bullet">17</span><div class="text"><cite id="cit18">  <span class="author">Sirotnak FM</span>, <span class="author">She Y</span>, <span class="author">Lee F</span>, <span class="author">Chen J</span>, <span class="author">Scher HI</span>. <span class="articleTitle">Studies
 with CWR22 xenografts in nude mice suggest that ZD1839 may have a role 
in the treatment of both androgen-dependent and androgen-independent 
human prostate cancer</span>. <span class="journalTitle">Clin Cancer Res</span>  <span class="pubYear">2002</span>; <span class="vol">8</span>: <span class="pageFirst">3870</span>–<span class="pageLast">6</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=12473602" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD38XpslCjtLc%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clin%20Cancer%20Res&amp;rft.atitle=Studies%20with%20CWR22%20xenografts%20in%20nude%20mice%20suggest%20that%20ZD1839%20may%20have%20a%20role%20in%20the%20treatment%20of%20both%20androgen%E2%80%90dependent%20and%20androgen%E2%80%90independent%20human%20prostate%20cancer&amp;rft.volume=8&amp;rft.spage=3870&amp;rft.epage=6&amp;rft.date=2002&amp;rft.aulast=Sirotnak&amp;rft.aufirst=FM&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib18"><span class="bullet">18</span><div class="text"><cite id="cit19">  <span class="author">Heideman DA</span>, <span class="author">Snijders PJ</span>, <span class="author">Craanen ME</span>, <span class="author">Bloemena E</span>, <span class="author">Meijer CJ</span>, <span class="author">Meuwissen SG</span>, <span class="author">van Beusechem VW</span>, <span class="author">Pinedo HM</span>, <span class="author">Curiel DT</span>, <span class="author">Haisma HJ</span>, <span class="author">Gerritsen WR</span>. <span class="articleTitle">Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors</span>. <span class="journalTitle">Cancer Gene Ther</span>  <span class="pubYear">2001</span>; <span class="vol">8</span>: <span class="pageFirst">342</span>–<span class="pageLast">51</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1038/sj.cgt.7700313" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11477454" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3MXlsVOju7w%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer%20Gene%20Ther&amp;rft.atitle=Selective%20gene%20delivery%20toward%20gastric%20and%20esophageal%20adenocarcinoma%20cells%20via%20EpCAM%E2%80%90targeted%20adenoviral%20vectors&amp;rft.volume=8&amp;rft.spage=342&amp;rft.epage=51&amp;rft.date=2001&amp;rft.aulast=Heideman&amp;rft.aufirst=DA&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib19"><span class="bullet">19</span><div class="text"><cite id="cit20">  <span class="author">Haisma HJ</span>, <span class="author">Pinedo HM</span>, <span class="author">Rijswijk A</span>, <span class="author">der Meulen-Muileman I</span>, <span class="author">Sosnowski BA</span>, <span class="author">Ying W</span>, <span class="author">Beusechem VW</span>, <span class="author">Tillman BW</span>, <span class="author">Gerritsen WR</span>, <span class="author">Curiel DT</span>. <span class="articleTitle">Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM</span>. <span class="journalTitle">Gene Ther</span>  <span class="pubYear">1999</span>; <span class="vol">6</span>: <span class="pageFirst">1469</span>–<span class="pageLast">74</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1038/sj.gt.3300969" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=10467371" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DyaK1MXlt1CisL0%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Gene%20Ther&amp;rft.atitle=Tumor%E2%80%90specific%20gene%20transfer%20via%20an%20adenoviral%20vector%20targeted%20to%20the%20pan%E2%80%90carcinoma%20antigen%20EpCAM&amp;rft.volume=6&amp;rft.spage=1469&amp;rft.epage=74&amp;rft.date=1999&amp;rft.aulast=Haisma&amp;rft.aufirst=HJ&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib20"><span class="bullet">20</span><div class="text"><cite id="cit21">  <span class="author">Slamon DJ</span>, <span class="author">Leyland-Jones B</span>, <span class="author">Shak S</span>, <span class="author">Fuchs H</span>, <span class="author">Paton V</span>, <span class="author">Bajamonde A</span>, <span class="author">Fleming T</span>, <span class="author">Eiermann W</span>, <span class="author">Wolter J</span>, <span class="author">Pegram M</span>, <span class="author">Baselga J</span>, <span class="author">Norton L</span>. <span class="articleTitle">Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2</span>. <span class="journalTitle">N Engl J Med</span>  <span class="pubYear">2001</span>; <span class="vol">344</span>: <span class="pageFirst">783</span>–<span class="pageLast">92</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1056/NEJM200103153441101" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11248153" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3MXisVGktrc%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=N%20Engl%20J%20Med&amp;rft.atitle=Use%20of%20chemotherapy%20plus%20a%20monoclonal%20antibody%20against%20HER2%20for%20metastatic%20breast%20cancer%20that%20overexpresses%20HER2&amp;rft.volume=344&amp;rft.spage=783&amp;rft.epage=92&amp;rft.date=2001&amp;rft.aulast=Slamon&amp;rft.aufirst=DJ&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib21"><span class="bullet">21</span><div class="text"><cite id="cit22">  <span class="author">Lara PN, Jr.</span>, <span class="author">Chee KG</span>, <span class="author">Longmate J</span>, <span class="author">Ruel C</span>, <span class="author">Meyers FJ</span>, <span class="author">Gray CR</span>, <span class="author">Edwards RG</span>, <span class="author">Gumerlock PH</span>, <span class="author">Twardowski P</span>, <span class="author">Doroshow JH</span>, <span class="author">Gandara DR</span>. <span class="articleTitle">Trastuzumab
 plus docetaxel in HER-2/neu-positive prostate carcinoma: final results 
from the California Cancer Consortium Screening and Phase II Trial</span>. <span class="journalTitle">Cancer</span>  <span class="pubYear">2004</span>; <span class="vol">100</span>: <span class="pageFirst">2125</span>–<span class="pageLast">31</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/cncr.20228/abstract" shape="rect">Abstract</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/cncr.20228/full" shape="rect">Full Article (HTML)</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/cncr.20228/pdf" shape="rect">PDF(89K)</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/cncr.20228/references" shape="rect">References</a></li></ul></div><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer&amp;rft.atitle=Trastuzumab%20plus%20docetaxel%20in%20HER%E2%80%902%2Fneu%E2%80%90positive%20prostate%20carcinoma%3A%20final%20results%20from%20the%20California%20Cancer%20Consortium%20Screening%20and%20Phase%20II%20Trial&amp;rft.volume=100&amp;rft.spage=2125&amp;rft.epage=31&amp;rft.date=2004&amp;rft.aulast=Lara&amp;rft.aufirst=PN&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib22"><span class="bullet">22</span><div class="text"><cite id="cit23">  <span class="author">Neckers L</span>. <span class="articleTitle">Heat
 shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin:
 a novel therapeutic approach for treating hormone-refractory prostate 
cancer</span>. <span class="journalTitle">Clin Cancer Res</span>  <span class="pubYear">2002</span>; <span class="vol">8</span>: <span class="pageFirst">962</span>–<span class="pageLast">6</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=12006507" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD38XksVSqtbk%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clin%20Cancer%20Res&amp;rft.atitle=Heat%20shock%20protein%2090%20inhibition%20by%2017%E2%80%90allylamino%E2%80%9017%E2%80%90%20demethoxygeldanamycin%3A%20a%20novel%20therapeutic%20approach%20for%20treating%20hormone%E2%80%90refractory%20prostate%20cancer&amp;rft.volume=8&amp;rft.spage=962&amp;rft.epage=6&amp;rft.date=2002&amp;rft.aulast=Neckers&amp;rft.aufirst=L&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib23"><span class="bullet">23</span><div class="text"><cite id="cit24">  <span class="author">Solit DB</span>, <span class="author">Scher HI</span>, <span class="author">Rosen N</span>. <span class="articleTitle">Hsp90 as a therapeutic target in prostate cancer</span>. <span class="journalTitle">Semin Oncol</span>  <span class="pubYear">2003</span>; <span class="vol">30</span>: <span class="pageFirst">709</span>–<span class="pageLast">16</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1016/S0093-7754%2803%2900346-4" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=14571418" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3sXpt1Gksbk%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Semin%20Oncol&amp;rft.atitle=Hsp90%20as%20a%20therapeutic%20target%20in%20prostate%20cancer&amp;rft.volume=30&amp;rft.spage=709&amp;rft.epage=16&amp;rft.date=2003&amp;rft.aulast=Solit&amp;rft.aufirst=DB&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib24"><span class="bullet">24</span><div class="text"><cite id="cit25">  <span class="author">Marotta A</span>, <span class="author">Tan C</span>, <span class="author">Gray V</span>, <span class="author">Malik S</span>, <span class="author">Gallinger S</span>, <span class="author">Sanghera J</span>, <span class="author">Dupuis B</span>, <span class="author">Owen D</span>, <span class="author">Dedhar S</span>, <span class="author">Salh B</span>. <span class="articleTitle">Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis</span>. <span class="journalTitle">Oncogene</span>  <span class="pubYear">2001</span>; <span class="vol">20</span>: <span class="pageFirst">6250</span>–<span class="pageLast">7</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1038/sj.onc.1204791" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11593435" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3MXnsFOhsrw%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Oncogene&amp;rft.atitle=Dysregulation%20of%20integrin%E2%80%90linked%20kinase%20%28ILK%29%20signaling%20in%20colonic%20polyposis&amp;rft.volume=20&amp;rft.spage=6250&amp;rft.epage=7&amp;rft.date=2001&amp;rft.aulast=Marotta&amp;rft.aufirst=A&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib25"><span class="bullet">25</span><div class="text"><cite id="cit26">  <span class="author">Yoganathan TN</span>, <span class="author">Costello P</span>, <span class="author">Chen X</span>, <span class="author">Jabali M</span>, <span class="author">Yan J</span>, <span class="author">Leung D</span>, <span class="author">Zhang Z</span>, <span class="author">Yee A</span>, <span class="author">Dedhar S</span>, <span class="author">Sanghera J</span>. <span class="articleTitle">Integrin-linked kinase (ILK): a “hot” therapeutic target</span>. <span class="journalTitle">Biochem Pharmacol</span>  <span class="pubYear">2000</span>; <span class="vol">60</span>: <span class="pageFirst">1115</span>–<span class="pageLast">9</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1016/S0006-2952%2800%2900444-5" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11007949" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3cXmslOjsbs%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Biochem%20Pharmacol&amp;rft.atitle=Integrin%E2%80%90linked%20kinase%20%28ILK%29%3A%20a%20%E2%80%9Chot%E2%80%9D%20therapeutic%20target&amp;rft.volume=60&amp;rft.spage=1115&amp;rft.epage=9&amp;rft.date=2000&amp;rft.aulast=Yoganathan&amp;rft.aufirst=TN&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib26"><span class="bullet">26</span><div class="text"><cite id="cit27">  <span class="author">Lein M</span>, <span class="author">Jung K</span>, <span class="author">Ortel B</span>, <span class="author">Stephan C</span>, <span class="author">Rothaug W</span>, <span class="author">Juchem R</span>, <span class="author">Johannsen M</span>, <span class="author">Deger S</span>, <span class="author">Schnorr D</span>, <span class="author">Loening S</span>, <span class="author">Krell HW</span>. <span class="articleTitle">The
 new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) 
reduces tumor growth and prolongs survival in a prostate cancer standard
 rat model</span>. <span class="journalTitle">Oncogene</span>  <span class="pubYear">2002</span>; <span class="vol">21</span>: <span class="pageFirst">2089</span>–<span class="pageLast">96</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1038/sj.onc.1205267" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11960381" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD38XivVelurc%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Oncogene&amp;rft.atitle=The%20new%20synthetic%20matrix%20metalloproteinase%20inhibitor%20%28Roche%2028%E2%80%902653%29%20reduces%20tumor%20growth%20and%20prolongs%20survival%20in%20a%20prostate%20cancer%20standard%20rat%20model&amp;rft.volume=21&amp;rft.spage=2089&amp;rft.epage=96&amp;rft.date=2002&amp;rft.aulast=Lein&amp;rft.aufirst=M&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib27"><span class="bullet">27</span><div class="text"><cite id="cit28">  <span class="author">Holle L</span>, <span class="author">Song W</span>, <span class="author">Holle E</span>, <span class="author">Wei Y</span>, <span class="author">Wagner T</span>, <span class="author">Yu X</span>. <span class="articleTitle">A matrix metalloproteinase 2 cleavable melittin/avidin conjugate specifically targets tumor cells in vitro and in vivo</span>. <span class="journalTitle">Int J Oncol</span>  <span class="pubYear">2003</span>; <span class="vol">22</span>: <span class="pageFirst">93</span>–<span class="pageLast">8</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=12469190" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3sXhsVSnsw%3D%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Int%20J%20Oncol&amp;rft.atitle=A%20matrix%20metalloproteinase%202%20cleavable%20melittin%2Favidin%20conjugate%20specifically%20targets%20tumor%20cells%20in%20vitro%20and%20in%20vivo&amp;rft.volume=22&amp;rft.spage=93&amp;rft.epage=8&amp;rft.date=2003&amp;rft.aulast=Holle&amp;rft.aufirst=L&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib28"><span class="bullet">28</span><div class="text"><cite id="cit29">  <span class="author">Akewanlop C</span>, <span class="author">Watanabe M</span>, <span class="author">Singh B</span>, <span class="author">Walker M</span>, <span class="author">Kufe DW</span>, <span class="author">Hayes DF</span>. <span class="articleTitle">Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody</span>. <span class="journalTitle">Cancer Res</span>  <span class="pubYear">2001</span>; <span class="vol">61</span>: <span class="pageFirst">4061</span>–<span class="pageLast">5</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11358826" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3MXktVWqtrw%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer%20Res&amp;rft.atitle=Phagocytosis%20of%20breast%20cancer%20cells%20mediated%20by%20anti%E2%80%90MUC%E2%80%901%20monoclonal%20antibody%2C%20DF3%2C%20and%20its%20bispecific%20antibody&amp;rft.volume=61&amp;rft.spage=4061&amp;rft.epage=5&amp;rft.date=2001&amp;rft.aulast=Akewanlop&amp;rft.aufirst=C&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib29"><span class="bullet">29</span><div class="text"><cite id="cit30">  <span class="author">Imai M</span>, <span class="author">Hwang HY</span>, <span class="author">Norris JS</span>, <span class="author">Tomlinson S</span>. <span class="articleTitle">The
 effect of dexamethasone on human mucin 1 expression and 
antibody-dependent complement sensitivity in a prostate cancer cell line
 in vitro and in vivo</span>. <span class="journalTitle">Immunology</span>  <span class="pubYear">2004</span>; <span class="vol">111</span>: <span class="pageFirst">291</span>–<span class="pageLast">7</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="http://onlinelibrary.wiley.com/doi/10.1111/j.0019-2805.2004.01815.x/abstract" shape="rect">Abstract</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1111/j.0019-2805.2004.01815.x/full" shape="rect">Full Article (HTML)</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1111/j.0019-2805.2004.01815.x/pdf" shape="rect">PDF(156K)</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1111/j.0019-2805.2004.01815.x/references" shape="rect">References</a></li></ul></div><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Immunology&amp;rft.atitle=The%20effect%20of%20dexamethasone%20on%20human%20mucin%201%20expression%20and%20antibody%E2%80%90dependent%20complement%20sensitivity%20in%20a%20prostate%20cancer%20cell%20line%20in%20vitro%20and%20in%20vivo&amp;rft.volume=111&amp;rft.spage=291&amp;rft.epage=7&amp;rft.date=2004&amp;rft.aulast=Imai&amp;rft.aufirst=M&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib30"><span class="bullet">30</span><div class="text"><cite id="cit31">  <span class="author">Mikata K</span>, <span class="author">Uemura H</span>, <span class="author">Ohuchi H</span>, <span class="author">Ohta S</span>, <span class="author">Nagashima Y</span>, <span class="author">Kubota Y</span>. <span class="articleTitle">Inhibition of growth of human prostate cancer xenograft by transfection of p53 gene: gene transfer by electroporation</span>. <span class="journalTitle">Mol Cancer Ther</span>  <span class="pubYear">2002</span>; <span class="vol">1</span>: <span class="pageFirst">247</span>–<span class="pageLast">52</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=12467220" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD38XitlSrt74%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Mol%20Cancer%20Ther&amp;rft.atitle=Inhibition%20of%20growth%20of%20human%20prostate%20cancer%20xenograft%20by%20transfection%20of%20p53%20gene%3A%20gene%20transfer%20by%20electroporation&amp;rft.volume=1&amp;rft.spage=247&amp;rft.epage=52&amp;rft.date=2002&amp;rft.aulast=Mikata&amp;rft.aufirst=K&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib31"><span class="bullet">31</span><div class="text"><cite id="cit32">  <span class="author">Merritt JA</span>, <span class="author">Roth JA</span>, <span class="author">Logothetis CJ</span>. <span class="articleTitle">Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies</span>. <span class="journalTitle">Semin Oncol</span>  <span class="pubYear">2001</span>; <span class="vol">28</span>: <span class="pageFirst">105</span>–<span class="pageLast">14</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1016/S0093-7754%2801%2990288-X" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11706402" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3MXpt1Wnsrw%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Semin%20Oncol&amp;rft.atitle=Clinical%20evaluation%20of%20adenoviral%E2%80%90mediated%20p53%20gene%20transfer%3A%20review%20of%20INGN%20201%20studies&amp;rft.volume=28&amp;rft.spage=105&amp;rft.epage=14&amp;rft.date=2001&amp;rft.aulast=Merritt&amp;rft.aufirst=JA&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib32"><span class="bullet">32</span><div class="text"><cite id="cit33">  <span class="author">Dhodapkar KM</span>, <span class="author">Krasovsky J</span>, <span class="author">Williamson B</span>, <span class="author">Dhodapkar MV</span>. <span class="articleTitle">Antitumor
 monoclonal antibodies enhance cross-presentation of cellular antigens 
and the generation of myeloma-specific killer T cells by dendritic cells</span>. <span class="journalTitle">J Exp Med</span>  <span class="pubYear">2002</span>; <span class="vol">195</span>: <span class="pageFirst">125</span>–<span class="pageLast">33</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1084/jem.20011097" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11781371" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD38XjslOjtQ%3D%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Exp%20Med&amp;rft.atitle=Antitumor%20monoclonal%20antibodies%20enhance%20cross%E2%80%90presentation%20of%20cellular%20antigens%20and%20the%20generation%20of%20myeloma%E2%80%90specific%20killer%20T%20cells%20by%20dendritic%20cells&amp;rft.volume=195&amp;rft.spage=125&amp;rft.epage=33&amp;rft.date=2002&amp;rft.aulast=Dhodapkar&amp;rft.aufirst=KM&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib33"><span class="bullet">33</span><div class="text"><cite id="cit34">  <span class="author">Bubendorf L</span>, <span class="author">Sauter G</span>, <span class="author">Moch H</span>, <span class="author">Jordan P</span>, <span class="author">Blochlinger A</span>, <span class="author">Gasser TC</span>, <span class="author">Mihatsch MJ</span>. <span class="articleTitle">Prognostic significance of Bcl-2 in clinically localized prostate cancer</span>. <span class="journalTitle">Am J Pathol</span>  <span class="pubYear">1996</span>; <span class="vol">148</span>: <span class="pageFirst">1557</span>–<span class="pageLast">65</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=8623924" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:STN:280:DyaK283gvVWgsw%3D%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Am%20J%20Pathol&amp;rft.atitle=Prognostic%20significance%20of%20Bcl%E2%80%902%20in%20clinically%20localized%20prostate%20cancer&amp;rft.volume=148&amp;rft.spage=1557&amp;rft.epage=65&amp;rft.date=1996&amp;rft.aulast=Bubendorf&amp;rft.aufirst=L&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib34"><span class="bullet">34</span><div class="text"><cite id="cit35">  <span class="author">Torhorst J</span>, <span class="author">Bucher C</span>, <span class="author">Kononen J</span>, <span class="author">Haas P</span>, <span class="author">Zuber M</span>, <span class="author">Kochli OR</span>, <span class="author">Mross F</span>, <span class="author">Dieterich H</span>, <span class="author">Moch H</span>, <span class="author">Mihatsch M</span>, <span class="author">Kallioniemi OP</span>, <span class="author">Sauter G</span>. <span class="articleTitle">Tissue microarrays for rapid linking of molecular changes to clinical endpoints</span>. <span class="journalTitle">Am J Pathol</span>  <span class="pubYear">2001</span>; <span class="vol">159</span>: <span class="pageFirst">2249</span>–<span class="pageLast">56</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11733374" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD38Xhslejtg%3D%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Am%20J%20Pathol&amp;rft.atitle=Tissue%20microarrays%20for%20rapid%20linking%20of%20molecular%20changes%20to%20clinical%20endpoints&amp;rft.volume=159&amp;rft.spage=2249&amp;rft.epage=56&amp;rft.date=2001&amp;rft.aulast=Torhorst&amp;rft.aufirst=J&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib35"><span class="bullet">35</span><div class="text"><cite id="cit36">  <span class="author">Zellweger T</span>, <span class="author">Ninck C</span>, <span class="author">Mirlacher M</span>, <span class="author">Annefeld M</span>, <span class="author">Glass AG</span>, <span class="author">Gasser TC</span>, <span class="author">Mihatsch MJ</span>, <span class="author">Gelmann EP</span>, <span class="author">Bubendorf L</span>. <span class="articleTitle">Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer</span>. <span class="journalTitle">Prostate</span>  <span class="pubYear">2003</span>; <span class="vol">55</span>: <span class="pageFirst">20</span>-<span class="pageLast">9</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/pros.10209/abstract" shape="rect">Abstract</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/pros.10209/pdf" shape="rect">PDF(447K)</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/pros.10209/references" shape="rect">References</a></li></ul></div><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Prostate&amp;rft.atitle=Tissue%20microarray%20analysis%20reveals%20prognostic%20significance%20of%20syndecan%E2%80%901%20expression%20in%20prostate%20cancer&amp;rft.volume=55&amp;rft.spage=20&amp;rft.epage=9&amp;rft.date=2003&amp;rft.aulast=Zellweger&amp;rft.aufirst=T&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib36"><span class="bullet">36</span><div class="text"><cite id="cit37">  <span class="author">Gleason DF</span>, <span class="author">Mellinger GT</span>. <span class="articleTitle">Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging</span>. <span class="journalTitle">J Urol</span>  <span class="pubYear">1974</span>; <span class="vol">111</span>: <span class="pageFirst">58</span>–<span class="pageLast">64</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=4813554" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:STN:280:DyaE2c7gt1Clug%3D%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Urol&amp;rft.atitle=Prediction%20of%20prognosis%20for%20prostatic%20adenocarcinoma%20by%20combined%20histological%20grading%20and%20clinical%20staging&amp;rft.volume=111&amp;rft.spage=58&amp;rft.epage=64&amp;rft.date=1974&amp;rft.aulast=Gleason&amp;rft.aufirst=DF&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib37"><span class="bullet">37</span><div class="text"><cite id="cit38">  <span class="author">Stattin P</span>, <span class="author">Damber JE</span>, <span class="author">Karlberg L</span>, <span class="author">Nordgren H</span>, <span class="author">Bergh A</span>. <span class="articleTitle">Bcl-2
 immunoreactivity in prostate tumorigenesis in relation to prostatic 
intraepithelial neoplasia, grade, hormonal status, metastatic growth and
 survival</span>. <span class="journalTitle">Urol Res</span>  <span class="pubYear">1996</span>; <span class="vol">24</span>: <span class="pageFirst">257</span>–<span class="pageLast">64</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1007/BF00304774" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=8931289" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DyaK28XnsVegu7s%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Urol%20Res&amp;rft.atitle=Bcl%E2%80%902%20immunoreactivity%20in%20prostate%20tumorigenesis%20in%20relation%20to%20prostatic%20intraepithelial%20neoplasia%2C%20grade%2C%20hormonal%20status%2C%20metastatic%20growth%20and%20survival&amp;rft.volume=24&amp;rft.spage=257&amp;rft.epage=64&amp;rft.date=1996&amp;rft.aulast=Stattin&amp;rft.aufirst=P&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib38"><span class="bullet">38</span><div class="text"><cite id="cit39">  <span class="author">Baltaci S</span>, <span class="author">Orhan D</span>, <span class="author">Ozer G</span>, <span class="author">Tolunay O</span>, <span class="author">Gogous O</span>. <span class="articleTitle">Bcl-2 proto-oncogene expression in low- and high-grade prostatic intraepithelial neoplasia</span>. <span class="journalTitle">BJU Int</span>  <span class="pubYear">2000</span>; <span class="vol">85</span>: <span class="pageFirst">155</span>–<span class="pageLast">9</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="http://onlinelibrary.wiley.com/doi/10.1046/j.1464-410x.2000.00388.x/abstract" shape="rect">Abstract</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1046/j.1464-410x.2000.00388.x/full" shape="rect">Full Article (HTML)</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1046/j.1464-410x.2000.00388.x/pdf" shape="rect">PDF(144K)</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1046/j.1464-410x.2000.00388.x/references" shape="rect">References</a></li></ul></div><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=BJU%20Int&amp;rft.atitle=Bcl%E2%80%902%20proto%E2%80%90oncogene%20expression%20in%20low%E2%80%90%20and%20high%E2%80%90grade%20prostatic%20intraepithelial%20neoplasia&amp;rft.volume=85&amp;rft.spage=155&amp;rft.epage=9&amp;rft.date=2000&amp;rft.aulast=Baltaci&amp;rft.aufirst=S&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib39"><span class="bullet">39</span><div class="text"><cite id="cit40">  <span class="author">Poczatek RB</span>, <span class="author">Myers RB</span>, <span class="author">Manne U</span>, <span class="author">Oelschlager DK</span>, <span class="author">Weiss HL</span>, <span class="author">Bostwick DG</span>, <span class="author">Grizzle WE</span>. <span class="articleTitle">Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia</span>. <span class="journalTitle">J Urol</span>  <span class="pubYear">1999</span>; <span class="vol">162</span>: <span class="pageFirst">1462</span>–<span class="pageLast">6</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1016/S0022-5347%2805%2968341-3" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=10492238" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:STN:280:DyaK1MvhvF2rtQ%3D%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Urol&amp;rft.atitle=Ep%E2%80%90Cam%20levels%20in%20prostatic%20adenocarcinoma%20and%20prostatic%20intraepithelial%20neoplasia&amp;rft.volume=162&amp;rft.spage=1462&amp;rft.epage=6&amp;rft.date=1999&amp;rft.aulast=Poczatek&amp;rft.aufirst=RB&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib40"><span class="bullet">40</span><div class="text"><cite id="cit41">  <span class="author">Alaiya A</span>, <span class="author">Roblick U</span>, <span class="author">Egevad L</span>, <span class="author">Carlsson A</span>, <span class="author">Franzen B</span>, <span class="author">Volz D</span>, <span class="author">Huwendiek S</span>, <span class="author">Linder S</span>, <span class="author">Auer G</span>. <span class="articleTitle">Polypeptide expression in prostate hyperplasia and prostate adenocarcinoma</span>. <span class="journalTitle">Anal Cell Pathol</span>  <span class="pubYear">2000</span>; <span class="vol">21</span>: <span class="pageFirst">1</span>–<span class="pageLast">9</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11254220" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3MXivFCmtbw%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Anal%20Cell%20Pathol&amp;rft.atitle=Polypeptide%20expression%20in%20prostate%20hyperplasia%20and%20prostate%20adenocarcinoma&amp;rft.volume=21&amp;rft.spage=1&amp;rft.epage=9&amp;rft.date=2000&amp;rft.aulast=Alaiya&amp;rft.aufirst=A&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib41"><span class="bullet">41</span><div class="text"><cite id="cit42">  <span class="author">Sauter G</span>, <span class="author">Simon R</span>, <span class="author">Hillan K</span>. <span class="articleTitle">Tissue microarrays in drug discovery</span>. <span class="journalTitle">Nat Rev Drug Discov</span>  <span class="pubYear">2003</span>; <span class="vol">2</span>: <span class="pageFirst">962</span>–<span class="pageLast">72</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1038/nrd1254" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3sXpvFCgtrw%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nat%20Rev%20Drug%20Discov&amp;rft.atitle=Tissue%20microarrays%20in%20drug%20discovery&amp;rft.volume=2&amp;rft.spage=962&amp;rft.epage=72&amp;rft.date=2003&amp;rft.aulast=Sauter&amp;rft.aufirst=G&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib42"><span class="bullet">42</span><div class="text"><cite id="cit43">  <span class="author">Bubendorf L</span>, <span class="author">Sauter G</span>, <span class="author">Moch H</span>, <span class="author">Schmid HP</span>, <span class="author">Gasser TC</span>, <span class="author">Jordan P</span>, <span class="author">Mihatsch MJ</span>. <span class="articleTitle">Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy</span>. <span class="journalTitle">J Pathol</span>  <span class="pubYear">1996</span>; <span class="vol">178</span>: <span class="pageFirst">437</span>–<span class="pageLast">41</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/%28SICI%291096-9896%28199604%29178:4%3C437::AID-PATH484%3E3.0.CO;2-4/abstract" shape="rect">Abstract</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/%28SICI%291096-9896%28199604%29178:4%3C437::AID-PATH484%3E3.0.CO;2-4/pdf" shape="rect">PDF(607K)</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/%28SICI%291096-9896%28199604%29178:4%3C437::AID-PATH484%3E3.0.CO;2-4/references" shape="rect">References</a></li></ul></div><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Pathol&amp;rft.atitle=Ki67%20labelling%20index%3A%20an%20independent%20predictor%20of%20progression%20in%20prostate%20cancer%20treated%20by%20radical%20prostatectomy&amp;rft.volume=178&amp;rft.spage=437&amp;rft.epage=41&amp;rft.date=1996&amp;rft.aulast=Bubendorf&amp;rft.aufirst=L&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib43"><span class="bullet">43</span><div class="text"><cite id="cit44">  <span class="author">Keshgegian AA</span>, <span class="author">Johnston E</span>, <span class="author">Cnaan A</span>. <span class="articleTitle">Bcl-2
 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are 
independent predictive markers for recurrence in prostate carcinoma</span>. <span class="journalTitle">Am J Clin Pathol</span>  <span class="pubYear">1998</span>; <span class="vol">110</span>: <span class="pageFirst">443</span>–<span class="pageLast">9</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=9763029" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DyaK1cXmsF2lsbk%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Am%20J%20Clin%20Pathol&amp;rft.atitle=Bcl%E2%80%902%20oncoprotein%20positivity%20and%20high%20MIB%E2%80%901%20%28Ki%E2%80%9067%29%20proliferative%20rate%20are%20independent%20predictive%20markers%20for%20recurrence%20in%20prostate%20carcinoma&amp;rft.volume=110&amp;rft.spage=443&amp;rft.epage=9&amp;rft.date=1998&amp;rft.aulast=Keshgegian&amp;rft.aufirst=AA&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib44"><span class="bullet">44</span><div class="text"><cite id="cit45">  <span class="author">Bauer JJ</span>, <span class="author">Sesterhenn IA</span>, <span class="author">Mostofi FK</span>, <span class="author">McLeod DG</span>, <span class="author">Srivastava S</span>, <span class="author">Moul JW</span>. <span class="articleTitle">Elevated
 levels of apoptosis regulator proteins p53 and bcl-2 are independent 
prognostic biomarkers in surgically treated clinically localized 
prostate cancer</span>. <span class="journalTitle">J Urol</span>  <span class="pubYear">1996</span>; <span class="vol">156</span>: <span class="pageFirst">1511</span>–<span class="pageLast">6</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1016/S0022-5347%2801%2965641-6" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=8808919" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:STN:280:DyaK28vgsVOkug%3D%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Urol&amp;rft.atitle=Elevated%20levels%20of%20apoptosis%20regulator%20proteins%20p53%20and%20bcl%E2%80%902%20are%20independent%20prognostic%20biomarkers%20in%20surgically%20treated%20clinically%20localized%20prostate%20cancer&amp;rft.volume=156&amp;rft.spage=1511&amp;rft.epage=6&amp;rft.date=1996&amp;rft.aulast=Bauer&amp;rft.aufirst=JJ&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib45"><span class="bullet">45</span><div class="text"><cite id="cit46">  <span class="author">Voeller HJ</span>, <span class="author">Sugars LY</span>, <span class="author">Pretlow T</span>, <span class="author">Gelmann EP</span>. <span class="articleTitle">p53 oncogene mutations in human prostate cancer specimens</span>. <span class="journalTitle">J Urol</span>  <span class="pubYear">1994</span>; <span class="vol">151</span>: <span class="pageFirst">492</span>–<span class="pageLast">5</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=7904314" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:STN:280:DyaK2c7htFagtw%3D%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Urol&amp;rft.atitle=p53%20oncogene%20mutations%20in%20human%20prostate%20cancer%20specimens&amp;rft.volume=151&amp;rft.spage=492&amp;rft.epage=5&amp;rft.date=1994&amp;rft.aulast=Voeller&amp;rft.aufirst=HJ&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib46"><span class="bullet">46</span><div class="text"><cite id="cit47">  <span class="author">Navone NM</span>, <span class="author">Troncoso P</span>, <span class="author">Pisters LL</span>, <span class="author">Goodrow TL</span>, <span class="author">Palmer JL</span>, <span class="author">Nichols WW</span>, <span class="author">von Eschenbach AC</span>, <span class="author">Conti CJ</span>. <span class="articleTitle">p53 protein accumulation and gene mutation in the progression of human prostate carcinoma</span>. <span class="journalTitle">J Natl Cancer Inst</span>  <span class="pubYear">1993</span>; <span class="vol">85</span>: <span class="pageFirst">1657</span>–<span class="pageLast">69</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1093/jnci/85.20.1657" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=7692074" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DyaK2cXhvVyntro%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Natl%20Cancer%20Inst&amp;rft.atitle=p53%20protein%20accumulation%20and%20gene%20mutation%20in%20the%20progression%20of%20human%20prostate%20carcinoma&amp;rft.volume=85&amp;rft.spage=1657&amp;rft.epage=69&amp;rft.date=1993&amp;rft.aulast=Navone&amp;rft.aufirst=NM&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib47"><span class="bullet">47</span><div class="text"><cite id="cit48">  <span class="author">Myers RB</span>, <span class="author">Oelschlager D</span>, <span class="author">Srivastava S</span>, <span class="author">Grizzle WE</span>. <span class="articleTitle">Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas</span>. <span class="journalTitle">Prostate</span>  <span class="pubYear">1994</span>; <span class="vol">25</span>: <span class="pageFirst">243</span>–<span class="pageLast">8</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/pros.2990250504/abstract" shape="rect">Abstract</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/pros.2990250504/pdf" shape="rect">PDF(1963K)</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/pros.2990250504/references" shape="rect">References</a></li></ul></div><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Prostate&amp;rft.atitle=Accumulation%20of%20the%20p53%20protein%20occurs%20more%20frequently%20in%20metastatic%20than%20in%20localized%20prostatic%20adenocarcinomas&amp;rft.volume=25&amp;rft.spage=243&amp;rft.epage=8&amp;rft.date=1994&amp;rft.aulast=Myers&amp;rft.aufirst=RB&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib48"><span class="bullet">48</span><div class="text"><cite id="cit49">  <span class="author">McDonnell TJ</span>, <span class="author">Troncoso P</span>, <span class="author">Brisbay SM</span>, <span class="author">Logothetis C</span>, <span class="author">Chung LW</span>, <span class="author">Hsieh JT</span>, <span class="author">Tu SM</span>, <span class="author">Campbell ML</span>. <span class="articleTitle">Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer</span>. <span class="journalTitle">Cancer Res</span>  <span class="pubYear">1992</span>; <span class="vol">52</span>: <span class="pageFirst">6940</span>–<span class="pageLast">4</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=1458483" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DyaK3sXjs1yltg%3D%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer%20Res&amp;rft.atitle=Expression%20of%20the%20protooncogene%20bcl%E2%80%902%20in%20the%20prostate%20and%20its%20association%20with%20emergence%20of%20androgen%E2%80%90independent%20prostate%20cancer&amp;rft.volume=52&amp;rft.spage=6940&amp;rft.epage=4&amp;rft.date=1992&amp;rft.aulast=McDonnell&amp;rft.aufirst=TJ&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib49"><span class="bullet">49</span><div class="text"><cite id="cit50">  <span class="author">Di Lorenzo G</span>, <span class="author">Tortora G</span>, <span class="author">D'Armiento FP</span>, <span class="author">De Rosa G</span>, <span class="author">Staibano S</span>, <span class="author">Autorino R</span>, <span class="author">D'Armiento M</span>, <span class="author">De Laurentiis M</span>, <span class="author">De Placido S</span>, <span class="author">Catalano G</span>, <span class="author">Bianco AR</span>, <span class="author">Ciardiello F</span>. <span class="articleTitle">Expression
 of epidermal growth factor receptor correlates with disease relapse and
 progression to androgen-independence in human prostate cancer</span>. <span class="journalTitle">Clin Cancer Res</span>  <span class="pubYear">2002</span>; <span class="vol">8</span>: <span class="pageFirst">3438</span>–<span class="pageLast">44</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=12429632" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD38XpsVCgt7Y%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clin%20Cancer%20Res&amp;rft.atitle=Expression%20of%20epidermal%20growth%20factor%20receptor%20correlates%20with%20disease%20relapse%20and%20progression%20to%20androgen%E2%80%90independence%20in%20human%20prostate%20cancer&amp;rft.volume=8&amp;rft.spage=3438&amp;rft.epage=44&amp;rft.date=2002&amp;rft.aulast=Di%20Lorenzo&amp;rft.aufirst=G&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib50"><span class="bullet">50</span><div class="text"><cite id="cit51">  <span class="author">Signoretti S</span>, <span class="author">Montironi R</span>, <span class="author">Manola J</span>, <span class="author">Altimari A</span>, <span class="author">Tam C</span>, <span class="author">Bubley G</span>, <span class="author">Balk S</span>, <span class="author">Thomas G</span>, <span class="author">Kaplan I</span>, <span class="author">Hlatky L</span>, <span class="author">Hahnfeldt P</span>, <span class="author">Kantoff P</span>, et al. <span class="articleTitle">Her-2-neu expression and progression toward androgen independence in human prostate cancer</span>. <span class="journalTitle">J Natl Cancer Inst</span>  <span class="pubYear">2000</span>; <span class="vol">92</span>: <span class="pageFirst">1918</span>–<span class="pageLast">25</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1093/jnci/92.23.1918" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11106683" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3cXptVehu7Y%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Natl%20Cancer%20Inst&amp;rft.atitle=Her%E2%80%902%E2%80%90neu%20expression%20and%20progression%20toward%20androgen%20independence%20in%20human%20prostate%20cancer&amp;rft.volume=92&amp;rft.spage=1918&amp;rft.epage=25&amp;rft.date=2000&amp;rft.aulast=Signoretti&amp;rft.aufirst=S&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib51"><span class="bullet">51</span><div class="text"><cite id="cit52">  <span class="author">Colombel M</span>, <span class="author">Symmans F</span>, <span class="author">Gil S</span>, <span class="author">O'Toole KM</span>, <span class="author">Chopin D</span>, <span class="author">Benson M</span>, <span class="author">Olsson CA</span>, <span class="author">Korsmeyer S</span>, <span class="author">Buttyan R</span>. <span class="articleTitle">Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers</span>. <span class="journalTitle">Am J Pathol</span>  <span class="pubYear">1993</span>; <span class="vol">143</span>: <span class="pageFirst">390</span>–<span class="pageLast">400</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=7688182" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:STN:280:DyaK3szktlWqtA%3D%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Am%20J%20Pathol&amp;rft.atitle=Detection%20of%20the%20apoptosis%E2%80%90suppressing%20oncoprotein%20bc1%E2%80%902%20in%20hormone%E2%80%90refractory%20human%20prostate%20cancers&amp;rft.volume=143&amp;rft.spage=390&amp;rft.epage=400&amp;rft.date=1993&amp;rft.aulast=Colombel&amp;rft.aufirst=M&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib52"><span class="bullet">52</span><div class="text"><cite id="cit53">  <span class="author">Joensuu H</span>, <span class="author">Pylkkanen L</span>, <span class="author">Toikkanen S</span>. <span class="articleTitle">Bcl-2 protein expression and long-term survival in breast cancer</span>. <span class="journalTitle">Am J Pathol</span>  <span class="pubYear">1994</span>; <span class="vol">145</span>: <span class="pageFirst">1191</span>–<span class="pageLast">8</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=7977649" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:STN:280:DyaK2M%2FmvValtw%3D%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Am%20J%20Pathol&amp;rft.atitle=Bcl%E2%80%902%20protein%20expression%20and%20long%E2%80%90term%20survival%20in%20breast%20cancer&amp;rft.volume=145&amp;rft.spage=1191&amp;rft.epage=8&amp;rft.date=1994&amp;rft.aulast=Joensuu&amp;rft.aufirst=H&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib53"><span class="bullet">53</span><div class="text"><cite id="cit54">  <span class="author">Hori M</span>, <span class="author">Nogami T</span>, <span class="author">Itabashi M</span>, <span class="author">Yoshimi F</span>, <span class="author">Ono H</span>, <span class="author">Koizumi S</span>. <span class="articleTitle">Expression
 of Bcl-2 in human breast cancer: correlation between hormone receptor 
status, p53 protein accumulation and DNA strand breaks associated with 
apoptosis</span>. <span class="journalTitle">Pathol Int</span>  <span class="pubYear">1997</span>; <span class="vol">47</span>: <span class="pageFirst">757</span>–<span class="pageLast">62</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1827.1997.tb04453.x/abstract" shape="rect">Abstract</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1827.1997.tb04453.x/pdf" shape="rect">PDF(2833K)</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1827.1997.tb04453.x/references" shape="rect">References</a></li></ul></div><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Pathol%20Int&amp;rft.atitle=Expression%20of%20Bcl%E2%80%902%20in%20human%20breast%20cancer%3A%20correlation%20between%20hormone%20receptor%20status%2C%20p53%20protein%20accumulation%20and%20DNA%20strand%20breaks%20associated%20with%20apoptosis&amp;rft.volume=47&amp;rft.spage=757&amp;rft.epage=62&amp;rft.date=1997&amp;rft.aulast=Hori&amp;rft.aufirst=M&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib54"><span class="bullet">54</span><div class="text"><cite id="cit55">Ben- <span class="author">Ezra JM</span>, <span class="author">Kornstein MJ</span>, <span class="author">Grimes MM</span>, <span class="author">Krystal G</span>. <span class="articleTitle">Small cell carcinomas of the lung express the Bcl-2 protein</span>. <span class="journalTitle">Am J Pathol</span>  <span class="pubYear">1994</span>; <span class="vol">145</span>: <span class="pageFirst">1036</span>–<span class="pageLast">40</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=7977636" shape="rect">PubMed</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Am%20J%20Pathol&amp;rft.atitle=Small%20cell%20carcinomas%20of%20the%20lung%20express%20the%20Bcl%E2%80%902%20protein&amp;rft.volume=145&amp;rft.spage=1036&amp;rft.epage=40&amp;rft.date=1994&amp;rft.aulast=Ezra&amp;rft.aufirst=JM&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib55"><span class="bullet">55</span><div class="text"><cite id="cit56">  <span class="author">Laudanski J</span>, <span class="author">Chyczewski L</span>, <span class="author">Niklinska WE</span>, <span class="author">Kretowska M</span>, <span class="author">Furman M</span>, <span class="author">Sawicki B</span>, <span class="author">Niklinski J</span>. <span class="articleTitle">Expression of bcl-2 protein in non-small cell lung cancer: correlation with clinicopathology and patient survival</span>. <span class="journalTitle">Neoplasma</span>  <span class="pubYear">1999</span>; <span class="vol">46</span>: <span class="pageFirst">25</span>–<span class="pageLast">30</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=10355530" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:STN:280:DyaK1M3otFKlsw%3D%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Neoplasma&amp;rft.atitle=Expression%20of%20bcl%E2%80%902%20protein%20in%20non%E2%80%90small%20cell%20lung%20cancer%3A%20correlation%20with%20clinicopathology%20and%20patient%20survival&amp;rft.volume=46&amp;rft.spage=25&amp;rft.epage=30&amp;rft.date=1999&amp;rft.aulast=Laudanski&amp;rft.aufirst=J&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib56"><span class="bullet">56</span><div class="text"><cite id="cit57">  <span class="author">Johnson MI</span>, <span class="author">Robinson MC</span>, <span class="author">Marsh C</span>, <span class="author">Robson CN</span>, <span class="author">Neal DE</span>, <span class="author">Hamdy FC</span>. <span class="articleTitle">Expression
 of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial 
neoplasia and localized prostate cancer: relationship with apoptosis and
 proliferation</span>. <span class="journalTitle">Prostate</span>  <span class="pubYear">1998</span>; <span class="vol">37</span>: <span class="pageFirst">223</span>–<span class="pageLast">9</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/%28SICI%291097-0045%2819981201%2937:4%3C223::AID-PROS3%3E3.0.CO;2-O/abstract" shape="rect">Abstract</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/%28SICI%291097-0045%2819981201%2937:4%3C223::AID-PROS3%3E3.0.CO;2-O/pdf" shape="rect">PDF(477K)</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/%28SICI%291097-0045%2819981201%2937:4%3C223::AID-PROS3%3E3.0.CO;2-O/references" shape="rect">References</a></li></ul></div><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Prostate&amp;rft.atitle=Expression%20of%20Bcl%E2%80%902%2C%20Bax%2C%20and%20p53%20in%20high%E2%80%90grade%20prostatic%20intraepithelial%20neoplasia%20and%20localized%20prostate%20cancer%3A%20relationship%20with%20apoptosis%20and%20proliferation&amp;rft.volume=37&amp;rft.spage=223&amp;rft.epage=9&amp;rft.date=1998&amp;rft.aulast=Johnson&amp;rft.aufirst=MI&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib57"><span class="bullet">57</span><div class="text"><cite id="cit58">  <span class="author">Matsushima H</span>, <span class="author">Hosaka Y</span>, <span class="author">Suzuki M</span>, <span class="author">Mizutani T</span>, <span class="author">Ishizuka H</span>, <span class="author">Kawabe K</span>. <span class="articleTitle">bcl-2 Expression on prostate cancer and its relationship to cell cycle and prognosis</span>. <span class="journalTitle">Int J Urol</span>  <span class="pubYear">1996</span>; <span class="vol">3</span>: <span class="pageFirst">113</span>–<span class="pageLast">7</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1442-2042.1996.tb00494.x/abstract" shape="rect">Abstract</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1442-2042.1996.tb00494.x/pdf" shape="rect">PDF(2271K)</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1442-2042.1996.tb00494.x/references" shape="rect">References</a></li></ul></div><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Int%20J%20Urol&amp;rft.atitle=bcl%E2%80%902%20Expression%20on%20prostate%20cancer%20and%20its%20relationship%20to%20cell%20cycle%20and%20prognosis&amp;rft.volume=3&amp;rft.spage=113&amp;rft.epage=7&amp;rft.date=1996&amp;rft.aulast=Matsushima&amp;rft.aufirst=H&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib58"><span class="bullet">58</span><div class="text"><cite id="cit59">  <span class="author">Osman I</span>, <span class="author">Scher HI</span>, <span class="author">Drobnjak M</span>, <span class="author">Verbel D</span>, <span class="author">Morris M</span>, <span class="author">Agus D</span>, <span class="author">Ross JS</span>, <span class="author">Cordon-Cardo C</span>. <span class="articleTitle">HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer</span>. <span class="journalTitle">Clin Cancer Res</span>  <span class="pubYear">2001</span>; <span class="vol">7</span>: <span class="pageFirst">2643</span>–<span class="pageLast">7</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11555574" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3MXnsFSitrw%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clin%20Cancer%20Res&amp;rft.atitle=HER%E2%80%902%2Fneu%20%28p185neu%29%20protein%20expression%20in%20the%20natural%20or%20treated%20history%20of%20prostate%20cancer&amp;rft.volume=7&amp;rft.spage=2643&amp;rft.epage=7&amp;rft.date=2001&amp;rft.aulast=Osman&amp;rft.aufirst=I&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib59"><span class="bullet">59</span><div class="text"><cite id="cit60">  <span class="author">Craft N</span>, <span class="author">Shostak Y</span>, <span class="author">Carey M</span>, <span class="author">Sawyers CL</span>. <span class="articleTitle">A
 mechanism for hormone-independent prostate cancer through modulation of
 androgen receptor signaling by the HER-2/neu tyrosine kinase</span>. <span class="journalTitle">Nat Med</span>  <span class="pubYear">1999</span>; <span class="vol">5</span>: <span class="pageFirst">280</span>–<span class="pageLast">5</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1038/6495" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=10086382" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DyaK1MXhsVSmtr0%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nat%20Med&amp;rft.atitle=A%20mechanism%20for%20hormone%E2%80%90independent%20prostate%20cancer%20through%20modulation%20of%20androgen%20receptor%20signaling%20by%20the%20HER%E2%80%902%2Fneu%20tyrosine%20kinase&amp;rft.volume=5&amp;rft.spage=280&amp;rft.epage=5&amp;rft.date=1999&amp;rft.aulast=Craft&amp;rft.aufirst=N&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib60"><span class="bullet">60</span><div class="text"><cite id="cit61">  <span class="author">Wen Y</span>, <span class="author">Hu MC</span>, <span class="author">Makino K</span>, <span class="author">Spohn B</span>, <span class="author">Bartholomeusz G</span>, <span class="author">Yan DH</span>, <span class="author">Hung MC</span>. <span class="articleTitle">HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway</span>. <span class="journalTitle">Cancer Res</span>  <span class="pubYear">2000</span>; <span class="vol">60</span>: <span class="pageFirst">6841</span>–<span class="pageLast">5</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11156376" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3MXjsVKrtQ%3D%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer%20Res&amp;rft.atitle=HER%E2%80%902%2Fneu%20promotes%20androgen%E2%80%90independent%20survival%20and%20growth%20of%20prostate%20cancer%20cells%20through%20the%20Akt%20pathway&amp;rft.volume=60&amp;rft.spage=6841&amp;rft.epage=5&amp;rft.date=2000&amp;rft.aulast=Wen&amp;rft.aufirst=Y&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib61"><span class="bullet">61</span><div class="text"><cite id="cit62">  <span class="author">Pegram MD</span>, <span class="author">Lopez A</span>, <span class="author">Konecny G</span>, <span class="author">Slamon DJ</span>. <span class="articleTitle">Trastuzumab and chemotherapeutics: drug interactions and synergies</span>. <span class="journalTitle">Semin Oncol</span>  <span class="pubYear">2000</span>; <span class="vol">27</span>: <span class="pageFirst">21</span>–<span class="pageLast">5</span>; discussion 92–100.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11236023" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3MXhsFGktro%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Semin%20Oncol&amp;rft.atitle=Trastuzumab%20and%20chemotherapeutics%3A%20drug%20interactions%20and%20synergies&amp;rft.volume=27&amp;rft.spage=21&amp;rft.epage=5&amp;rft.date=2000&amp;rft.aulast=Pegram&amp;rft.aufirst=MD&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib62"><span class="bullet">62</span><div class="text"><cite id="cit63">  <span class="author">Agus DB</span>, <span class="author">Scher HI</span>, <span class="author">Higgins B</span>, <span class="author">Fox WD</span>, <span class="author">Heller G</span>, <span class="author">Fazzari M</span>, <span class="author">Cordon-Cardo C</span>, <span class="author">Golde DW</span>. <span class="articleTitle">Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models</span>. <span class="journalTitle">Cancer Res</span>  <span class="pubYear">1999</span>; <span class="vol">59</span>: <span class="pageFirst">4761</span>–<span class="pageLast">4</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=10519379" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DyaK1MXmslWktr0%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer%20Res&amp;rft.atitle=Response%20of%20prostate%20cancer%20to%20anti%E2%80%90Her%E2%80%902%2Fneu%20antibody%20in%20androgen%E2%80%90dependent%20and%20%E2%80%90independent%20human%20xenograft%20models&amp;rft.volume=59&amp;rft.spage=4761&amp;rft.epage=4&amp;rft.date=1999&amp;rft.aulast=Agus&amp;rft.aufirst=DB&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib63"><span class="bullet">63</span><div class="text"><cite id="cit64">  <span class="author">Bubendorf L</span>, <span class="author">Kononen J</span>, <span class="author">Koivisto P</span>, <span class="author">Schraml P</span>, <span class="author">Moch H</span>, <span class="author">Gasser TC</span>, <span class="author">Willi N</span>, <span class="author">Mihatsch MJ</span>, <span class="author">Sauter G</span>, <span class="author">Kallioniemi OP</span>. <span class="articleTitle">Survey
 of gene amplifications during prostate cancer progression by 
high-throughout fluorescence in situ hybridization on tissue microarrays</span>. <span class="journalTitle">Cancer Res</span>  <span class="pubYear">1999</span>; <span class="vol">59</span>: <span class="pageFirst">803</span>–<span class="pageLast">6</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=10029066" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DyaK1MXht1Sjurc%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer%20Res&amp;rft.atitle=Survey%20of%20gene%20amplifications%20during%20prostate%20cancer%20progression%20by%20high%E2%80%90throughout%20fluorescence%20in%20situ%20hybridization%20on%20tissue%20microarrays&amp;rft.volume=59&amp;rft.spage=803&amp;rft.epage=6&amp;rft.date=1999&amp;rft.aulast=Bubendorf&amp;rft.aufirst=L&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib64"><span class="bullet">64</span><div class="text"><cite id="cit65">  <span class="author">Savinainen KJ SO</span>, <span class="author">Linja MJ</span>, <span class="author">Bratt O</span>, <span class="author">Tammela TL</span>, <span class="author">Isola JJ</span>, <span class="author">Visakorpi T</span>. <span class="articleTitle">Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer</span>. <span class="journalTitle">Am J Pathol</span>  <span class="pubYear">2002</span>; <span class="vol">160</span>: <span class="pageFirst">339</span>–<span class="pageLast">45</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11786427" shape="rect">PubMed</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Am%20J%20Pathol&amp;rft.atitle=Expression%20and%20gene%20copy%20number%20analysis%20of%20ERBB2%20oncogene%20in%20prostate%20cancer&amp;rft.volume=160&amp;rft.spage=339&amp;rft.epage=45&amp;rft.date=2002&amp;rft.aulast=Savinainen%20KJ&amp;rft.aufirst=SO&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib65"><span class="bullet">65</span><div class="text"><cite id="cit66">  <span class="author">Lara PN, Jr.</span>, <span class="author">Meyers FJ</span>, <span class="author">Gray CR</span>, <span class="author">Edwards RG</span>, <span class="author">Gumerlock PH</span>, <span class="author">Kauderer C</span>, <span class="author">Tichauer G</span>, <span class="author">Twardowski P</span>, <span class="author">Doroshow JH</span>, <span class="author">Gandara DR</span>. <span class="articleTitle">HER-2/neu
 is overexpressed infrequently in patients with prostate carcinoma: 
results from the California Cancer Consortium Screening Trial</span>. <span class="journalTitle">Cancer</span>  <span class="pubYear">2002</span>; <span class="vol">94</span>: <span class="pageFirst">2584</span>–<span class="pageLast">9</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/cncr.10526/abstract" shape="rect">Abstract</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/cncr.10526/full" shape="rect">Full Article (HTML)</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/cncr.10526/pdf" shape="rect">PDF(718K)</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/cncr.10526/references" shape="rect">References</a></li></ul></div><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer&amp;rft.atitle=HER%E2%80%902%2Fneu%20is%20overexpressed%20infrequently%20in%20patients%20with%20prostate%20carcinoma%3A%20results%20from%20the%20California%20Cancer%20Consortium%20Screening%20Trial&amp;rft.volume=94&amp;rft.spage=2584&amp;rft.epage=9&amp;rft.date=2002&amp;rft.aulast=Lara&amp;rft.aufirst=PN&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib66"><span class="bullet">66</span><div class="text"><cite id="cit67">  <span class="author">Sanchez KM</span>, <span class="author">Sweeney CJ</span>, <span class="author">Mass R</span>, <span class="author">Koch MO</span>, <span class="author">Eckert GJ</span>, <span class="author">Geary WA</span>, <span class="author">Baldridge LA</span>, <span class="author">Zhang S</span>, <span class="author">Eble JN</span>, <span class="author">Cheng L</span>. <span class="articleTitle">Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology</span>. <span class="journalTitle">Cancer</span>  <span class="pubYear">2002</span>; <span class="vol">95</span>: <span class="pageFirst">1650</span>–<span class="pageLast">5</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/cncr.10839/abstract" shape="rect">Abstract</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/cncr.10839/full" shape="rect">Full Article (HTML)</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/cncr.10839/pdf" shape="rect">PDF(596K)</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/cncr.10839/references" shape="rect">References</a></li></ul></div><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer&amp;rft.atitle=Evaluation%20of%20HER%E2%80%902%2Fneu%20expression%20in%20prostatic%20adenocarcinoma%3A%20a%20requested%20for%20a%20standardized%2C%20organ%20specific%20methodology&amp;rft.volume=95&amp;rft.spage=1650&amp;rft.epage=5&amp;rft.date=2002&amp;rft.aulast=Sanchez&amp;rft.aufirst=KM&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib67"><span class="bullet">67</span><div class="text"><cite id="cit68">  <span class="author">Blackledge G</span>, <span class="author">Averbuch S</span>, <span class="author">Kay A</span>, <span class="author">Barton J</span>. <span class="articleTitle">Anti-EGF receptor therapy</span>. <span class="journalTitle">Prostate Cancer Prostatic Dis</span>  <span class="pubYear">2000</span>; <span class="vol">3</span>: <span class="pageFirst">296</span>–<span class="pageLast">302</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1038/sj.pcan.4500488" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=12497082" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3MXht1Sit7k%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Prostate%20Cancer%20Prostatic%20Dis&amp;rft.atitle=Anti%E2%80%90EGF%20receptor%20therapy&amp;rft.volume=3&amp;rft.spage=296&amp;rft.epage=302&amp;rft.date=2000&amp;rft.aulast=Blackledge&amp;rft.aufirst=G&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib68"><span class="bullet">68</span><div class="text"><cite id="cit69">  <span class="author">Sirotnak FM</span>. <span class="articleTitle">Studies with ZD1839 in preclinical models</span>. <span class="journalTitle">Semin Oncol</span>  <span class="pubYear">2003</span>; <span class="vol">30</span>: <span class="pageFirst">12</span>–<span class="pageLast">20</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1053/sonc.2003.50028" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=12644980" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3sXislKgsL8%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Semin%20Oncol&amp;rft.atitle=Studies%20with%20ZD1839%20in%20preclinical%20models&amp;rft.volume=30&amp;rft.spage=12&amp;rft.epage=20&amp;rft.date=2003&amp;rft.aulast=Sirotnak&amp;rft.aufirst=FM&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib69"><span class="bullet">69</span><div class="text"><cite id="cit70">  <span class="author">Baselga J</span>, <span class="author">Rischin D</span>, <span class="author">Ranson M</span>, <span class="author">Calvert H</span>, <span class="author">Raymond E</span>, <span class="author">Kieback DG</span>, <span class="author">Kaye SB</span>, <span class="author">Gianni L</span>, <span class="author">Harris A</span>, <span class="author">Bjork T</span>, <span class="author">Averbuch SD</span>, <span class="author">Feyereislova A</span>, et al. <span class="articleTitle">Phase
 I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a 
selective oral epidermal growth factor receptor tyrosine kinase 
inhibitor, in patients with five selected solid tumor types</span>. <span class="journalTitle">J Clin Oncol</span>  <span class="pubYear">2002</span>; <span class="vol">20</span>: <span class="pageFirst">4292</span>–<span class="pageLast">302</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1200/JCO.2002.03.100" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=12409327" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD38Xpt1CjtLo%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Clin%20Oncol&amp;rft.atitle=Phase%20I%20safety%2C%20pharmacokinetic%2C%20and%20pharmacodynamic%20trial%20of%20ZD1839%2C%20a%20selective%20oral%20epidermal%20growth%20factor%20receptor%20tyrosine%20kinase%20inhibitor%2C%20in%20patients%20with%20five%20selected%20solid%20tumor%20types&amp;rft.volume=20&amp;rft.spage=4292&amp;rft.epage=302&amp;rft.date=2002&amp;rft.aulast=Baselga&amp;rft.aufirst=J&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib70"><span class="bullet">70</span><div class="text"><cite id="cit71">  <span class="author">Ranson M</span>, <span class="author">Hammond LA</span>, <span class="author">Ferry D</span>, <span class="author">Kris M</span>, <span class="author">Tullo A</span>, <span class="author">Murray PI</span>, <span class="author">Miller V</span>, <span class="author">Averbuch S</span>, <span class="author">Ochs J</span>, <span class="author">Morris C</span>, <span class="author">Feyereislova A</span>, <span class="author">Swaisland H</span>, et al. <span class="articleTitle">ZD1839,
 a selective oral epidermal growth factor receptor-tyrosine kinase 
inhibitor, is well tolerated and active in patients with solid, 
malignant tumors: results of a phase I trial</span>. <span class="journalTitle">J Clin Oncol</span>  <span class="pubYear">2002</span>; <span class="vol">20</span>: <span class="pageFirst">2240</span>–<span class="pageLast">50</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1200/JCO.2002.10.112" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11980995" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD38XktVKrsrc%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Clin%20Oncol&amp;rft.atitle=ZD1839%2C%20a%20selective%20oral%20epidermal%20growth%20factor%20receptor%E2%80%90tyrosine%20kinase%20inhibitor%2C%20is%20well%20tolerated%20and%20active%20in%20patients%20with%20solid%2C%20malignant%20tumors%3A%20results%20of%20a%20phase%20I%20trial&amp;rft.volume=20&amp;rft.spage=2240&amp;rft.epage=50&amp;rft.date=2002&amp;rft.aulast=Ranson&amp;rft.aufirst=M&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib71"><span class="bullet">71</span><div class="text"><cite id="cit72">  <span class="author">Lynch TJ</span>, <span class="author">Bell DW</span>, <span class="author">Sordella R</span>, <span class="author">Gurubhagavatula S</span>, <span class="author">Okimoto RA</span>, <span class="author">Brannigan BW</span>, <span class="author">Harris PL</span>, <span class="author">Haserlat SM</span>, <span class="author">Supko JG</span>, <span class="author">Haluska FG</span>, <span class="author">Louis DN</span>, <span class="author">Christiani DC</span>, et al. <span class="articleTitle">Activating
 mutations in the epidermal growth factor receptor underlying 
responsiveness of non-small-cell lung cancer to gefitinib</span>. <span class="journalTitle">N Engl J Med</span>  <span class="pubYear">2004</span>; <span class="vol">350</span>: <span class="pageFirst">2129</span>–<span class="pageLast">39</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1056/NEJMoa040938" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=15118073" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD2cXktF2js7c%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=N%20Engl%20J%20Med&amp;rft.atitle=Activating%20mutations%20in%20the%20epidermal%20growth%20factor%20receptor%20underlying%20responsiveness%20of%20non%E2%80%90small%E2%80%90cell%20lung%20cancer%20to%20gefitinib&amp;rft.volume=350&amp;rft.spage=2129&amp;rft.epage=39&amp;rft.date=2004&amp;rft.aulast=Lynch&amp;rft.aufirst=TJ&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib72"><span class="bullet">72</span><div class="text"><cite id="cit73">  <span class="author">Paez JG</span>, <span class="author">Janne PA</span>, <span class="author">Lee JC</span>, <span class="author">Tracy S</span>, <span class="author">Greulich H</span>, <span class="author">Gabriel S</span>, <span class="author">Herman P</span>, <span class="author">Kaye FJ</span>, <span class="author">Lindeman N</span>, <span class="author">Boggon TJ</span>, <span class="author">Naoki K</span>, <span class="author">Sasaki H</span>, et al. <span class="articleTitle">EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</span>. <span class="journalTitle">Science</span>  <span class="pubYear">2004</span>; <span class="vol">304</span>: <span class="pageFirst">1497</span>–<span class="pageLast">500</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1126/science.1099314" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=15118125" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD2cXksVGmsbs%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Science&amp;rft.atitle=EGFR%20mutations%20in%20lung%20cancer%3A%20correlation%20with%20clinical%20response%20to%20gefitinib%20therapy&amp;rft.volume=304&amp;rft.spage=1497&amp;rft.epage=500&amp;rft.date=2004&amp;rft.aulast=Paez&amp;rft.aufirst=JG&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib73"><span class="bullet">73</span><div class="text"><cite id="cit74">  <span class="author">Amler LC</span>, <span class="author">Agus DB</span>, <span class="author">LeDuc C</span>, <span class="author">Sapinoso ML</span>, <span class="author">Fox WD</span>, <span class="author">Kern S</span>, <span class="author">Lee D</span>, <span class="author">Wang V</span>, <span class="author">Leysens M</span>, <span class="author">Higgins B</span>, <span class="author">Martin J</span>, <span class="author">Gerald W</span>, et al. <span class="articleTitle">Dysregulated
 expression of androgen-responsive and nonresponsive genes in the 
androgen-independent prostate cancer xenograft model CWR22-R1</span>. <span class="journalTitle">Cancer Res</span>  <span class="pubYear">2000</span>; <span class="vol">60</span>: <span class="pageFirst">6134</span>–<span class="pageLast">41</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11085537" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3cXotV2lsb0%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer%20Res&amp;rft.atitle=Dysregulated%20expression%20of%20androgen%E2%80%90responsive%20and%20nonresponsive%20genes%20in%20the%20androgen%E2%80%90independent%20prostate%20cancer%20xenograft%20model%20CWR22%E2%80%90R1&amp;rft.volume=60&amp;rft.spage=6134&amp;rft.epage=41&amp;rft.date=2000&amp;rft.aulast=Amler&amp;rft.aufirst=LC&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib74"><span class="bullet">74</span><div class="text"><cite id="cit75">  <span class="author">Bernfield M</span>, <span class="author">Sanderson RD</span>. <span class="articleTitle">Syndecan, a developmentally regulated cell surface proteoglycan that binds extracellular matrix and growth factors</span>. <span class="journalTitle">Philos Trans R Soc Lond B Biol Sci</span>  <span class="pubYear">1990</span>; <span class="vol">327</span>: <span class="pageFirst">171</span>–<span class="pageLast">86</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1098/rstb.1990.0052" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=1969657" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DyaK3cXksFCgu7g%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Philos%20Trans%20R%20Soc%20Lond%20B%20Biol%20Sci&amp;rft.atitle=Syndecan%2C%20a%20developmentally%20regulated%20cell%20surface%20proteoglycan%20that%20binds%20extracellular%20matrix%20and%20growth%20factors&amp;rft.volume=327&amp;rft.spage=171&amp;rft.epage=86&amp;rft.date=1990&amp;rft.aulast=Bernfield&amp;rft.aufirst=M&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib75"><span class="bullet">75</span><div class="text"><cite id="cit76">  <span class="author">Filla MS</span>, <span class="author">Dam P</span>, <span class="author">Rapraeger AC</span>. <span class="articleTitle">The cell surface proteoglycan syndecan-1 mediates fibroblast growth factor-2 binding and activity</span>. <span class="journalTitle">J Cell Physiol</span>  <span class="pubYear">1998</span>; <span class="vol">174</span>: <span class="pageFirst">310</span>–<span class="pageLast">21</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/%28SICI%291097-4652%28199803%29174:3%3C310::AID-JCP5%3E3.0.CO;2-R/abstract" shape="rect">Abstract</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/%28SICI%291097-4652%28199803%29174:3%3C310::AID-JCP5%3E3.0.CO;2-R/pdf" shape="rect">PDF(366K)</a></li><li><a href="http://onlinelibrary.wiley.com/doi/10.1002/%28SICI%291097-4652%28199803%29174:3%3C310::AID-JCP5%3E3.0.CO;2-R/references" shape="rect">References</a></li></ul></div><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Cell%20Physiol&amp;rft.atitle=The%20cell%20surface%20proteoglycan%20syndecan%E2%80%901%20mediates%20fibroblast%20growth%20factor%E2%80%902%20binding%20and%20activity&amp;rft.volume=174&amp;rft.spage=310&amp;rft.epage=21&amp;rft.date=1998&amp;rft.aulast=Filla&amp;rft.aufirst=MS&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib76"><span class="bullet">76</span><div class="text"><cite id="cit77">  <span class="author">Inki P</span>, <span class="author">Jalkanen M</span>. <span class="articleTitle">The role of syndecan-1 in malignancies</span>. <span class="journalTitle">Ann Med</span>  <span class="pubYear">1996</span>; <span class="vol">28</span>: <span class="pageFirst">63</span>–<span class="pageLast">7</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.3109/07853899608999076" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=8932508" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DyaK28XjtVGku7g%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Ann%20Med&amp;rft.atitle=The%20role%20of%20syndecan%E2%80%901%20in%20malignancies&amp;rft.volume=28&amp;rft.spage=63&amp;rft.epage=7&amp;rft.date=1996&amp;rft.aulast=Inki&amp;rft.aufirst=P&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib77"><span class="bullet">77</span><div class="text"><cite id="cit78">  <span class="author">Wu X</span>, <span class="author">Kan M</span>, <span class="author">Wang F</span>, <span class="author">Jin C</span>, <span class="author">Yu C</span>, <span class="author">McKeehan WL</span>. <span class="articleTitle">A
 rare premalignant prostate tumor epithelial cell syndecan-1 forms a 
fibroblast growth factor-binding complex with progression-promoting 
ectopic fibroblast growth factor receptor 1</span>. <span class="journalTitle">Cancer Res</span>  <span class="pubYear">2001</span>; <span class="vol">61</span>: <span class="pageFirst">5295</span>–<span class="pageLast">302</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11431373" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3MXltVCjsL4%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer%20Res&amp;rft.atitle=A%20rare%20premalignant%20prostate%20tumor%20epithelial%20cell%20syndecan%E2%80%901%20forms%20a%20fibroblast%20growth%20factor%E2%80%90binding%20complex%20with%20progression%E2%80%90promoting%20ectopic%20fibroblast%20growth%20factor%20receptor%201&amp;rft.volume=61&amp;rft.spage=5295&amp;rft.epage=302&amp;rft.date=2001&amp;rft.aulast=Wu&amp;rft.aufirst=X&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib78"><span class="bullet">78</span><div class="text"><cite id="cit79">  <span class="author">von Mensdorff-Pouilly S</span>, <span class="author">Snijdewint FG</span>, <span class="author">Verstraeten AA</span>, <span class="author">Verheijen RH</span>, <span class="author">Kenemans P</span>. <span class="articleTitle">Human MUC1 mucin: a multifaceted glycoprotein</span>. <span class="journalTitle">Int J Biol Markers</span>  <span class="pubYear">2000</span>; <span class="vol">15</span>: <span class="pageFirst">343</span>–<span class="pageLast">56</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11192832" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3MXktVykug%3D%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Int%20J%20Biol%20Markers&amp;rft.atitle=Human%20MUC1%20mucin%3A%20a%20multifaceted%20glycoprotein&amp;rft.volume=15&amp;rft.spage=343&amp;rft.epage=56&amp;rft.date=2000&amp;rft.aulast=von%20Mensdorff%E2%80%90Pouilly&amp;rft.aufirst=S&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib79"><span class="bullet">79</span><div class="text"><cite id="cit80">  <span class="author">Kirschenbaum A</span>, <span class="author">Itzkowitz SH</span>, <span class="author">Wang JP</span>, <span class="author">Yao S</span>, <span class="author">Eliashvili M</span>, <span class="author">Levine AC</span>. <span class="articleTitle">MUC1 expression in prostate carcinoma: correlation with grade and stage</span>. <span class="journalTitle">Mol Urol</span>  <span class="pubYear">1999</span>; <span class="vol">3</span>: <span class="pageFirst">163</span>–<span class="pageLast">68</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=10851319" shape="rect">PubMed</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Mol%20Urol&amp;rft.atitle=MUC1%20expression%20in%20prostate%20carcinoma%3A%20correlation%20with%20grade%20and%20stage&amp;rft.volume=3&amp;rft.spage=163&amp;rft.epage=68&amp;rft.date=1999&amp;rft.aulast=Kirschenbaum&amp;rft.aufirst=A&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib80"><span class="bullet">80</span><div class="text"><cite id="cit81">  <span class="author">Morse MA</span>. <span class="articleTitle">Technology evaluation: BLP-25, Biomira, Inc</span>. <span class="journalTitle">Curr Opin Mol Ther</span>  <span class="pubYear">2001</span>; <span class="vol">3</span>: <span class="pageFirst">102</span>–<span class="pageLast">5</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11249725" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3MXhs1SrsLo%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Curr%20Opin%20Mol%20Ther&amp;rft.atitle=Technology%20evaluation%3A%20BLP%E2%80%9025%2C%20Biomira%2C%20Inc&amp;rft.volume=3&amp;rft.spage=102&amp;rft.epage=5&amp;rft.date=2001&amp;rft.aulast=Morse&amp;rft.aufirst=MA&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib81"><span class="bullet">81</span><div class="text"><cite id="cit82">  <span class="author">Doehn C</span>, <span class="author">Jocham D</span>. <span class="articleTitle">Technology evaluation: TG-1031, Transgene SA</span>. <span class="journalTitle">Curr Opin Mol Ther</span>  <span class="pubYear">2000</span>; <span class="vol">2</span>: <span class="pageFirst">106</span>–<span class="pageLast">11</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11249647" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3cXhvFOgtbw%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Curr%20Opin%20Mol%20Ther&amp;rft.atitle=Technology%20evaluation%3A%20TG%E2%80%901031%2C%20Transgene%20SA&amp;rft.volume=2&amp;rft.spage=106&amp;rft.epage=11&amp;rft.date=2000&amp;rft.aulast=Doehn&amp;rft.aufirst=C&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib82"><span class="bullet">82</span><div class="text"><cite id="cit83">  <span class="author">Graff JR</span>, <span class="author">Deddens JA</span>, <span class="author">Konicek BW</span>, <span class="author">Colligan BM</span>, <span class="author">Hurst BM</span>, <span class="author">Carter HW</span>, <span class="author">Carter JH</span>. <span class="articleTitle">Integrin-linked kinase expression increases with prostate tumor grade</span>. <span class="journalTitle">Clin Cancer Res</span>  <span class="pubYear">2001</span>; <span class="vol">7</span>: <span class="pageFirst">1987</span>–<span class="pageLast">91</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11448915" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:STN:280:DC%2BD3MzpslensQ%3D%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clin%20Cancer%20Res&amp;rft.atitle=Integrin%E2%80%90linked%20kinase%20expression%20increases%20with%20prostate%20tumor%20grade&amp;rft.volume=7&amp;rft.spage=1987&amp;rft.epage=91&amp;rft.date=2001&amp;rft.aulast=Graff&amp;rft.aufirst=JR&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib83"><span class="bullet">83</span><div class="text"><cite id="cit84">  <span class="author">Wu C</span>, <span class="author">Keightley SY</span>, <span class="author">Leung-Hagesteijn C</span>, <span class="author">Radeva G</span>, <span class="author">Coppolino M</span>, <span class="author">Goicoechea S</span>, <span class="author">McDonald JA</span>, <span class="author">Dedhar S</span>. <span class="articleTitle">Integrin-linked protein kinase regulates fibronectin matrix assembly, E-cadherin expression, and tumorigenicity</span>. <span class="journalTitle">J Biol Chem</span>  <span class="pubYear">1998</span>; <span class="vol">273</span>: <span class="pageFirst">528</span>–<span class="pageLast">36</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1074/jbc.273.1.528" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=9417112" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DyaK1cXjvFCmtw%3D%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Biol%20Chem&amp;rft.atitle=Integrin%E2%80%90linked%20protein%20kinase%20regulates%20fibronectin%20matrix%20assembly%2C%20E%E2%80%90cadherin%20expression%2C%20and%20tumorigenicity&amp;rft.volume=273&amp;rft.spage=528&amp;rft.epage=36&amp;rft.date=1998&amp;rft.aulast=Wu&amp;rft.aufirst=C&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib84"><span class="bullet">84</span><div class="text"><cite id="cit85">  <span class="author">Persad S</span>, <span class="author">Attwell S</span>, <span class="author">Gray V</span>, <span class="author">Delcommenne M</span>, <span class="author">Troussard A</span>, <span class="author">Sanghera J</span>, <span class="author">Dedhar S</span>. <span class="articleTitle">Inhibition
 of integrin-linked kinase (ILK) suppresses activation of protein kinase
 B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant 
prostate cancer cells</span>. <span class="journalTitle">Proc Natl Acad Sci U S A</span>  <span class="pubYear">2000</span>; <span class="vol">97</span>: <span class="pageFirst">3207</span>–<span class="pageLast">12</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1073/pnas.060579697" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=10716737" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3cXitlWqs7o%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;rft.atitle=Inhibition%20of%20integrin%E2%80%90linked%20kinase%20%28ILK%29%20suppresses%20activation%20of%20protein%20kinase%20B%2FAkt%20and%20induces%20cell%20cycle%20arrest%20and%20apoptosis%20of%20PTEN%E2%80%90mutant%20prostate%20cancer%20cells&amp;rft.volume=97&amp;rft.spage=3207&amp;rft.epage=12&amp;rft.date=2000&amp;rft.aulast=Persad&amp;rft.aufirst=S&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib85"><span class="bullet">85</span><div class="text"><cite id="cit86">  <span class="author">Cairns P</span>, <span class="author">Okami K</span>, <span class="author">Halachmi S</span>, <span class="author">Halachmi N</span>, <span class="author">Esteller M</span>, <span class="author">Herman JG</span>, <span class="author">Jen J</span>, <span class="author">Isaacs WB</span>, <span class="author">Bova GS</span>, <span class="author">Sidransky D</span>. <span class="articleTitle">Frequent inactivation of PTEN/MMAC1 in primary prostate cancer</span>. <span class="journalTitle">Cancer Res</span>  <span class="pubYear">1997</span>; <span class="vol">57</span>: <span class="pageFirst">4997</span>–<span class="pageLast">5000</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=9371490" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DyaK2sXnsV2kt74%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer%20Res&amp;rft.atitle=Frequent%20inactivation%20of%20PTEN%2FMMAC1%20in%20primary%20prostate%20cancer&amp;rft.volume=57&amp;rft.spage=4997&amp;rft.epage=5000&amp;rft.date=1997&amp;rft.aulast=Cairns&amp;rft.aufirst=P&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib86"><span class="bullet">86</span><div class="text"><cite id="cit87">  <span class="author">Novak A</span>, <span class="author">Hsu SC</span>, <span class="author">Leung-Hagesteijn C</span>, <span class="author">Radeva G</span>, <span class="author">Papkoff J</span>, <span class="author">Montesano R</span>, <span class="author">Roskelley C</span>, <span class="author">Grosschedl R</span>, <span class="author">Dedhar S</span>. <span class="articleTitle">Cell adhesion and the integrin-linked kinase regulate the LEF-1 and beta-catenin signaling pathways</span>. <span class="journalTitle">Proc Natl Acad Sci U S A</span>  <span class="pubYear">1998</span>; <span class="vol">95</span>: <span class="pageFirst">4374</span>–<span class="pageLast">9</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1073/pnas.95.8.4374" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=9539744" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DyaK1cXis1OhurY%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;rft.atitle=Cell%20adhesion%20and%20the%20integrin%E2%80%90linked%20kinase%20regulate%20the%20LEF%E2%80%901%20and%20beta%E2%80%90catenin%20signaling%20pathways&amp;rft.volume=95&amp;rft.spage=4374&amp;rft.epage=9&amp;rft.date=1998&amp;rft.aulast=Novak&amp;rft.aufirst=A&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib87"><span class="bullet">87</span><div class="text"><cite id="cit88">  <span class="author">Shen R</span>, <span class="author">Sumitomo M</span>, <span class="author">Dai J</span>, <span class="author">Hardy DO</span>, <span class="author">Navarro D</span>, <span class="author">Usmani B</span>, <span class="author">Papandreou CN</span>, <span class="author">Hersh LB</span>, <span class="author">Shipp MA</span>, <span class="author">Freedman LP</span>, <span class="author">Nanus DM</span>. <span class="articleTitle">Identification and characterization of two androgen response regions in the human neutral endopeptidase gene</span>. <span class="journalTitle">Mol Cell Endocrinol</span>  <span class="pubYear">2000</span>; <span class="vol">170</span>: <span class="pageFirst">131</span>–<span class="pageLast">42</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1016/S0303-7207%2800%2900326-9" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11162897" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3MXitlyksQ%3D%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Mol%20Cell%20Endocrinol&amp;rft.atitle=Identification%20and%20characterization%20of%20two%20androgen%20response%20regions%20in%20the%20human%20neutral%20endopeptidase%20gene&amp;rft.volume=170&amp;rft.spage=131&amp;rft.epage=42&amp;rft.date=2000&amp;rft.aulast=Shen&amp;rft.aufirst=R&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib88"><span class="bullet">88</span><div class="text"><cite id="cit89">  <span class="author">Mousses S</span>, <span class="author">Wagner U</span>, <span class="author">Chen Y</span>, <span class="author">Kim JW</span>, <span class="author">Bubendorf L</span>, <span class="author">Bittner M</span>, <span class="author">Pretlow T</span>, <span class="author">Elkahloun AG</span>, <span class="author">Trepel JB</span>, <span class="author">Kallioniemi OP</span>. <span class="articleTitle">Failure
 of hormone therapy in prostate cancer involves systematic restoration 
of androgen responsive genes and activation of rapamycin sensitive 
signaling</span>. <span class="journalTitle">Oncogene</span>  <span class="pubYear">2001</span>; <span class="vol">20</span>: <span class="pageFirst">6718</span>–<span class="pageLast">23</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1038/sj.onc.1204889" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11709706" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3MXotFahtrw%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Oncogene&amp;rft.atitle=Failure%20of%20hormone%20therapy%20in%20prostate%20cancer%20involves%20systematic%20restoration%20of%20androgen%20responsive%20genes%20and%20activation%20of%20rapamycin%20sensitive%20signaling&amp;rft.volume=20&amp;rft.spage=6718&amp;rft.epage=23&amp;rft.date=2001&amp;rft.aulast=Mousses&amp;rft.aufirst=S&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib89"><span class="bullet">89</span><div class="text"><cite id="cit90">  <span class="author">Druker BJ</span>, <span class="author">Talpaz M</span>, <span class="author">Resta DJ</span>, <span class="author">Peng B</span>, <span class="author">Buchdunger E</span>, <span class="author">Ford JM</span>, <span class="author">Lydon NB</span>, <span class="author">Kantarjian H</span>, <span class="author">Capdeville R</span>, <span class="author">Ohno-Jones S</span>, <span class="author">Sawyers CL</span>. <span class="articleTitle">Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia</span>. <span class="journalTitle">N Engl J Med</span>  <span class="pubYear">2001</span>; <span class="vol">344</span>: <span class="pageFirst">1031</span>–<span class="pageLast">7</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1056/NEJM200104053441401" shape="rect">CrossRef</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11287972" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3MXivFGnu70%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=N%20Engl%20J%20Med&amp;rft.atitle=Efficacy%20and%20safety%20of%20a%20specific%20inhibitor%20of%20the%20BCR%E2%80%90ABL%20tyrosine%20kinase%20in%20chronic%20myeloid%20leukemia&amp;rft.volume=344&amp;rft.spage=1031&amp;rft.epage=7&amp;rft.date=2001&amp;rft.aulast=Druker&amp;rft.aufirst=BJ&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib90"><span class="bullet">90</span><div class="text"><cite id="cit91">  <span class="author">Joensuu H</span>. <span class="articleTitle">Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec)</span>. <span class="journalTitle">Med Klin</span>  <span class="pubYear">2002</span>; <span class="vol">97</span>: <span class="pageFirst">28</span>–<span class="pageLast">30</span>.</cite><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Med%20Klin&amp;rft.atitle=Treatment%20of%20inoperable%20gastrointestinal%20stromal%20tumor%20%28GIST%29%20with%20Imatinib%20%28Glivec%2C%20Gleevec%29&amp;rft.volume=97&amp;rft.spage=28&amp;rft.epage=30&amp;rft.date=2002&amp;rft.aulast=Joensuu&amp;rft.aufirst=H&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib91"><span class="bullet">91</span><div class="text"><cite id="cit92">  <span class="author">Specht K</span>, <span class="author">Richter T</span>, <span class="author">Muller U</span>, <span class="author">Walch A</span>, <span class="author">Werner M</span>, <span class="author">Hofler H</span>. <span class="articleTitle">Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue</span>. <span class="journalTitle">Am J Pathol</span>  <span class="pubYear">2001</span>; <span class="vol">158</span>: <span class="pageFirst">419</span>–<span class="pageLast">29</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11159180" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DC%2BD3MXhsFWmtrk%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Am%20J%20Pathol&amp;rft.atitle=Quantitative%20gene%20expression%20analysis%20in%20microdissected%20archival%20formalin%E2%80%90fixed%20and%20paraffin%E2%80%90embedded%20tumor%20tissue&amp;rft.volume=158&amp;rft.spage=419&amp;rft.epage=29&amp;rft.date=2001&amp;rft.aulast=Specht&amp;rft.aufirst=K&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li><li id="bib92"><span class="bullet">92</span><div class="text"><cite id="cit93">  <span class="author">Wolf HK</span>, <span class="author">Dittrich KL</span>. <span class="articleTitle">Detection of proliferating cell nuclear antigen in diagnostic histopathology</span>. <span class="journalTitle">J Histochem Cytochem</span>  <span class="pubYear">1992</span>; <span class="vol">40</span>: <span class="pageFirst">1269</span>–<span class="pageLast">73</span>.</cite><ul class="externalReferences"><li><a href="http://onlinelibrary.wiley.com/resolve/reference/PMED?id=1354677" shape="rect">PubMed</a>,</li><li><a href="http://onlinelibrary.wiley.com/resolve/reference/CAS?id=1:CAS:528:DyaK38XlvVOltLs%3D" shape="rect">ChemPort</a></li></ul><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/full?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Histochem%20Cytochem&amp;rft.atitle=Detection%20of%20proliferating%20cell%20nuclear%20antigen%20in%20diagnostic%20histopathology&amp;rft.volume=40&amp;rft.spage=1269&amp;rft.epage=73&amp;rft.date=1992&amp;rft.aulast=Wolf&amp;rft.aufirst=HK&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary" shape="rect"></a></div></li></ul></div></div>         <div xmlns:doc="urn://wiley-online-library/content/document" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml" class="viewFullArticleAndPdf"><div class="viewFullArticleAndPdfOptions"><a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.20615/pdf" title="Article in pdf format" class="pdfLink" shape="rect">Get PDF (681K)</a></div></div>               <!-- SiteCatalyst code version: H.20.3. -->     <script language="JavaScript" type="text/javascript" src="2004%20Int%20J%20Cancer%20Zellweger_files/s_code_wileyonlinelibrary-production.js" xml:space="preserve"></script>          <script language="JavaScript" type="text/javascript" xml:space="preserve">
        <!--
        /* You may give each page an identifying name, server, and channel on the next lines. */
            
    s.pageName=""
    s.server=""
    s.channel="JOURNALS" 
    s.pageType=""
    s.prop1="FULLTEXT"
    s.prop2="FULLTEXT_HTML" 
    s.prop3="International Journal of Cancer"
    s.prop4="MDH0"
    s.prop5=""
    s.prop6=""
    s.prop7="Expression patterns of potential therapeutic targets in prostate cancer"
    s.prop8="113/4"
    /* Conversion Variables */
    s.campaign=""
    s.state=""
    s.zip=""
    s.events=""
    s.products=""
    s.purchaseID=""
    s.eVar1="10.1002/ijc.20615"
    s.eVar2=""
    s.eVar3=""
    s.eVar4=""
    s.eVar5="" 
  
        /************* DO NOT ALTER ANYTHING BELOW THIS LINE ! **************/
        var s_code=s.t();if(s_code)document.write(s_code)//-->
    </script>              <script language="JavaScript" type="text/javascript" xml:space="preserve">
        <!--
        if(navigator.appVersion.indexOf('MSIE')>=0)document.write(unescape('%3C')+'\!-'+'-')
        //-->
    </script>     <noscript><a href="http://www.omniture.com" title="Web Analytics" shape="rect">
        <img src="http://wileypublishing.112.2o7.net/b/ss/wileyonlinelibrary-development/1/H.20.3--NS/0?[AQB]&amp;cdp=3&amp;[AQE]" height="1" width="1" border="0" alt="" /></a></noscript>     <!--/DO NOT REMOVE/-->     <!-- End SiteCatalyst code version: H.20.3. -->                  <div id="relatedArticles">     <div class="sectionHeading">         <h3>More content like this</h3>     </div>     <span id="findArticlesHeading">Find more content:</span>     <ul class="findArticles"><li><a href="http://onlinelibrary.wiley.com/advanced/search/results?articleDoi=10.1002%2Fijc.20615&amp;scope=allContent&amp;start=1&amp;resultsPerPage=20" title="Link to articles like this" shape="rect">like this article</a></li></ul>     <span xmlns="http://www.w3.org/1999/xhtml" id="articlesWrittenByHeading">Find more content written by:</span><ul xmlns="http://www.w3.org/1999/xhtml" class="articlesWrittenBy"><li><a title="Link to more articles by Tobias Zellweger" href="http://onlinelibrary.wiley.com/advanced/search/results?searchRowCriteria[0].queryString=%22Tobias%20Zellweger%22&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">Tobias Zellweger</a></li><li><a title="Link to more articles by Christoph Ninck" href="http://onlinelibrary.wiley.com/advanced/search/results?searchRowCriteria[0].queryString=%22Christoph%20Ninck%22&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">Christoph Ninck</a></li><li><a title="Link to more articles by Michael Bloch" href="http://onlinelibrary.wiley.com/advanced/search/results?searchRowCriteria[0].queryString=%22Michael%20Bloch%22&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">Michael Bloch</a></li><li><a title="Link to more articles by Martina Mirlacher" href="http://onlinelibrary.wiley.com/advanced/search/results?searchRowCriteria[0].queryString=%22Martina%20Mirlacher%22&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">Martina Mirlacher</a></li><li><a title="Link to more articles by Pasi A. Koivisto" href="http://onlinelibrary.wiley.com/advanced/search/results?searchRowCriteria[0].queryString=%22Pasi%20A.%20Koivisto%22&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">Pasi A. Koivisto</a></li><li><a title="Link to more articles by Heikki J. Helin" href="http://onlinelibrary.wiley.com/advanced/search/results?searchRowCriteria[0].queryString=%22Heikki%20J.%20Helin%22&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">Heikki J. Helin</a></li><li><a title="Link to more articles by Michael J. Mihatsch" href="http://onlinelibrary.wiley.com/advanced/search/results?searchRowCriteria[0].queryString=%22Michael%20J.%20Mihatsch%22&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">Michael J. Mihatsch</a></li><li><a title="Link to more articles by Thomas C. Gasser" href="http://onlinelibrary.wiley.com/advanced/search/results?searchRowCriteria[0].queryString=%22Thomas%20C.%20Gasser%22&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">Thomas C. Gasser</a></li><li><a title="Link to more articles by Lukas Bubendorf" href="http://onlinelibrary.wiley.com/advanced/search/results?searchRowCriteria[0].queryString=%22Lukas%20Bubendorf%22&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">Lukas Bubendorf</a></li><li class="lastItem"><a title="Link to more articles by the present authors" href="http://onlinelibrary.wiley.com/advanced/search/results?searchRowCriteria[0].queryString=%22Tobias%20Zellweger%22%20%22Christoph%20Ninck%22%20%22Michael%20Bloch%22%20%22Martina%20Mirlacher%22%20%22Pasi%20A.%20Koivisto%22%20%22Heikki%20J.%20Helin%22%20%22Michael%20J.%20Mihatsch%22%20%22Thomas%20C.%20Gasser%22%20%22Lukas%20Bubendorf%22&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">All Authors</a></li></ul> </div>         </div>  </div>                  <div id="footer">                     <div id="indexBottomLeftCorner"></div>                     <div id="indexBottomRightCorner"></div>                     <ul><li><a href="http://olabout.wiley.com/WileyCDA/Section/id-390001.html" shape="rect">ABOUT US</a></li><li><a href="http://onlinelibrary.custhelp.com/" shape="rect">HELP</a></li><li><a href="http://olabout.wiley.com/WileyCDA/Section/id-397203.html" shape="rect">CONTACT US</a></li><li><a href="http://olabout.wiley.com/WileyCDA/Section/id-390243.html" shape="rect">AGENTS</a></li><li><a href="http://olabout.wiley.com/WileyCDA/Section/id-390236.html" shape="rect">ADVERTISERS</a></li><li><a href="http://olabout.wiley.com/WileyCDA/Section/id-390242.html" shape="rect">MEDIA</a></li><li><a href="http://onlinelibrary.wiley.com/privacyPolicy" shape="rect">PRIVACY</a></li><li><a href="http://onlinelibrary.wiley.com/termsAndConditions" shape="rect">TERMS &amp; CONDITIONS</a></li><li><a href="http://onlinelibrary.wiley.com/siteMap" shape="rect">SITE MAP</a></li></ul>                     <p>                         Copyright © 1999-2010 John Wiley &amp; Sons, Inc. All Rights Reserved.                     </p>                 </div>                                  <!-- Start Google Analytics -->                 <script type="text/javascript" xml:space="preserve">
                var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
                document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
                </script><script src="2004%20Int%20J%20Cancer%20Zellweger_files/ga.js" type="text/javascript"></script>                 <script type="text/javascript" xml:space="preserve">
                try {
                var pageTracker = _gat._getTracker("UA-11972776-3");
                pageTracker._trackPageview();
                } catch(err) {}</script>                 <!-- End Google Analytics -->        </div>     </div><script type="text/javascript" src="2004%20Int%20J%20Cancer%20Zellweger_files/jquery-1.js" xml:space="preserve"></script><script type="text/javascript" src="2004%20Int%20J%20Cancer%20Zellweger_files/jquery.js" xml:space="preserve"></script><script type="text/javascript" src="2004%20Int%20J%20Cancer%20Zellweger_files/jquery_002.js" xml:space="preserve"></script><script type="text/javascript" src="2004%20Int%20J%20Cancer%20Zellweger_files/ol.js" xml:space="preserve"></script><script type="text/javascript" src="2004%20Int%20J%20Cancer%20Zellweger_files/jquery_007.js" xml:space="preserve"></script><script type="text/javascript" src="2004%20Int%20J%20Cancer%20Zellweger_files/jquery_003.js" xml:space="preserve"></script><script type="text/javascript" src="2004%20Int%20J%20Cancer%20Zellweger_files/wol.js" xml:space="preserve"></script><script type="text/javascript" src="2004%20Int%20J%20Cancer%20Zellweger_files/jquery_006.js" xml:space="preserve"></script><script type="text/javascript" src="2004%20Int%20J%20Cancer%20Zellweger_files/jquery_004.js" xml:space="preserve"></script><script type="text/javascript" src="2004%20Int%20J%20Cancer%20Zellweger_files/jquery_005.js" xml:space="preserve"></script><script type="text/javascript" src="2004%20Int%20J%20Cancer%20Zellweger_files/wol_004.js" xml:space="preserve"></script><script type="text/javascript" src="2004%20Int%20J%20Cancer%20Zellweger_files/wol_002.js" xml:space="preserve"></script><script type="text/javascript" src="2004%20Int%20J%20Cancer%20Zellweger_files/wol_003.js" xml:space="preserve"></script></body></html>